Download - William D. Chey, MD Professor of Internal Medicine …apnm2020.org/data/cv/William_D_Chey.pdfWilliam Chey, MD 1/2/2020 1 William D. Chey, MD Professor of Internal Medicine Director,

William Chey, MD 1/2/2020 1

William D. Chey, MD

Professor of Internal Medicine

Director, GI Physiology Laboratory

3912 Taubman Center, SPC 5362

Ann Arbor, MI 48109

734-936-4780

[email protected]

Title and Contents

Education and Training Page 2

Certification and Licensure Page 2

Academic, Administrative, and Clinical Appointments Page 2

Research Interests Page 2

Grants/Patents Page 3

Honors and Awards Page 10

Memberships in Professional Societies Page 12

Editorial Positions, Boards, and Peer-Review Service Page 12

Teaching Page 13

Committee, Organizational, and Volunteer Service Page 15

Consulting Positions Page 17

Visiting Professorships, Seminars, and Extramural Invited Presentations Page 17

Bibliography Page 30

mailto:[email protected]


Education and Training

09/1978-05/1982 University of Pennsylvania, Bachelor of Arts in Biology

09/1982-06/1986 Emory University School of Medicine, MD

07/1986-06/1989 Residency Training in Internal Medicine, Emory Affiliated

Hospitals

07/1990-06/1993 Fellowship in Gastroenterology, University of Michigan

Certification and Licensure

Diplomat of NBME (7/87)

Licensed to Practice Medicine in the State of Michigan (#4301056884), Expire 01/31/2018

American Board of Internal Medicine Certification, 1989

American Board of Internal Medicine Subspecialty Certification in Gastroenterology, 1993,

Successful recertification 2003, 2013

Academic, Administrative, and Clinical Appointments

Academic

07/1989-06/1990 Senior Associate, Department of Internal Medicine,

Emory University School of Medicine, Atlanta, Georgia

07/1993-08/1996 Lecturer in Internal Medicine,

University of Michigan, Ann Arbor, Michigan

09/1996-08/2001 Assistant Professor, Department of Internal Medicine,


09/2001-08/2007 Associate Professor, Department of Internal Medicine,


09/2007-present Professor, Department of Internal Medicine, University of

Michigan, Ann Arbor, Michigan

02/2015-present Timothy T. Nostrant Collegiate Professorship in

Gastroenterology, Department of Internal Medicine,


07/2015- present Professor, Department of Nutritional Sciences, University of

Michigan, Ann Arbor, Michigan

Clinical

07/1993-present Director, GI Physiology Laboratory,

University of Michigan Health System

Ann Arbor, Michigan

01/2009-present Co-Director, Michigan Bowel Control Program

University of Michigan Health System

Ann Arbor, Michigan


01/2015-present Director, Digestive Diseases Nutrition & Behavioral Health

Program, Division of Gastroenterology, University of

Michigan Health System, Ann Arbor, Michigan

09/2018-present Director, University of Michigan Food for Life Kitchen

Private Sector Appointments

Co-Founder and Co-CMO My Total Health, Los Angeles, California

Research Interests

1. The pathophysiology and management of functional bowel disorders

2. The role of diet and nutrition in functional bowel and motility disorders

3. The emerging role of health information technology in medicine

4. Diagnosis and treatment of Helicobacter pylori and acid-peptic disorders

Active Research Funding: IBS

Sponsor: Vibrant

Title: “A prospective, Multicenter, Randomized, Sample Size Adaptive,

Single Blind, Placebo-Controlled Study to Assess the Efficacy and

Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of

Chronic Idiopathic Constipation (CIC)”

Principal Investigator: William D. Chey, MD

Funding period: 8/1/19-10/1/19 ($77,933)

Sponsor: Urovant

Title: “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to

Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12

Weeks to Women with Irritable Bowel Syndrome”


Funding period: 5/1/19-9/14/20 ($106,314)

Sponsor: Biomerica

Title: “An antibody guided dietary restriction trial using Biomerica

InFoods 24G test in patients with Irritable Bowel Syndrome” Principal Investigator: William D. Chey, MD

Funding period: 7/1/18-9/30/19 ($181,015)

Sponsor: Commonwealth Diagnostics International

Title: “The role of breath testing in enriching the likelihood of response

to rifaximin in patients with non-constipated IBS”


Co-investigator: Borko Nojkov, MD

Funding period: 9/10/19-8/31/21 ($155,122)

Sponsor: QOL Medical


Title: “Sucrase-Isomaltase Deficiency in Irritable Bowel Syndrome and

Diarrhea - Hiding in Plain Sight?” Principal Investigator: Shanti Eswaran, MD

Project Mentor: William D. Chey, MD

Funding period: 4/1/19-3/30/20 ($150,676)

Sponsor: ACG Institute

Title: “Low FODMAP plus PEG 3350 for the treatment of patients with

Irritable Bowel Syndrome-Constipation” Principal Investigator: Stacy Menees, MD


Funding period: 7/1/18-9/30/19 ($56,151)

Sponsor: Nestle HealthCare Nutrition

Title: “Charting a course to a less restrictive diet for IBS patients”

Principal Investigator: Shanti Eswaran, MD


Funding period: 11/4/17-9/30/19 ($116,248)

Sponsor: MICHR Pilot Grant Program




Funding period: 1/1/17-1/1/18 ($50,000)

Chronic Constipation:

Sponsor: Vibrant

Title: “A Prospective, Randomized, Multi-center, Single-Blinded,

Placebo-Controlled, 3-Arm Clinical Study to Assess the Efficacy

and Safety of Vibrant Capsule for the Treatment of Chronic

Idiopathic Constipation”


Co-investigators: Shanti Eswaran, Borko Nojkov

Funding period: 1/22/19 – 9/30/19 ($77,933)

Sponsor: UM Fast Forward GI Innovation Fund

Title: “Tier II – Development of an office-based, disposable rectal

expulsion device to screen for dyssynergic defecation in

constipated patients” Principal Investigator: William D. Chey, MD

Project Mentor: Eric Shah, MD

Funding period: 7/1/18-6/30/19 ($100,000)

Sponsor: Zespri

Title: “A randomized, controlled pilot study to compare the efficacy of Kiwifruit,

prunes, or psyllium on abdominal and bowel symptoms in US patients


with chronic constipation”



Funding period: 5/1/18-9/1/19 ($176,844)

Other:

Sponsor: Craig H. Nelson Foundation

Title: “The Wireless Motility Capsule for Neurogenic Bowel in Spinal

Cord Injury”

Principal Investigator: Gianna Rodriguez, MD

Co-investigators: William D. Chey, MD, Jason Baker, Richard Saad, MD

Funding period: 7/31/17-7/30/19 ($300,000)

Past

GCRC-CAP Award for "Visceral Afferent Dysfunction in Diabetic Constipation",

Principal Investigator: WD Chey

Funding period from 4/1/94 to 3/31/97 ($196,400)

Glaxo Institute of Digestive Health Clinical Research Award for "Role of Hyperglycemia on

Efferent Neural and Myogenic Function in the Human Colon",



Glaxo Institute of Digestive Health Clinical Research Award for "Visceral Afferent Neural

Dysfunction in Diabetic Constipation",



Sandoz Pharma Ltd for "A randomized, double-blind, placebo-controlled, multicenter, dose

ranging study to assess the safety and efficacy of SDZ HTF 919 at four dose levels in subjects

with constipation-prone irritable bowel syndrome"

Principal Investigator: Chung Owyang, MD

Co-investigators: WD Chey, JL Barnett, G Elta, W Hasler, T Nostrant, J Scheiman,

J Wiley.

Funding period from 4/95 to 2/96 ($97,988)

Astra-Merck for "Prolonged effect of omeprazole on the 14C-urea breath test",



Chemtrak for "Accumeter H. pylori test: Cut-off verification, clinical performance, and

reproducibility",

Principal Investigator: WD Chey.



Abbott Pharmaceuticals for "The efficacy of 2 different 7 day treatment programs for

Helicobacter pylori infection",


Funding period from 9/95 to 10/96 ($3000)

Solvay Pharmaceuticals for “Double-blind placebo-controlled, randomized, multicenter, parallel

group dose finding study to investigate the efficacy of cilansetron in patients with irritable bowel

syndrome and increased rectal visceral sensitivity”

Principal Investigator: Chung Owyang, MD

Co-investigators: WD Chey, MD

Funding period from 10/96 – 4/97

Chemtrak for "Accumeter H. pylori Test",

Principal Investigator: WD Chey.

Funding period from 9/96-2/97 ($5,100)

GCRC Funding for “The effect of hyperglycemia on forebrain and brainstem activation resulting

from rectal distention”


Funding period from 4/18/96-11/1/97 ($24,000)

Pfizer Pharmaceuticals for “The efficacy of Ranitidine Bismuth Citrate, Azithromycin, and

Amoxicillin for 7 versus 10 days to cure H. pylori infection”



Phase I SBIR award for “Non-invasive breath test for measuring gastric emptying”

Principal Investigator: KJ Goodman

Co-investigator: WD Chey

Funding period from 9/1/97-8/31/98 ($61,782 total costs; $32,552 subcontract to UMMC)

Phase II SBIR award for “Investigation of a blood test (EZ-HBT) for the diagnosis of

Helicobacter pylori infection”

Principal Investigator: DA Wagner, PhD

Co-investigators: WD Chey, PA Toskes, AF Cutler

Funding period from 4/1/98-3/31/00 ($15,600 from subcontract to UMMC)

John and Suzanne Munn endowed research fund of the University of Michigan Comprehensive

Cancer Center for “Converting sigmoidoscopy to colonoscopy: a randomized, controlled trial to

assess clinical and economic outcomes of a novel colorectal cancer screening strategy”

Principal Investigator: WD Chey, MD

Co-investigators: M Stern, AM Fendrick, R Mosely

5/14/98 to indefinite ($7,200)

GCRC Funding for “Differential cortical activation in response to visceral and somatic

stimulation in healthy volunteers and patients with noncardiac chest pain (#1575)”



Funding period from 8/13/98- 8/99 ($24,600)

Phase II SBIR for “Non-invasive breath test for measuring gastric emptying”

Principal Investigator: KJ Goodman, PhD

Co-investigators: WD Chey, HP Parkman

Funding period from 7/1/99 to 6/30/01 ($646,500 total award with $117,546 from subcontract to

UMMC)

Solvay Pharmaceuticals for “Double-blind, placebo-controlled, randomized, multicenter,

parallel-group dose ranging study to investigate the efficacy and safety of Cilansetron in non-

constipated patients with Irritable Bowel Syndrome”


Co-Investigators: C Owyang, WL Hasler, J Barnett, J Wiley

Funding period from 3/99- ($89,647)

Dia Sorin for “Appropriate test selection for patients undergoing the test and treat strategy for H.

pylori”

Principal Investigator: AM Fendrick, MD

Co-Investigator: WD Chey

Funding period from 11/99-5/2000 ($74,963)

Ballard Medical Products for “The effect of proton pump inhibitors on non-invasive testing for

H. pylori”


Funding from 9/99-8/2000 ($5,000)

Solvay Pharmaceuticals for “Double-blind, placebo-controlled, long-term extension to evaluate

the nine month safety profile of Cilansetron in non-constipated IBS patients”


Co-Investigators: C Owyang, WL Hasler, J Barnett, J Wiley


Glaxo-Wellcome for “A 24 week randomized, open label study of Health care resource use,

quality of life and productivity with Alosetron 1 mg BID vs. traditional therapy in females with

non-constipated IBS”



Glaxo-Wellcome for “The effect of Alosetron on anal sphincter function in healthy volunteers

and patients with fecal incontinence”


Co-Investigator: WM Sun



Solvay for “A randomized, placebo controlled, multi-center study to investigate the safety and

efficacy of 2mg cilansetron in non-constipated subjects with established irritable bowel

syndrome”


Co-Investigators: C Owyang, G Elta, J Barnett


Astra-Zeneca for “A comparative efficacy and safety study of Nexium (esomeprazole

magnesium) delayed release capsules(40mg qd and 20mg qd) versus placebo for the prevention

of gastric ulcers associated with daily NSAID use in patients at risk” Principal Investigator:

James Scheiman,

Sub Investigators: William Chey, Grace Elta, Andrea Todisco, Michelle Anderson. Funding

period: 2/01-12/02 ($50,000)

Novartis for “A randomized, double-blind, placebo controlled multi-center study to assess the

efficacy, safety, and tolerability of tegaserod 2 mg bid and 6 mg bid given orally vs. placebo in

patients with chronic constipation”


Co-Investigators: C Owyang, G Elta, J Barnett

Funding period from: 5/1/01-11/1/02 ($49,675)

Astra-Zeneca for “Effect of functional bowel disease on outcome after surgical anti-reflux

therapy”


Co-Investigators: Lisa Colletti, David Axelrod, Michael Shaw, A. Mark Fendrick


Phase II SBIR for “A breath test to detect bacterial overgrowth in the elderly”

Principal Investigator: D Wagner, PhD

Co-investigators: WD Chey, HP Parkman, P Toskes

Funding period from: 4/1/02-3/31/04 ($74,972 from subcontract to UMMC)

Janssen Pharmaceuticals for “Nonerosive Reflux Disease: A study to understand etiology and

predictors of response to PPI therapy”


Co-investigators: M Cleary, M Shaw, J Inadomi


Phase I SBIR for “A novel diagnostic test for irritable bowel syndrome”

Principal Investigator: D Wagner, PhD

Co-investigators: WD Chey


Forest Laboratories for “Safety and efficacy of dexloxiglumide in female patients with

constipation-predominant irritable bowel syndrome”



Co-Investigators: C Owyang, G Elta


Vela Pharmaceuticals for “A double-blind randomized, placebo-controlled study of R-Tofisopam

in outpatients with Irritable Bowel Syndrome”


Co-Investigators: C Owyang, WL Hasler, J Wiley


Prometheus Laboratories for “The value of diagnostic testing in Irritable Bowel Syndrome”


Co-Investigators: B Cash


Janssen Pharmaceuticals for "Esophageal sensation in patients with heartburn:

Correlation of esophageal sensation with response to PPI"


Co-investigators: J Rubenstein, B Nojkov


Novartis Pharmaceuticals for "A 4-week, multicenter, double-blind, placebo-controlled,

randomized, parallel-group, clinical study to evaluate the efficacy of tegaserod in relieving the

symptoms of female patients with IBS, excluding those with predominant diarrhea IBS"


Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher


Novartis for “A 6 week randomized, double-blind, double-dummy placebo controlled,

multicenter study to assess the effect of tegaserod 2mg TID on dyspeptic symptoms in diabetic

patients with symptoms of diabetic gastropathy”




Trine Pharmaceuticals for “A randomized, double-blind, placebo-controlled study to assess the

safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant irritable

bowel syndrome”




Smart Pill Diagnostics for “Medical Utilization in patients with gastroparesis”

Principal Investigator: WL Hasler, MD

Co-investigators: John Wo, WD Chey



Rome Foundation for Disorders of GI Function for “Validation of the Rome III modular

questionnaire”


Co-investigators: R Saad, MD


Sucampo Pharmaceuticals for “An double-blind study of lubiprostone for constipation-

predominant irritable bowel syndrome”



Date:1/1/06-3/31/2007

Funding amount: $52,614

Novartis for “The effects of tegaserod on orocecal transit in elderly patients

with chronic constipation”


Co-investigators: H Parkman, I Bottoli, D Joseph

Date: 7/1/06-6/30/07

Funding amount: $750,000 for 3 sites - $244,000 to UM

Salix for “A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess

the efficacy and safety of 3 different doses of rifaximin bid for 2 or 4 weeks in the treatment of

patients with IBS-D”



Date: 5/1/06-9/30/07

Funding amount: $44,075

Trine Pharmaceuticals for “A randomized, double-blind placebo controlled study to assess

the safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant IBS

in females”


Co-investigators: R Saad MD, D Brenner MD

Funding period: 10/16/06-10/31/07 ($33,064)

GCRC for “Pilot feasibility study of structure-function relationships in pediatric fecal

incontinence”

Principal Investigator: Cheryl Gariepy, MD

Co-investigators: WD Chey, B Felt, P Strouse

Date: 11/01/05-4/30/07 ($26,108)

Allergan Pharmaceuticals for “A multicenter, multiple-dose, double-blind, randomized, placebo

controlled, parallel group study of the safety and efficacy of oral AGN 203818 given twice daily

for 4 weeks for the relief of IBS pain”


Co-investigators: R Saad, MD D Brenner MD


Date: 5/1/07- 5/08 ($24,045)

Microbia, Inc. for “A randomized, multi-center, double-blind, placebo controlled dose-range-

finding parallel-group, phase 2 trial of oral linaclotide acetate administered to patients with

chronic constipation”



Date: 5/1/07- 4/08 ($26,628)

Microbia, Inc. “A randomized, multi-center, double-blind, placebo controlled dose-range-finding

parallel-design, phase 2 trial of oral linaclotide acetate administered to patients with irritable

bowel syndrome with constipation”



Date: 7/30/07- 4/08 ($36,040)

Alizyme “A phase III, multicenter, open label, extension study to evaluate the long-term safety

of renzapride in women with constipation-predominant IBS”



Date: 5/1/06-6/30/08 ($43,704)

Prometheus Laboratories, Inc. for “Procurement of blood samples for use in the development of

a gastrointestinal disease test panel”



Date: 9/1/07- 8/08 ($ 35,950)

TAP Pharmaceuticals “Non-steroidal anti-inflammatory drug and aspirin utilization amongst US

primary care physicians: A follow-up survey”


Co-investigators: N Elnachef, JS Scheiman, AM Fendrick, CW Howden, MD

Date: 4/06-8/08 ($18,649)

Pharmos Corporation “A double-blind, randomized, placebo-controlled phase 2b study of 100,

200, and 300 mg BID Dextofisopam in female outpatients with irritable bowel syndrome”


Co-investigators: R Saad, MD D Brenner MD

Funding period: 9/1/07-3/31/09 ($54,759)

Bill & Melinda Gates Foundation “A clinical trial of H. pylori eradication in Latin America”

Principal Investigator: Laurence Baker, DO

Study Executive Officer &

Steering Committee: William D. Chey, MD

Funding period: 7/24/08 – 7/24/10 ($2,300,000 – 10% effort)


American College of Gastroenterology “Pilot study to determine the key characteristics which

aid in the diagnosis of constipated patients with dyssynergic defecation”

Principal Investigator: Monthira Maneerattanaporn, MD


Funding period: 7/1/10 – 6/30/11 ($10,000 – 0% effort)

American Gastroenterological Association “The differences in physiologic mechanisms

underlying chronic constipation in elderly versus younger adults with constipation”

Principal Investigator: Richard Saad, MD


Funding period: 7/1/08 – 6/30/11 ($225,000)

National Institutes of Health, “Development and Initial Validation of PROMIS GI Distress

Scale”

Principle Investigator: Dinesh Khanna, MD, MS and Brennan Spiegel MD, MSHS

External Consultant: William D. Chey, M.D.

Funding Period: 9/1/09 – 7/31/13 ($2,063,004 – 0% effort)

Coulter Translational Research Partnership Program, “Digital Manometry: A Disposable, Point-

of-Service Device to Diagnose Dyssynergic Defecation”

Principle Investigator

(Clinician): William D. Chey, M.D.


(Bio-Medical Engineer): James Ashton-Miller, Ph.D.

Funding Period: 7/1/2012-12/31/2013 ($99,734 – 5% effort)

Sponsor: Ironwood Pharmaceuticals

Title: “Development of My GI Health Consumer Portal”

PI Brennan Spiegel, MD

Co-investigators William D. Chey, MD, Roger Bolus, PhD

Funding Period 7/1/2013- 12/31/14 ($427,908, $87,052 to UM – 10% effort)


Title: “My GI Health Educational Assets V1.5”

PI William D. Chey, MD

Co-investigators Lawrence An MD, Lin Chang MD

Funding Period 7/1/2013- 6/30/14 ($242,620 – 0% effort)

Sponsor: VA Cooperative Studies Program #573

Title: “A Randomized Trial of Medical and Surgical Treatments for

Patients with GERD Symptoms that are Refractory to Proton Pump

Inhibitors”

Principal Investigator: Stuart Spechler MD

Executive Committee: William D. Chey MD, Donald Castell MD, Douglas Drossman

MD, Ronald Hinder MD

Funding Period: 1/2012 – 1/2015 ($11,066,620)


Sponsor: Coulter Translational Research Partnership Program

Title: “Digital Manometry: A Disposable, Point-of-Service Device to

Diagnose Functional Defecation Disorders: Year 2”


(Clinician): William D. Chey, MD


(Bio-Medical Engineer): James Ashton-Miller, Ph.D.


Sponsor: Michigan Initiative for Innovation & Entrepreneurship

Title: Digital Manometry: An inexpensive, disposable, point of service device to evaluate

human anorectal function

Principal Investigator: Jack Minor

Co-investigators: William D. Chey MD, Thomas Marten, James Ashton-Miller PhD


Sponsor: Michigan Nutrition & Obesity Research Center

Title: “Low FODMAP diet vs. standard dietary recommendations for

patients with irritable bowel syndrome with diarrhea (IBS-D): a

randomized, controlled trial and gastrointestinal microbiome

analysis”

Principle Investigator : Shanti Eswaran, M.D.

Project Mentor: William D. Chey, M.D.


Sponsor: Prometheus Laboratories, Inc.

Title: “Low FODMAP diet vs. standard dietary recommendations for

patients with irritable bowel syndrome with diarrhea (IBS-D): a

randomized, controlled trial and gastrointestinal microbiome

analysis”

Principle Investigator: Shanti Eswaran, M.D.



Sponsor: Rome Foundation

Title: “Rome IV Clinical Validation Study”


Co-investigators Olaf Paulsson MD, William Whitehead PhD

Funding Period 3/1/201- 9/15/15 ($165,000, $24.5K to UM, 2% effort)

Sponsor: Perrigo Company

Title: “Assessment of Gastroenterologists understanding of over-the-

counter GI medications”

Principle Investigator : William D. Chey, M.D

Co-investigators: Stacy Menees, MD, Amanda Guenter, MD.



Sponsor: Vibrant

Title: “A multinational, multicenter, prospective double-blind, sham

controlled, randomized study to assess the performance, efficacy and

safety of Vibrating Capsule medical device in aiding relieving

Constipated Individuals”


Co-investigators Shanti Eswaran MD, Richard Saad MD

Funding Period 2/1/2015- 1/31/16 ($83,786, 2.5% effort)

Sponsor: National Institutes of Health

Title: “Validation of GI PROMIS® Measures in Clinical Practice: A

Pragmatic Trial Using a Novel e-‐Platform”

PI Brennan Spiegel MD

Co-investigators William D. Chey, MD Dinesh Khanna, MD

Funding Period 7/1/13 -2/28/16 ($200,000, $50K to UM)


Title: “Development and validation of the Automated Evaluation of

Gastrointestinal Symptoms (AEGIS) Platform”

Principal Investigators: William D. Chey, MD & Brennan Spiegel, MD

Funding period: 7/1/11 – 10/31/16 ($1,920,170 total, $1,028,267 UM – 20% effort)


Title: “Creation and Validation of a Paired Survey Instrument to Study

the Quality of Patient-Physician Relationships in Irritable Bowel

Syndrome”


Co-investigators: Jacob Kurlander, MD, Douglas Drossman, MD

Funding period: 7/1/12 – 11/31/16 ($114,637 – 5% effort)

Sponsor: GI Health Foundation

Title: GSID Patient Journey Screening and Survey


Funding period: 12/1/16-6/1/17 ($17,100)

Sponsor: Ardelyx Pharmaceuticals

Title: “A 26-Week, Randomized, Double-Blind, Placebo-Controlled

Study to Evaluate the Efficacy and Safety of Tenapanor for the

Treatment of Constipation-Predominant Irritable Bowel Syndrome

(IBS-C)/TEN-01-302”


Funding period: 10/18/2016 - 9/30/2018 ($61,387)

Sponsor: MTRAC Title: “Digital Manometry: A disposable, point of service diagnostic

device for patients with fecal incontinence”



Co-investigators James Ashton-Miller, Ali Attari, Jason R. Baker

Funding Period 2/1/2016 - 4/31/17 ($104,802, 5% effort)

Sponsor: Rome Foundation.

Title: “Low FODMAP diet vs. psyllium for patients with fecal

incontinence and loose stools: a randomized, controlled trial”

Principle Investigator: Stacy Menees, M.D.



Sponsor: Nestle Health Sciences

Title: “My GI Health Virtual Dietician Platform”


Co-investigators Lawrence An MD, Brennan Spiegel MD

Funding Period 1/1/2014- 12/31/17 ($750,000, $450K to UM, 10% effort)

Sponsor: UM Fast Forward GI Innovation Fund

Title: “Development of an office-based, disposable rectal expulsion

device (RED) to screen for dyssynergic defecation in constipated

patients”


Co-investigators: Jason Baker, Eric Shah, MD

Funding period: 6/15/17-6/14/18 ($38,000)

Sponsor: Nestle Health Sciences

Title: “Creation of the My Nutrition Health Mobile App and a FODMAP

Food Frequency Questionnaire”


Co-investigators: Brennan Spiegel MD, Chris Almario MD

Funding period: 4/1/17-4/1/18 ($301,930)





Funding period: 1/1/17-1/1/18 ($50,000)


Title: “Probe-based Confocal Laser Endomicroscopy to Detect Structural and

Functional Duodenal Mucosal Abnormalities in Patients with Functional

Dyspepsia” Principal Investigator: Borko Nojkov, MD


Funding period: 1/1/17-1/1/18 ($50,000)


Patents

Digital Manometry: a finger-mountable sensor device

Serial Number: 13/714,728

International Application Number: PCT/US2012/069680

US Patent Application Filed 12/14/2012

Rectal Expulsion Device

Invention Report 6563

University of Michigan Office of Technology Transfer 2/9/15

Honors and Awards

1978-1981 Dean's List, University of Pennsylvania

1981 American Gastroenterological Association Student Research

Award for "The Effect of CCK on Calcium Flux in Gut

Smooth Muscle", WM Snape, Jr., MD, University of

Pennsylvania

1981-1982 Alpha Epsilon Delta Pre-Medical Honor Society

1986-1987 Commendation for "Outstanding Performance" During the

Internship Year

1994-1995 Glaxo Institute for Digestive Health Award for Clinical

Research

1995-1996 Glaxo Institute for Digestive Health Award for Clinical

Research

1995 Award for one of the top ten abstracts submitted to the

Department of Internal Medicine's Research Day, University

of Michigan Medical Center, April 29, 1995 for

"Hyperglycemia blunts the perception of electrical rectal

stimulation by effects on central processing of afferent

input."

1995 Travel Scholarship Award to the Third International

Symposium on Brain-Gut Interactions, Cambridge, UK

1996 Plenary Poster Session, Digestive Diseases Week, San

Francisco, CA for “Hyperglycemia blunts rectal afferent

transmission and increases rectal compliance in diabetic

patients: A possible model of diabetic constipation”

1998 President’s Plenary Poster, World Congress of

Gastroenterology, Vienna, Austria for “Validation of the 13C-

urea blood test for H. pylori infection: a US, multicenter

trial”

2002 Honored as one of the “Best Doctors in Detroit”, Hour

Detroit Magazine, September

2003 Selected to the Rome III Committees on Functional GI

Disorders –Design of Treatment Trials Committee and Bowel

Function Committee


2003 Award for “Excellence in Teaching” from 2003 University of

Michigan GI fellowship class

2003 Michigan Chapter American College of Physicians –

“Governor’s Award” for service to the MI Chapter

2004 Rewarded for teaching excellence – Department of Internal

Medicine, University of Michigan Internal Medicine

Residency Program

2005 Award for “Excellence in Mentorship” from 2005 University

of Michigan GI fellowship class

2006 Named as one of “America’s Top Physicians”

2007 Marquis Who’s Who in America 2007-

2007 “Metro Detroit’s Best Doctors” Hour Detroit Magazine,

October

2007 ACG/Novartis Motility Award for “Prevalence and impact of

co-morbid psychological distress on response to PPI therapy

in patients with GERD”, Annual Meeting of the American

College of Gastroenterology October, 2007

2009 ACG/Salix Leadership Training Award – “Leadership

Reflections and Insights” Harvard Business School, July 5-9,

2010

2010-3 Selected Co-editor-in-chief: American Journal of

Gastroenterology

2010 “75 Best Gastroenterologists in America” Becker’s ASC

Review (http://www.beckersasc.com/gastroenterology-and-

endoscopy/75-of-the-best-gastroenterologists-in-

america.html)

2012 “125 Best Gastroenterologists in America” Becker’s ASC

Review

2012, 2013 Top 1% of US Gastroenterologists, US News and World

Report (http://health.usnews.com/top-

doctors/search?doctor=chey&specialist=Gastroenterologists

&doctor_gender=&location=Ann+Arbor%2C+MI&distance

=25&hospital=Hospital+Name&x=55&y=14)

2012 “Top Docs” in Metro Detroit, Hour Detroit Magazine

2013-6 Reappointed Co-editor-in-chief: American Journal of

Gastroenterology

2014 Academiae Laureati Medici Clinical Excellence Society,

Department of Internal Medicine, UMHS

2014 Dean’s Award for “Outstanding Clinician”, UMHS

2014 “160 Gastroenterologists to Know” Becker’s ASC Review

(http://www.beckersasc.com/160-gastroenterologists-to-

know-2014/160-gastroenterologists-to-know-2014.html)

2014 League of Research Excellence, University of Michigan

Medical School

2015 Selected as inaugural Timothy T. Nostrant Collegiate

Professor of Gastroenterology

http://health.usnews.com/top-doctors/search?doctor=chey&specialist=Gastroenterologists&doctor_gender=&location=Ann+Arbor%2C+MI&distance=25&hospital=Hospital+Name&x=55&y=14




http://www.beckersasc.com/160-gastroenterologists-to-know-2014/160-gastroenterologists-to-know-2014.html

http://www.beckersasc.com/160-gastroenterologists-to-know-2014/160-gastroenterologists-to-know-2014.html


2015-18 Elected President-elect (2015-16), President (2016-18),

Clinical Excellence Society, Department of Internal

Medicine, UMHS.

2015 League of Clinical Excellence, University of Michigan

Medical School

2015 Distinguished Clinician Award, American

Gastroenterological Association

2015 “190 Gastroenterologists to Know” Becker’s ASC Review

(http://www.beckersasc.com/lists/190-gastroenterologists-to-

know-2015.html)

2016 Alfred Hospital WTMS Visiting Professor Scholarship,

Monash University, Melbourne, Australia, July 2016.

2016 Selected “Fulbright Specialist Roster”, Fullbright US Scholar

Program, Washington, DC.

2016 “Healio Gastroenterology 200” Leading innovators in GI &

Hepatology, Healio Gastroenterology, September 2016

2016, 2017 “Top Docs” in Metro Detroit, Hour Detroit Magazine

2010-2019 “America’s Top Doctors” Castle Connolly

2001-2019 “Best Doctors in America”, Best Doctors, Inc, Aiken, SC

2019 “Healio 200” leaders and innovators in Gastroenterology,

Healio Gastroenterology, May 2019.

2019 Dean’s Award for Innovation & Commercialization,

University of Michigan Medical School

2019 “Clinical Innovation Disruptor Award”, Healio

Gastroenterology, October 2019.

Memberships in Professional Societies

American Gastroenterological Association (AGA)

Fellow – American Gastroenterological Association (5/1/06)

American College of Physicians (ACP)

Fellow – American College of Physicians (7/1/99)

Council Member for the Michigan Chapter – ACP (2002-3)

American College of Gastroenterology (ACG)

Fellow - American College of Gastroenterology (6/98)

American Society of Gastrointestinal Endoscopy (ASGE), 1993-present

Bockus International Society of Gastroenterology (inducted 2004)

Central Society for Clinical Research, 1993-present

Crohns and Colitis Foundation of America, 1998-2008

Detroit GI Society

Secretary (1999)

President Elect (2000)

President (2001)

International Foundation of Functional Gastrointestinal Disorders, 1993-present

Michigan Gut Peptide Center, 1993-present

http://www.beckersasc.com/lists/190-gastroenterologists-to-know-2015.html

http://www.beckersasc.com/lists/190-gastroenterologists-to-know-2015.html


Rome Foundation, 2004-present

Fellow (2013)

Southwest Oncology Group: A National Clinical Research Group, 2008-present

Editorial Positions, Boards, and Peer-Review Service

Journals Refereed: Alimentary Pharmacology & Therapeutics, 1994-present

American Journal of Gastroenterology, 1994-present

American Journal of Physiology, 1994-2000

Annals of Internal Medicine – recognized as a “best

reviewer” (top 30% of reviewers) - 2008

Archives of Internal Medicine, 1996-present

BMJ, 2018

Clinical Gastroenterology and Hepatology, 2000-present

Gastroenterology, 1994-present

Gut, 2000-present

Helicobacter, 1996-present

Journal of Clinical Gastroenterology, 1999

Journal of Neurogastroenterology & Motility, 2014-present

Lancet, 2017-present

Neurogastroenterology & Motility, 2010-present

New England Journal of Medicine, 2017

World Journal of Gastroenterology, 2000

Editorial Boards American Journal of Gastroenterology, 2004-present

Clinical Endoscopy, 2011-2016

Clinical Gastroenterology and Hepatology, 2007-10

Digestive Health Matters, 2003-present

Gastroenterology - Selected Summaries Staff, 2008-2011

Gastroenterology & Hepatology, 2005-present, Section

Editor 2016-present

Healio Gastroenterology, 2016-present

Journal of Clinical Gastroenterology, Associate Editor,

2017-present

Journal of Medicine, 2008-2012

Journal of Neurogastroenterology & Motility, Associate

Editor, 2014-present

Participate (International Foundation of Functional GI

Disorders), 2000-3

Prevention Magazine, Medical Review Board, 2019-present

Primary Care Special Edition, 2006-8

World Journal of Gastroenterology, 2007-11

Co-Editor in Chief American Journal of Gastroenterology 2010-2015

Clinical & Translational Gastroenterology 2010-2014


Editor in Chief Current Treatment Options in Gastroenterology 2020-present

Study Section Reviews Data and Safety Monitoring Board for the NIH study,

“Antidepressant therapy for Functional Dyspepsia” Primary

Investigator: Nicholas Talley, MD, 2006-13

Planning Committee for Veteran’s Administration

Cooperative Study #573: “A randomized trial of medical and

surgical treatments for patients with GERD symptoms that

are refractory to PPIs”. Principal Investigator: Stuart

Spechler, MD, 2008-2017

Critical Path Institute Patient-reported Outcomes

Consortium: IBS Working Group Advisory Board Member,

Stephen Coons PhD, Director PRO consortium, 2010-present

Critical Path Institute Patient Reported Outcomes

Consortium: Defining the symptoms of Functional

Dyspepsia, Patrick Marquis, MD, MBA, Adelphia Values,

2012-2014

Teaching

Housestaff Training

Rounding activities:

3rd and 4th year medical students and medical residents teaching during GI inpatient

service or GI consult service rounds 6-8 weeks/year, 1993-present

Clinic activities:

4th year medical student, medical resident, and/or GI fellow teaching 1.25 day/week

in GI and IBS clinics, 1993-present, IBS clinic and Michigan Bowel Control Clinic

one day per month, 2004-present

Endoscopy activity:

o GI fellow teaching 1 day/week, 1993-present

o Therapeutic ERCP teaching 0.5 day/ week 1993-2005

Other Teaching/Media Activities

Spokesperson for the American College of Gastroenterology, American Gastroenterological

Association and Division of Gastroenterology/Department of Public Relations at the University

of Michigan Health System (numerous radio, television, and print media interviews incl. Esquire,

Family Circle, Ladies Home Journal, Men’s Health, NY Times, Prevention, Self, USA Today,

US News and World Report), 1995-present.

Featured expert for the Michigan Minute on the “Irritable Bowel Syndrome” 4/2007.


“Peptic ulcer disease” section for Online Teaching Resource Recent Advances in

Gastroenterology, Temple University 2007.

Featured expert for the Michigan Health Minute on “Gastroesophageal Reflux Disease” 11/2006.

Editor – The Gastroenterology Fellow: Selected Reports from the 69th Annual Scientific Meeting

of the American College of Gastroenterology. Spring 2005.

Participant in the REDUCE campaign of the AGA on NSAID-related GI disease 12/03.

Featured expert for the Michigan Health Minute on the “Irritable Bowel Syndrome” 11/2003.

Expert Commentator for Acid Related Disorders: A Medscape Special Report,

www.medscape.com, 2003.

Faculty contributor to Irritable Bowel Syndrome: A comprehensive approach to effective

management, Medcases, http://www.ibscases.com/product/MedCasesFrame.asp, 2003.

Motility and Irritable Bowel Syndrome, Clinical Advances in Gastroenterology tape series for

the American College of Gastroenterology Vol 14, number 1, September 2002.

Morning report for senior internal medicine residents (1998-present).

Senior medical student Clinical Counselor (1997-present).

Author of the “Treatment section” of the H. pylori Foundation Web Page (1998-2000;

www.helico.com).

Expert for the “Discussions section” of the H. pylori Foundation Web Page (1995-2000).

Expert for the “H. pylori forum”, Physician’s Online, 1997.

Program Chair: National Advisory Council on continuing medical education for H. pylori

sponsored by Abbott Pharmaceuticals, 1995.

Contributor of questions to American Board of Internal Medicine recertification examination in

Internal Medicine. Submitted January 1993 and September 1995.

Clinical conference preceptor 1-2 times/year, 1993-present.

Journal club presenter 1-2 times/year, 1993-present.

Fellow orientation lectures in Gastrointestinal Physiology, 1993-present.

Lectures in Gastrointestinal Physiology for fellows visiting the GI Physiology Laboratory, 1993-

present.

Internal Medicine Resident's noon conference, once/year, 1994-present

Committee, Organizational, and Volunteer Service

Institutional

1993- University of Michigan Medical Procedures Unit

Interdisciplinary Committee

1995- University of Michigan, Division of Gastroenterology,

Fellow Evaluation Committee

1996- Outpatient Follow-up Restructuring Committee, University

of Michigan Medical Center

1996- Clinical Operations Committee, Division of

Gastroenterology, University of Michigan Medical Center

1997- Clinical Research Committee, Division of Gastroenterology,

University of Michigan Medical Center

http://www.medscape.com/

http://www.ibscases.com/product/MedCasesFrame.asp


2014- Clinical Excellence Society, Department of Internal

Medicine, University of Michigan Health System

President-elect 2015-2016

President 2016-2018

National

AMERICAN COLLEGE OF GASTROENTEROLOGY

Board of Trustees (2010-21)

ACG Institute, Board of Directors (2014-15)

ABIM recertification Committee (2004-7)

Educational Affairs Committee (2001-4)

ACG Annual Scientific Meeting Committee 2003, 2004

Practice Parameter Committee 2004-7, 2010-15

Sub-chair: Upper Gut Section (2004-5)

Chair: Upper Gut Section (2005-7)

Liaison to the Board of Trustees (2012-15)

Course Co-director: ACG Midwest Regional Postgraduate Course in Gastroenterology,

Chicago, IL, June 2007.

IBS Task Force (2007-9, 2017)

Research Committee (2007-9)

Publications Committee (2010-15)

Public Relations Committee liaison (2016-2018)

Communications Council (2013-2015)

ACG H. pylori Clinical Management Guideline (2015-2017)

Co-Chair, Alternative Certification Bodies, MOC Review (2017)

Co-Chair, ACG Functional GI Health and Nutrition Circle (2018)

Course Co-director: ACG Pharmacology Course, Philadelphia, PA, October 2018

Co-Chair, Task Force to revise online IBS screener and treatment matrix

ACG IBS Clinical Management Guideline (2018-2019)

Course Co-director: ACG Pharmacology Course, San Antonio, TX, October 2019

Course Co-director: ACG FBD School, 2019-present

AMERICAN GASTROENTEROLOGICAL ASSOCIATION:

AGA Council (2004-2008)

AGA Media Spokesperson (2004-2010)

Clinical Practice Section (1993- present)

Elected: Nominating Committee - Clinical Practice Section (1995-2000)

Committee Chairman - Clinical Practice Section (1996-8)

Outcomes research section abstract committee for Digestive Diseases Week

(1997)

GERD treatment abstract selection committee (2001)

DDW Program Development Committee (2000, 2001, 2002)

Committee Chairman - Clinical Practice Section (2003-4)

Elected: Vice Chair – Clinical Practice Section (2004-2006)


Chair – Clinical Practice Section (2006-8)

EGD Section (1997-present)

H. pylori diagnosis abstract selection committee for DDW (1998-2001),

Committee Chairman (1999, 2000)

H. pylori resistance abstract selection committee for DDW (2002, 2003)

Nominating Committee (2001-3)

Section on GI Motility and Nerve-Gut Interactions (1993- present)

IBS pharmacotherapy abstract selection committee for DDW (2002, 2005-8,

2010)

Nonulcer dyspepsia: Pathogenesis abstract selection committee for DDW (2003)

Scientific Advisory Board: Digestive Health Initiative Functional GI

Disorders Campaign (1998-9)

Online Member Survey Panel (2001-2)

Foundation for Digestive Health and Nutrition

Public Health Education Steering Committee (2001-4)

Scientific Advisory Board: Irritable Bowel Syndrome Educational Campaign (2004-5)

Course Co-director. Clinical Congress in Gastroenterology. Fort Lauderdale, FL,

December 9-11, 2005

Course Co-director. Clinical Congress in Gastroenterology and Hepatology. Las Vegas,

NV, January 23-25, 2009

Course Co-director. Freston Conference – “Food at the intersection of gut health and

disease”. Chicago, IL, August, 2019

AMERICAN NEUROGASTROENTEROLOGY & MOTILITY SOCIETY

ANMS Council (2016- )

Site Director: Clinical Training Program for GI Fellows & Jr Faculty (2007- )

Educational Affairs Committee (2015-6)

Meetings Committee (2017- )

AMERICAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY:

Informatics Committee (2001-3)

FUNTIONAL BRAIN GUT RESEARCH GROUP

Elected to FBG council (2003-5)

Co-chair: 4th Annual Young Investigator’s Conference (March 31, 2006)

Chair: 5th Annual Young Investigator’s Conference (March 23, 2007)

Chair: Awards Committee (2007-10)

INTERNATIONAL FOUNDATION FOR FUNCTIONAL GI DISORDERS

Scientific Advisor (2017-present)

Advisory Board (2005-present)

Planning Committee – International Symposium on FGIDs (2001- 2012)

ROME FOUNDATION FOR FUNCTIONAL GI DISORDERS

Section on Clinical Trial Design for Rome III consensus guidelines (2004-6)

Section of Bowel Disorders for Rome III consensus guidelines (2004-6)


Rome III slide set Committees

Chair: Management and design of treatment trials (2006-7)

Outcomes/Endpoints in Clinical Trials on FBDs Working Team (2007-8)

Board of Directors (2010-2022)

Strategic Planning Committee (2010)

Rome IV Editorial Board (2011-6)

Chair, Rome IV Launch Committee, Chair (2015-present)

Multi-dimensional Clinical Profile Committee (2011-16)

Section of Bowel Disorders for Rome IV consensus guidelines (2013-16)

Co-chair, Working Group on the role of food in FGIDs (2012-3)

Co-chair, Visiting Professor & Visiting Lecturer Program (2015-2018)

Co-chair, Membership & Rome Fellows Committee (2014-2019)

Rome Foundation Research Institute, Co-director, Clinical Research Core (2018- )

Executive Advisory Board: Functional Bowel and Motility Disorders Center, University of North

Carolina at Chapel Hill, 2013-2016

Consulting Positions Consultant

Allergan

Biomerica

Ironwood

IM Health

Nestle

Outpost

Prometheus

Scientific Advisory Board 2016-present

QoL Medical

Ritter

Salix Pharmaceuticals

Takeda Pharmaceutical

Selected Visiting Professorships, Seminars, and Extramural Invited

Presentations

Visiting Professorships

1. “Diagnostic strategies for H. pylori infection”, “The pathogenesis and management of

nonulcer dyspepsia”, Visiting Professor, Hanoi Medical College, Bach Mai Hospital,

Hanoi, Vietnam, November 12, 1997.

2. “Techniques to study brain-gut interactions”, Visiting Professor – Northwestern University,

Chicago, IL, January 27, 2000.

3. “Brain-Gut Interactions: What we know and how we know it” Visiting Professor –

University of North Carolina, Chapel Hill, NC, February 22, 2000.

4. “New insights into the Irritable Bowel Syndrome”, Visiting Professor – Bethesda Naval

Hospital, June 14, 2001.


5. “Dyspepsia: A Discussion of Bugs and Drugs”, GI Grand Rounds and Visiting Professor –

University of Alabama – Birmingham, September 6, 2001.

6. “Management of H. pylori infection”, Visiting Professor University of Arizona, Tuscon,

AZ. April 4, 2002.

7. “Appropriate diagnosis and treatment of H. pylori infection”, Visiting Professor, University

of Arizona Medical Center, Tucson, AZ, January 30-31, 2003.

8. “Update on the management of IBS”, Visiting Professor, University of Kansas Medical

Center, Kansas City, Kansas, April 22, 2003.

9. “Update on IBS”, Visiting Professor, Wake Forest Medical Center, Winston-Salem, NC,

June 6, 2003.

10. “The diagnosis and treatment of IBS: What does the evidence say?” Visiting Professor,

USC Medical Center, Los Angeles, CA, July 18, 2003.

11. “Update on the management of IBS”, GI Grand Rounds and Visiting Professor, Yale

University, New Haven, CT, September 9, 2003.

12. “NSAIDs and the GI tract”, Emerging Diagnostic and Therapeutic Options in GI Disorders:

An Update, Visiting Professor, Wake Forest University School of Medicine, Winston-

Salem, NC, September 27, 2003.

13. “Irritable Bowel Syndrome: Emerging concepts and promising therapies”, Visiting

Professor – Henry Ford Health System, Detroit, MI, May 13, 2004.

14. “Irritable Bowel Syndrome: Emerging concepts and promising therapies” Visiting

Professor - Bethesda Naval Hospital, Bethesda, MD, June 3, 2004.

15. “Emerging therapies for functional dyspepsia”, Visiting Professor - Bayview Medical

Center, Johns Hopkins University, Baltimore, MD, June 4, 2004.

16. “Evidence-based update on the irritable bowel syndrome”, Visiting Professor – Emory

University School of Medicine, Atlanta, GA, June 28, 2004.

17. “Management of functional dyspepsia” GI Grand Rounds and “Evidence-based update on

the irritable bowel syndrome” Internal Medicine Grand Rounds, Visiting Professor,

University of Cincinnati, Cincinnati, OH, March 23, 2005.

18. “New insights into the evaluation and treatment of functional dyspepsia”, Visiting

Professor – Division of Gastroenterology, University of Illinois, Chicago, IL, April 27,

2005.

19. “An evidence-based update on the management of chronic constipation”, Visiting Professor

– Division of Gastroenterology, University of Indiana, Indianapolis, IN, May 9, 2005.

20. “Management of Functional Dyspepsia”, Visiting Professor – Division of

Gastroenterology, University of Oklahoma, Oklahoma City, OK, June 8, 2005.

21. “GERD, Erosive Esophagitis, and NERD: the same or different diseases?” and Visiting

Professor – Division of Gastroenterology, State University of New York at Buffalo,

Buffalo, NY, June 23, 2005.

22. “Heartburn in 2005: Do findings at endoscopy really matter?” and Visiting Professor –

Division of Gastroenterology, McMaster University, Hamilton, Ontario, September 21,

2005.

23. “Update on dyspepsia and functional dyspepsia” and Visiting Professor – Division of

Gastroenterology, University of Alberta, Edmonton, Alberta, October 11, 2005.

24. “GERD, NERD and functional heartburn: Separate diseases or shades of gray?” and

Visiting Professor – Division of Gastroenterology, University of Calgary, Calgary, October

12, 2005.


25. “Management of GERD for primary care physicians”, “The irritable bowel syndrome in

2006”, “Evidence based update on the management of Functional Dyspepsia”, Pinit

Kullavanijaya Visiting Professor, Chulalongkorn University, Bangkok, Thailand, March

13-15, 2006.

26. “IBS: How new insights into pathogenesis are transforming treatment paradigms”, Visiting

Professor, Baylor Hospital, Dallas, TX, March 28, 2006.

27. “Evidence based update on the diagnosis and treatment of the irritable bowel syndrome”,

Visiting Professor, Metro Health Center, Cleveland, OH, April 20, 2006.

28. “The evolving management of functional dyspepsia”, Visiting Professor, Functional

Frontiers Conference – Case Western Reserve, Cleveland, OH, April 20, 2006.

29. “Management of chronic constipation in 2006” Visiting Professor, Cleveland Clinic

Foundation, Cleveland, OH, April 21, 2006.

30. “IBS: where we are and where we are going” Visiting Professor, Emory University School

of Medicine, Atlanta, GA, May 14, 2007.

31. “IBS: what’s new in 2007” Visiting Professor, University of Colorado, Denver, CO, June

1, 2007.

32. “Management of IBS in 2008” Visiting Professor, University of Rochester, NY, August 11-

12, 2008.

33. “GERD: New concepts and clinical practice” Gastroenterology Society of Taiwan, Taipei,

Taiwan, March 15, 2009.

34. “Benefits and Harms of Acid Suppressive Therapy” Visiting Professor, Kaoshiung Medical

University Hospital, Kaoshiung, Taiwan, March 16, 2009.

35. “Management of H. pylori infection in 2009” Visiting Professor, Medical University of

South Carolina, Charleston, SC, June 22, 2009.

36. “Medical management of the Irritable Bowel Syndrome” Visiting Professor, Cleveland

Clinic Foundation, Cleveland, OH, June 26, 2009.

37. “Evidence-based management of Chronic Constipation” Visiting Professor, Vanderbilt

University Medical Center – Division of Gastroenterology, Nashville, TN, September 24,

2009.

38. “Diagnosis of IBS: Evolution of a work in progress” Visiting Professor, UCLA Medical

Center – Division of Gastroenterology, Los Angeles, CA, October 15-16, 2009.

39. “Management of chronic constipation in 2009 and beyond” Visiting Professor, Medical

College of Georgia, Athens, GA, November 18, 2009.

40. “Management of ERD and NERD, are they different?”, “Overlap between GERD and

IBS” and “Management of Barrett’s Esophagus” Visiting Professor, Chulalongkorn

University, Bangkok, Thailand, May 28-29, 2010.

41. “Peering into the crystal ball at the future of IBS” Visiting Scholars Program, Takeda

Pharmaceuticals Headquarters, Chicago, IL, September 22, 2010.

42. “Erosive vs. Nonerosive GERD: The many faces of heartburn” Visiting Professor, Taipei

Mackay Memorial University Hospital, Taipei, Taiwan, October 1, 2010.

43. “The benefits and risks of long-term PPI therapy” Visiting Professor, Chang Gung

Memorial University Hospital, Linkou, Taiwan, October 2, 2010.

44. “Deciding who and who should not be treated with PPI therapy” Visiting Professor, Taipei

Veterans General Hospital, Taipei, Taiwan, October 4, 2010.

45. “IBS in 2010 and beyond” Visiting Professor, Northwestern University, Chicago, IL,

November 4, 2010.


46. “Food – the Forgotten Factor in IBS”, First Annual Lawrence Brandt Lecture, Montefoire

Medical Center, Bronx, NY, April 14, 2011.

47. “Dyssynergic Defecation: An underappreciated cause of chronic constipation”, Visiting

Professor, Montefoire Medical Center, Bronx, NY, April 14, 2011.

48. “Role of the Gut Microbiome and SIBO in IBS” Visiting Professor, Chinese PLA General

Hospital, Beijing, China, May 16, 2011.

49. “Emerging treatment strategies for IBS”, Hugh Butt Visiting Professor, Mayo Clinic,

Rochester, MN, October 7, 2011.

50. “Emerging medical therapies for the irritable bowel syndrome” Keio University Medical

School, Tokyo, Japan, November 11, 2011

51. “Diet and IBS: Food for thought…” and “Evidence-based management of irritable bowel

syndrome” H. Joyce Miller Visiting Professor, University of Iowa, Iowa City, IA, March 8,

2012.

52. “Food: the forgotten factor in IBS” Visiting Professor, University of Washington, Seattle,

WA, May 31-June 1, 2012.

53. “Emerging role of food in the management of the Irritable Bowel Syndrome” Visiting

Professor, Indiana University, Indianapolis, IN, August 27, 2012.

54. “The emerging role of the gut microbiome in the pathogenesis and treatment of IBS”

Visiting Professor, Medical GI Grand Rounds. Mayo Clinic, Scottsdale, AZ, March 15,

2013.

55. “Dietary management of IBS: Food for thought” and “Medical Management of IBS”

Visiting Professor, Baylor Medical College, Dallas, TX, April 8, 2014.

56. “Translating pathophysiologic insights to actionable management strategies for IBS”

Sundar Mehta Visiting Professor, University of Colorado, Denver, CO, April 24-25, 2014.

57. “Diet, Bugs, and Drugs: The evolving management of IBS” Visiting Professor, University

of Minnesota, Minneapolis, MN, August 14, 2014.

58. “The emerging role of diet in the pathogenesis and treatment of IBS” Visiting Professor,

University of Kentucky, Lexington, KY, April 23-24, 2015.

59. “The role of the gut microbiome in the pathogenesis and treatment of IBS” David M. Bull

Visiting Professor: Wayne State University, Detroit, MI, June 1, 2015.

60. “Diet or Deity – Is the Juice Worth the Squeeze for IBS?” and “How Health Information

Technology will Change Clinical Medicine”, ACG Visiting Professor, McMaster

University, Hamilton, Canada, June 24-25, 2015.

61. “Diet and IBS: Food for Thought” “Management of IBS in 2015”. Rome Foundation

Visiting Professor, Cleveland Clinic, Cleveland, OH, September 10-11, 2015.

62. “Food – at the intersection of health and disease” Rome Foundation Visiting Professor,

Brown University, November 12, 2015.

63. “The emerging role of food in the pathogenesis and treatment of IBS”. CAG Visiting

Professor, Division of Gastroenterology, University of Calgary, Calgary, Canada, January

15, 2016.

64. “Food: at the intersection of disease and wellness” and “Update on the management of

IBS” Advocate Lutheran General Health System, Park Ridge, IL, March 23, 2016.

65. “The emerging role of diet and lifestyle in the pathogenesis and treatment of IBS” Division

of Gastroenterology, Thomas Jefferson Medical Center, Philadelphia, PA, April 20, 2016.

66. “How diet is changing the treatment paradigm for Irritable Bowel Syndrome”. University

of Wisconsin, Madison, WI, June 7, 2016.


67. “Management of Irritable Bowel Syndrome”, “How health information technology will

transform Gastroenterology”, “Diagnosis of IBS in the Rome IV era”, “The University of

Michigan experience with the low FODAMP diet for IBS” Alfred Hospital WTMS Visiting

Professor, Monash University, Melbourne, Australia, July 11-22, 2016.

68. “Food as Medicine: The changing face of GI Nutrition” Rome Foundation Visiting

Professor: University of Alabama Birmingham, Birmingham, AL, September 26, 2016.

69. “Food: at the intersection of wellness and GI disease” Visiting Professor: University of

Southern Alabama, Mobile, AL, September 28-29, 2016.

70. “The Emerging Role of Diet in the Pathogenesis and Management of IBS”, “Case

presentations of patients with persistent H. pylori infection”, Rome Foundation Visiting

Professor, Mayo Clinic, Jacksonville, FLA, January 6, 2017.

71. “Food – the main course to digestive health and disease”, “Update on the management of

H. pylori infection”, Rome Foundation Visiting Professor, Medical College of Georgia,

Augusta, GA, April 17, 2017.

72. “How do we apply Rome IV in everyday practice?”, When should we stop studying a

patient with IBS Utility of biomarker in IBS”, “State of the Art: Management of IBS”,

“Interactive Clinical Case: Panel Discussion”. Auditorio Universidad Catolica Argentina,

Puerto Madero, Argentina, April 20-21, 2017.

73. “The role of diet and nutrition in the pathogenesis and treatment of IBS”, Visiting

Professor, St Louis University Medical Center, St. Louis, MO, September 8, 2017.

74. “Role of diet in the pathogenesis and treatment of IBS” Visiting Professor, University of

Virginia, Charlottesville, April 6, 2018.

75. “Food for life – the role of diet in IBS” Visiting Professor, Division of Gastroenterology &

Hepatology, Weill Cornell Medical Center, New York, NY, May 24, 2018.

76. “The evidence supporting diet therapies for IBS” Visiting Professor, Cook County Health

and Hospitals System, Chicago, IL, June 15, 2018.

77. “Food – at the crossroads of GI wellness and illness” Visiting Professor, Mayo Clinic,

Scottsdale, AZ, November 15, 2018.

78. “Nonpharmacological therapies for IBS” Visiting Professor, Brook Army Medical Center,

San Antonio, TX, April 5, 2019.

79. “Integrative care model for IBS” Visiting Professor, University of Washington, Seattle,

WA, April 12, 2019.

80. “Holistic management of IBS” Kirkendall Visiting Professor, University of Texas Houston,

Houston, TX, April 18, 2019.

81. “Management of IBS: Thinking Outside of the Colon” Visiting Professor, Tulane

University, New Orleans, LA, May 8, 2019.

82. “Management of IBS: Thinking Outside of the Colon” ACG Edgar Achkar Visiting

Professor, University of Colorado, Denver, CO, June 7, 2019.

83. “Embracing Change: The key to a long, happy career in gastroenterology” Fellows

Graduation Ceremony, Loyola University Medical Center, Chicago, IL, June 14, 2019.

84. “Small intestinal bacterial overgrowth”, “Exclusion diets for IBS”, “Patient-centered

approach to IBS” Visiting Professor, University of Newcastle, Newcastle, AU, July 24-26,

2019.

85. Visiting Professor, Friendship Hospital, Beijing, China, November 5, 2019.

86. Visiting Professor, University of Arizona, Tucson, AZ, March 5-6, 2020.

87. Robert Fischer Visiting Professor, Temple University, Philadelphia, PA, March 11, 2020.


Selected Extramural Invited Presentations

1. “Management of the Irritable Bowel Syndrome” and “Review of Celiac Sprue” The Third

Annual GI and Hepatology Update, University of Pennsylvania, Philadelphia, PA.

September 20, 2001.

2. “Expressions of IBS: Psychosocial, visceral and other symptoms” Strategies in the

treatment of IBS: From models to management. Annual Meeting of the American College

of Gastroenterology, Las Vegas, NV. October 19, 2001.

3. “Non-erosive esophageal disorders: Acid reflux or altered visceral perception” Symposium

on esophageal sensation. Satellite Meeting at the Annual Meeting of the American College

of Gastroenterology, Las Vegas, NV. October 22, 2001.

4. “Ignore H. pylori status: treat with a PPI or other therapies” Weighing the Odds in Acid-

related Disorders. Satellite Meeting at the Annual Meeting of the American College of

Gastroenterology, Las Vegas, NV. October 23, 2001.

5. “Diagnosis of H. pylori infection” and “Management of Dyspepsia” GI Update, University

of Cincinnati, Cincinnati, OH. November 9, 2001.

6. “Strategies to reduce the impact of NSAID-induced GI toxicity” American Society of

Hospital Pharmacists Mid-year Clinical Meeting, New Orleans, LA December 5, 2001.

7. Planning committee for State Medical Society Meetings “Update on GERD and

Dyspepsia” Beam Institute for Continuing Medical Education, New York, NY, 2002.

8. “GI Wrap-up 2001” Participant and Course Co-director, Captiva Island, FLA, February 8-

10, 2002.

9. “Diagnosis of H. pylori: State of the Art Talk”, GI Grand Rounds, Henry Ford Health

System, March19, 2002.

10. “Strategies to reduce GI toxicity associated with NSAIDs and Aspirin”, Division of

Rheumatology, University of Arizona, Tucson, AZ, April 5, 2002.

11. “Endoscopy-negative reflux disease is a functional disorder and should be treated

appropriately” Satellite symposium at Digestive Diseases Week, San Francisco, CA, May

19, 2002.

12. “Meet the Professor – PUD” Digestive Diseases Week, San Francisco, CA, May 20, 2002.

13. Moderator, AGA clinical topic forum: “Management of the Irritable Bowel Syndrome”

Digestive Diseases Week, San Francisco, CA, May 22, 2002.

14. “Strategies to reduce ‘Coxicity’ associated with NSAIDs and Aspirin”, Medical Grand

Rounds, University of California - Davis, Sacramento, CA, May 23, 2002.

15. “Non-erosive esophageal disorders”, “NSAID-related mucosal injury”, “Current diagnosis

of H. pylori” Update on Esophageal, Gastric and Swallowing Disorders for Primary Care.

Orlando Regional Medical Center/University of South Florida, Orlando, CA, June 8, 2002.

16. Participant and Course Co-director for Update in Office Gastroenterology, Grand

Traverse Resort, MI, August 18-21, 2002.

17. “Motility and IBS” Clinical Advances in Gastroenterology (Audio Tape series of the

American College of Gastroenterology), August 2002.

18. Participant and Course Co-director for the Annual American College of Physicians -

Michigan Chapter Scientific Meeting, Acme, MI, September 12-15, 2002.

19. “Management strategies for NSAID-associated peptic ulcer disease” Castle Medical

Center, Honolulu, HI, September 26, 2002.


20. “Management of H. pylori infection” and “Controversies on COXicity” Gastroenterology

Update, Queen’s Medical Center, Honolulu, HI, September 27-28, 2002.

21. Faculty participant “International clinical forum in gastroenterology and hepatology”

Heidelberg, Germany, October 14, 2002.

22. “Current treatments of IBS and constipation” Clinical Case Challenges in Irritable Bowel

Syndrome, Satellite symposium at the Meeting of the American College of

Gastroenterology, Seattle, WA, October 22, 2002.

23. “Beyond fiber – where will IBS go in the next 10 years” Meeting of the American College

of Gastroenterology, Seattle, WA, October 23, 2002.

24. Program Co-director – “Insights and Issues in the Management of Functional GI

Disorders”, UM sponsored CME lecture series from October 26 to December 7, 2002.

25. “The long-term management of GERD: PPIs vs. Endoscopic therapies vs. Surgery” Pri-

Med South, Broward County Convention Center, Ft. Lauderdale, Fla, February 14, 2003.

26. Course Director and Moderator for “First Annual Evening with the Experts 2003: New

Frontiers in GERD: Are the new diagnostic tests and endoscopic therapies ready for prime

time?” sponsored by the University of Michigan Medical School, Dearborn, MI, February

17, 2003.

27. “GI/Liver Wrap-up 2002” Participant and Course Co-director, Naples, FLA, February 28-

March 2, 2003.

28. “Case studies and diagnostic strategies – upper GI” and planning committee: 5th

International Symposium on Functional GI Disorders, Milwaukee, MI, April 4-6, 2003.

29. “IBS: Evidence-based approach to treatment” AGA Spring Postgraduate Course, Orlando,

FL, May 18, 2003.

30. “What is our current understanding of the pathophysiology of IBS” Program chair and

speaker at the Satellite symposium “Translating science into clinical outcomes: New

paradigms in the management of the IBS patient” at Digestive Diseases Week, Orlando,

May 18, 2003.

31. “Kill the Bug” in the Clinical Symposium “Dyspepsia management: Bugs, Drugs, or

Padded Cells” Digestive Diseases Week, Orlando, FL, May 20, 2003.

32. Moderator, AGA clinical topic forum: “Controversies in H. pylori” Digestive Diseases

Week, Orlando, FL, May 21, 2003.

33. “Management of Dyspepsia and NUD: the US Perspective” Transatlantic Dialogue:

Dichotomies and directions in acid-related disorders, Orlando, FL, May 22-23, 2003.

34. “NSAID related GI toxicity: Does an aspirin a day keep the doctor away?” University of

Colorado Medical Center, Denver, CO, July 17, 2003.

35. “NSAID-induced gastropathy” Florida Academy of Family Physicians, Orlando, FL, July

27, 2003.

36. “H. pylori for the primary care physician”, “Strategies to reduce NSAID associated GI

toxicity”, “Update on the Irritable Bowel Syndrome”, Summer Internal Medicine Update,

Mackinac Island, MI, August 1-3, 2003.

37. Participant and Course co-director, Update in Office Gastroenterology, University of

Michigan, Bellaire, MI August 15-17, 2003.

38. Participant and Course co-director, Annual American College of Physicians - Michigan

Chapter Scientific Meeting, Acme, MI, September 18-21, 2003.


39. “Evidence-based appraisal of the role of serotonergic agents in the treatment of IBS”,

Breakfast symposium “Coping with the Complexities of IBS” at the meeting of the

American College of Gastroenterology, Baltimore, MD, October 12, 2003.

40. “Alosetron”, Breakfast symposium “Irritable Bowel Syndrome – the world of new drugs”

at the meeting of the American College of Gastroenterology, Baltimore, MD, October 14,

2003.

41. “Serotonergic modulation: IBS and beyond”, Satellite symposium “The Challenge of

Irritable Bowel Syndrome in clinical practice: from science to solutions” at the meeting of

the American College of Gastroenterology, Baltimore, MD, October 14, 2003.

42. “Diagnosis and management of IBS” and “Dyspepsia: Bugs or Drugs?” Meeting of the

American College of Physicians: Southern California-Region III, Palm Springs, CA,

October 25-26, 2003.

43. “Dyspepsia: Scopes, Bugs or Drugs?”, Harvard CME GI Motility and IBS Symposium,

Beth Israel Deaconess Medical Center, Boston, MA, October 31-November 1, 2003.

44. “Management of H. pylori: A clinician’s guide”, Advances in Gastroenterology, University

of Tennessee, Chattanooga, TN, November 8, 2003.

45. “Non-erosive esophageal disorders”, “H. pylori and peptic ulcer disease”, “ GI

manifestations of NSAIDs”, “Management of uninvestigated dyspepsia”, Fifth Annual

Update for Clinicians, University of South Florida, Orlando, FL, December 4-6, 2003.

46. “Traditional and emerging therapies for functional dyspepsia”, New Frontiers in GERD

and Dyspepsia, University of Arizona, Tempe, AZ, January 25-26, 2004.

47. Participant and Course Director for “Helicobacter pylori/PUD” GI/Liver Wrap-Up,

University of Michigan, Naples, FL, February 27-29, 2004. Audio Digest Selection,

volume 18, issue 12, 2004.

48. “Constipation: chronic disorder or irritable bowel?” Pri-Med Update, Rosemont, IL, March

11, 2004.

49. “Current and future management of uninvestigated and functional dyspepsia” Division of

Gastroenterology, University of Montreal, Montreal, Canada, April 14, 2004.

50. “Evidence-based update on the management of the irritable bowel syndrome” Division of

Gastroenterology, McGill University, Montreal, Canada, April 14, 2004.

51. “Nonerosive esophageal disorders: All that’s heartburn isn’t GERD” Arapahoe

Gastroenterology Conference, Denver, CO, April 23, 2004.

52. “Treatment options for ENRD: PPIs vs other options” Satellite symposium “Building best

practices in tough to treat patients” at Digestive Diseases Week 2004, New Orleans, LA,

May 16, 2004.

53. “Emerging treatments for the Irritable Bowel Syndrome” as part of the AGA sponsored

symposium: Progress in IBS Management: Translating Science into Clinical Practice.

Digestive Diseases Week 2004, New Orleans, LA, May 17, 2004.

54. “Salvage therapies for H. pylori infection” as part of the Research Forum “H. pylori

antimicrobial resistance and rescue” Digestive Diseases Week 2004, New Orleans, LA,

May 18, 2004.

55. “Endoscopy negative reflux disease: definitions, epidemiology, and clinical impact” as part

of the Clinical Symposium “Nonerosive esophageal disorders: all that’s heartburn isn’t

NERD” Digestive Diseases Week 2004, New Orleans, LA, May 18, 2004.

56. “Dyspepsia: pH, Hp or alternative approaches?” Transatlantic Pacific Summit Meeting,

New Orleans, LA, May 19-21, 2004.


57. “Approach to functional dyspepsia” Second annual solutions for common GI motility

problems, University of Louisville, Louisville, KY, June 5, 2004.

58. “Irritable Bowel Syndrome: Emerging concepts and promising therapies” Medical Grand

Rounds, Butterworth Hospital, Grand Rapids, MI, June 17, 2004.

59. Participant and Course Director for “Peptic Ulcer Disease” Northern Michigan DDW

Wrap-Up, University of Michigan, Bay Harbor, MI, July 17-18, 2004.

60. “IBS case presentations” 13th Biennial American Motility Society Meeting, Mayo Clinic,

Rochester, MN, September 9-12, 2004.

61. “Pharmacological advances in the management of functional GI disorders” Texas Society

for Gastroenterology and Endoscopy and the American College of Gastroenterology: 29th

Annual Texas Program, Dallas, TX, September 17-19, 2004.

62. “Current understanding and management of IBS” 1st Annual Michigan GI Society

Symposium, Thompsonville, MI, October 1-3, 2004.

63. “Pharmacological therapy of functional bowel and GI motility disorders” American

College of Gastroenterology Pharmacology Course, Orlando, FL, October 29, 2004.

64. Presenter at the American College of Gastroenterology ABIM Board Recertification

Course, Orlando, FL, October 29, 2004.

65. “Pharmacological therapies for IBS and motility disorders: Now and the future” American

College of Gastroenterology Annual Postgraduate Course, Orlando, FL, October 31, 2004.

66. Panelist for “Irritable Bowel Syndrome: Evolving perspectives and treatment strategies”

Satellite Symposium at the Annual meeting of the American College of Gastroenterology,

Orlando, FL, October 31, 2004.

67. Moderator for “Case challenges in functional bowel disease: What to do when standard

treatment fails” Annual meeting of the American College of Gastroenterology, Orlando,

FL, November 2, 2004.

68. “Emerging treatments for the Irritable Bowel Syndrome” as part of the AGA sponsored

symposium: Progress in IBS Management: Translating Science into Clinical Practice, Los

Angeles, CA, November 13, 2004.

69. “NSAID associated GI toxicity: Focus on aspirin and the COXIBs” Meeting of the Phoenix

GI Society, Scottsdale, AZ, November 17, 2004.

70. “Update on the management of H. pylori infection for 2004” GI Grand Rounds – Mayo

Clinic Scottsdale, Scottsdale, AZ, November 18, 2004.

71. “Clinical approach to chronic constipation” and “Irritable bowel syndrome” 11th

Symposium on Neurogastroenterology, University of Iowa, Fort Myers, FL, February 4-6,

2005.


University of Michigan, Naples, FL, February 25-27, 2005.

73. “Obtaining industry-sponsored research funding” 3rd Annual Functional GI Disorders

Young Investigator’s Forum. Functional Brain-Gut Research Group, Del Mar, CA,

February 18-20, 2005.

74. “Traditional medical therapies for the irritable bowel syndrome” and Steering Committee

for the 6th International Symposium on Functional GI Disorders, University of Wisconsin

Medical School, Milwaukee, WI, April 8-10, 2005.

75. “Translating pathophysiology to novel therapies for the irritable bowel syndrome” Annual

Spring Symposium of the Korean Society of Neurogastroenterology and Motility, Seoul,

Korea, April 23, 2005.


76. “An evidence-based approach to dyspepsia” AGA 2005 Spring Postgraduate Course,

Chicago, IL, May 14, 2005.

77. Participant in “GI Motility and Sensory Disorders…making sense in clinical practice”

Satellite symposium at DDW 2005, May 15, 2005.

78. Chair for the Clinical Symposium “Controversies in the management of IBS”, Digestive

Diseases Week 2005, May 15, 2005.

79. Co-chair for the “Distinguished Abstract Plenary Session” for the Clinical Practice Section

of the AGA, Digestive Diseases Week 2005, May 16, 2005.

80. Co-chair for the Research Fora “Pharmacotherapeutics in Functional GI Disorders”,

Digestive Diseases Week 2005, May 17, 2005.

81. “Functional Disease States” as part of the Clinical Symposium “Dyspepsia and its many

causes” Digestive Diseases Week 2005, May 17, 2005.

82. “Diagnosis and treatment of chronic constipation” Medical Grand Rounds, Butterworth

Hospital, Grand Rapids, MI, June 2, 2005.

83. “Management of chronic constipation”, “Peptic ulcer disease update”, “Uninvestigated

dyspepsia: Bugs or Drugs” 41st Annual Northern Michigan Summer Conference: An update

on common clinical concerns in primary care. Department of Family Medicine, University

of Michigan, Bellaire, MI, June 15-16, 2005.

84. “New insights into functional dyspepsia”, “Salvage therapies for H. pylori infection”,

“Emerging therapies for the irritable bowel syndrome” Clinical Gastroenterology and

Videoendoscopy, University of South Florida Health Sciences Center, Edinburgh,

Scotland, August 8-10, 2005.


Wrap-Up, University of Michigan, Mackinac Island, MI, August 13-14, 2005.

86. “Update in the management of the irritable bowel syndrome” Florida GI Society and the

American College of Gastroenterology, Naples, FL, September 11, 2005.

87. “NSAID-induced GI toxicity: Focus on aspirin and the COXIBs” Medical Grand Rounds –

York Central Hospital, Toronto, Ontario, September 22, 2005.

88. “Evidence-based update on the management of chronic constipation” Edmonton GI Journal

Club, Edmonton, Alberta, October 11, 2005.

89. Participant and Course Director, “Board Recertification Course for Gastroenterology” at

the Annual Meeting of the American College of Gastroenterology, Honolulu, HI, October

28, 2005.

90. “Functional dyspepsia: looking beyond bugs and drugs” Postgraduate Course at the Annual

Meeting of the American College of Gastroenterology, Honolulu, HI, October 29, 2005.

91. “Antidepressant therapy for functional dyspepsia?” Simultaneous Session at the Annual

Meeting of the American College of Gastroenterology, Honolulu, HI, October 29, 2005.

92. “A case of irritable bowel syndrome” as part of the satellite symposium - Lessons from

Cases: Clinical perspectives in GI motility and sensory disorders at the Annual Meeting of

the American College of Gastroenterology, Honolulu, HI, November 1, 2005.

93. “Diagnosis of the Irritable Bowel Syndrome”, Moderator – Controversies in IBS section

and Course Co-Director, Clinical Congress of Gastroenterology, American

Gastroenterological Association, Ft. Lauderdale, FL, December 9-11, 2005.


University of Michigan, Naples, FL, February 24-26, 2006.


95. Course Co-Director and Participant, Functional Brain-Gut Research Group’s Young

Investigator’s Forum, Miami, FL, March 31-April 2, 2006.

96. “Emerging therapies for IBS” as part of the Clinical Symposium “Emerging GI therapies”

at Digestive Diseases Week, Los Angeles, CA, May 21, 2006.

97. Faculty Chair: Chronic Constipation: Translating novel mechanisms of action into

innovative therapeutic interventions. Satellite Symposium at Digestive Diseases Week 06,

Los Angeles, CA, May 21, 2006.

98. Program Moderator: Bacterial Overgrowth and IBS. Satellite Symposium at Digestive

Diseases Week 06, Los Angeles, CA, May 21, 2006.

99. Co-chair for the Clinical Symposia, “Controversies in IBS”. Digestive Diseases Week 06,


100. Co-chair for the Distinguished Abstract Plenary of the Clinical Practice Section, AGA.

Digestive Diseases Week 06, Los Angeles, CA, May 22, 2006.

101. “Medical management of functional dyspepsia” as part of the Satellite Symposium at

Digestive Diseases Week 06 - Fast Track Solutions to GI Motility and Sensory Disorders,


102. “The irritable bowel syndrome” - DDW Review. University of Kansas, Kansas City,

Kansas, June 7, 2006.

103. “Functional Dyspepsia: Moving beyond bugs and drugs”, GI Grand Rounds, Columbia

University, New York City, NY, June 19, 2006.


Wrap-Up, University of Michigan, Bay Harbor, MI, August 12-13, 2006.

105. “Update on the management of chronic constipation” Medical Grand Rounds, Akron

General Hospital, Akron, OH, September 13, 2006.

106. “Current and emerging therapies for constipation” Satellite Symposium at the 2006 Joint

International Neurogastroenterology and Motility Meeting, Boston, MA, September 16,

2006.

107. Faculty participant for the “Board Recertification Course for Gastroenterology” at the

Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, October

20, 2006.

108. “IBS: How new insights into pathogenesis are transforming treatment paradigms” Toledo

Gut Club, Toledo, OH, November 9, 2006.

109. “Motility/Functional Bowel Disease Update” GI Grand Rounds, University of Michigan,

November 21, 2006.

110. “Peptic ulcer disease update” GI Grand Rounds, University of Michigan, December 19,

2006.

111. Participant and Course Director for “Motility and Functional Bowel Disorders” GI/Liver

Wrap-Up, University of Michigan, Captiva Island, FL, March 2-4, 2007.

112. “Design of treatment trials for functional bowel disorders” Scripps Clinic, La Jolla, CA,

March 23, 2007.

113. Course Director and Participant, Functional Brain-Gut Research Group’s Young

Investigator’s Forum, Del Mar, CA, March 23-25, 2007.

114. “Traditional therapies for IBS” and “Receptor acting agents for IBS”, Meeting of the

International Foundation for the Functional GI Disorders, Milwaukee, WI, April 14-15,

2007.


115. “Evidence-based update on the management of IBS” Good Samaritan Hospital and Phoenix

VA Medical Center, Phoenix, AZ, April 27, 2007.

116. “The global GERD epidemic” and “H. pylori: what are the new must-know points?” as

part of the Satellite Symposium at DDW 07, “Expert insights in acid-related disorders”

Washington DC, May 21, 2007.

117. Co-chair for the Late-breaking abstract research forum of the AGA. Digestive Diseases

Week 07, Los Angeles, CA, May 22, 2007.



119. “Emerging medical therapies for chronic constipation” Digestive Diseases Week 2007,

Washington, DC, May 22, 2007.

120. “Pharmacological Treatment of the Irritable Bowel Syndrome” for Clinical Advances in

Gastroenterology, American College of Gastroenterology, Oakstone Publishing, June 2007.

121. Course Co-director and Participant for “Diagnosis and treatment of IBS”, Midwest

Regional Postgraduate Course of the American College of Gastroenterology, Chicago, IL,

June 29-July 1, 2007.


Wrap-Up, University of Michigan, Mackinac Island, MI, July 27-29, 2007.

123. “Update on IBS for 2007” and “Evidence based approach to chronic constipation”

Memorial Health University Medical Center, Savannah, GA, September 28, 2007.

124. “Management of Functional Dyspepsia in 2007” Georgia Gastroenterology and Endoscopy

Society Meeting, Atlanta, GA, September 29, 2007.

125. “Management of the Irritable Bowel Syndrome” Pharmacology Course, Annual Meeting of

the American College of Gastroenterology, Philadelphia, PA, October 12, 2007.

126. Moderator and Presenter “Board Recertification Course for Gastroenterology” at the

Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October

12, 2007.

127. “Developing Therapy for Chronic Constipation” Postgraduate Course at the Annual

Meeting of the American College of Gastroenterology, Philadelphia, PA, October 14, 2007.

128. “Best of DDW 07: Upper GI Disorders” United European Gastroenterology Week, Paris,

France, October 30, 2007.

129. “Functional Dyspepsia: Diagnosis and treatment”, “The IBS patient in the Office” La

Semana Nacional De Gastroenterologia, Associacion Mexicana De Gastroenterologia,

Leon, Guanajuanto, November 19, 2007.

130. “The diagnosis and treatment of IBS in 2008”, Clark GI Society, Washington DC, February

7, 2008.

131. Participant and Course Director for “Peptic ulcer disease and upper GI bleeding”

GI/Liver Wrap-Up, University of Michigan, Captiva Island, FL, February 22-24, 2008.

132. “Irritable Bowel Syndrome: Creative Offerings” 12th Annual Common Problems in Office

Practice, Department of Internal Medicine, University of Michigan Health System,

Plymouth, MI, March15, 2008

133. “Update on Functional Dyspepsia” Northwest GI Society, Seattle, WA, March 20, 2008.

134. “IBS: Translating recent scientific advances to management solutions” University of

Washington, Seattle, WA, March 21, 2008.


135. “The American College of Gastroenterology’s H. pylori guideline” for Clinical Advances

in Gastroenterology, American College of Gastroenterology, Oakstone Publishing, April

2008.

136. “Functional Dyspepsia” Luncheon Learning Session, AGA Postgraduate Course, San

Diego, CA, May 17-18, 2008.

137. “Irritable Bowel Syndrome” Clinical Challenge Session, AGA Postgraduate Course, San

Diego, CA, May 17-18, 2008.

138. “Emerging therapies for functional bowel disorders”, Digestive Diseases Week, San Diego,

CA, May 19, 2008.

139. Co-chair for the Late-breaking abstract research forum of the AGA. Digestive Diseases

Week 08, Los Angeles, CA, May 20, 2008.



141. “Management of IBS in 2008” International Meeting of Motility and

Neurogastroenterology, Wuhan, China, June 21, 2008.

142. “Gastric Disorders” as part of Highlights of Digestive Diseases Week 2008, Northwestern

University, Chicago, IL, June 28, 2008.

143. Participant and Course Director for “Peptic Ulcer Disease and Upper GI Bleeding”

Northern Michigan DDW Wrap-Up, University of Michigan, Bay Harbor, MI, July 18-20,

2008.

144. “Update on H. pylori infection: What are the remaining issues in 2008?” Meeting of the

San Diego GI Society, San Diego, CA, August 20, 2008.

145. “Management of IBS in 2008” Medical Grand Rounds, East Virginia Medical Center,

Norfolk, VA, September 24, 2008.

146. “Dyspepsia and vomiting” ACG Postgraduate Course, Orlando, FL, October 4, 2008.

147. “The new IBS guidelines: What the practitioner needs to know” ACG Allied Health

Professionals Symposium. Orlando, FL, October 5, 2008.

148. “Utility of diagnostic tests” as part of the symposium “ACG guidelines: An evidence based

approach to IBS. Annual Meeting of the American College of Gastroenterology, Orlando,

FL, October 6, 2008.

149. “Functional Dyspepsia” Neurogastroenterology and Motility: Joint International Meeting

2008, Lucerne, Switzerland, November 8, 2008.

150. “Advancing best practices in IBS-C” Drexel University College of Medicine, Philadelphia,

PA, November 20, 2008.

151. “All about H. pylori: Update for 2009”, “Update on the irritable bowel syndrome”, and

“Constipation: New treatment options for a chronic condition” Tenth Annual Disorders of

the Esophagus and GI tract. Orlando, FL, December 5-6, 2008.

152. “Management issues in Chronic Constipation” Beth Israel Medical Center, New York, NY,

December 10, 2008.

153. Course Co-director and Speaker for the American Gastroenterological Association’s

Clinical Congress of GI and Hepatology, Las Vegas, NV, January 22-25, 2009.

154. Participant and Course Director for “Peptic ulcer disease and upper GI bleeding”

GI/Liver Wrap-Up, University of Michigan, Captiva Island, FL, February 27-March 1,

2009.

155. Course planning committee, speaker, and moderator – Meeting of the International

Foundation of Functional GI Disorders, Milwaukee, WI, April 17-19, 2009.


156. “Management of the Irritable Bowel Syndrome: Translating novel insights into actionable

treatment strategies” University of Louisville, Louisville, KY, April 23, 2009.

157. “Tradtional treatments of the Irritable Bowel Syndrome” “The use of antibiotics,

probiotics, and prebiotics for IBS” IBS Summit 2009. Puerto Vallarta, Mexico, April 24-

26, 2009.

158. “Evidence-based management of chronic constipation” University of California at Fresno,

Fresno, CA, May 14, 2009.

159. “Clinical Challenge Session: Difficult cases in functional bowel disorders” AGA

Postgraduate Course, Digestive Diseases Week 2009, Chicago, IL, May 30-31, 2009.

160. “The role of colonic transit testing in patients with constipation” Clinical Symposium:

Motility Controversies in FGIDs. Digestive Diseases Week 2009, Chicago, IL, May 31,

2009.

161. “Evidence-based diagnosis of IBS” AGA sponsored satellite symposium, Digestive

Diseases Week 2009, Chicago, IL, May 31, 2009.

162. “Functional dyspepsia” Meet the Professor: Digestive Diseases Week 2009, Chicago, IL,

June 1, 2009.

163. “Medical treatments for GERD” Clinical Advances in Gastroenterology, American College

of Gastroenterology, Sanibel Island, FL, July 11, 2009.

164. Participant and Course Director for “Novel insights into the Irritable Bowel Syndrome”

Northern Michigan DDW Wrap-Up, University of Michigan, Mackinac Island, MI, July

17-19, 2009.

165. “Irritable Bowel Syndrome: Translating the latest science to practical management

solutions” Medical Grand Rounds, Department of Internal Medicine, University of

Michigan Health System, Ann Arbor, MI, August 7, 2009.

166. “Current controversies in the management of the irritable bowel syndrome” GI Grand

Rounds, New York University, New York, NY, August 18, 2009.

167. “Evidence-based management of Functional Dyspepsia” American College of

Gastroenterology Midwest Regional Postgraduate Course, Kansas City, MO, August 29,

2009.

168. “Recertification preparation and update course” Faculty Member, Annual Meeting of the

American College of Gastroenterology, San Diego, CA, October 23, 2009.

169. Moderator – “The upper gut” Postgraduate Course, Annual Meeting of the American

College of Gastroenterology, San Diego, CA, October 24, 2009.

170. “H. pylori in 2009: When to test, how to test and how to treat”, Postgraduate Course,

Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 24,

2009.

171. “Managing the sensitive gut: The NERD/GERD/IBS interface” Satellite Symposium at the

Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 25,

2009.

172. Faculty member in the Satellite Symposium: “Trial by Jury: Examining the ACG Position

Statement on the Management of IBS” San Diego, CA, October 26, 2009.

173. “Treatment options: Food, bugs or drugs?” as part of the simultaneous symposium: Is IBS

another IBD? Annual Meeting of the American College of Gastroenterology, San Diego,

CA, October 27, 2009.

174. “Evidence-based treatment of IBS” as part of the Symposium: “The Dark Side of IBS” at

United European Gastroenterology Week, London, UK, November 24, 2009.


175. “Functional Dyspepsia: How to manage in clinical practice” and “Breath Tests, Antibiotics,

Probiotics in IBS: When and who to test and treat” American Gastroenterological

Association Clinical Congress, Las Vegas, NV, January 15-16, 2010.

176. “Salvage therapy for H. pylori” and “IBS Update: Review of practice guidelines and

practical tips” ACG Governors/ASGE Best Practices Course, Las Vegas, NV, January 29-

31, 2010.

177. Participant and Course Director, GI-Liver Wrap Up, University of Michigan Medical

Center, Sarasota, FLA, February 19-21, 2010. Audio Digest Selection: IBS and celiac

disease: separating the wheat from the chaff. 2010;24:22.

178. “Newer concepts in the diagnosis and treatment of Irritable Bowel Syndrome” American

College of Gastroenterology Regional Postgraduate Course, New Orleans, LA, March 5-6,

2010.

179. “H. pylori: Handling recurrent and refractory cases” and “Evolving diagnosis and therapy

of functional dyspepsia” American College of Gastroenterology Regional Postgraduate

Course, New York, NY, March 20-21, 2010.

180. “Small Intestinal Bacterial Overgrowth” Michigan Bowel Control Program Grand Rounds,

University of Michigan Health System, Ann Arbor, MI, April 14, 2010.

181. “Handling the Complicated Functional Bowel Disease Patient” AGA Postgraduate Course

Clinical Challenge Session. Digestive Diseases Week, New Orleans, LA, May 1-2, 2010.

182. “What’s up With Bacterial Overgrowth? IBS & Beyond” AGA Postgraduate Course

General Session. Digestive Diseases Week, New Orleans, LA, May 2, 2010.

183. “Emerging Therapies for Functional Bowel Disease” AGA Clinical Symposium. Digestive

Diseases Week, New Orleans, LA, May 2, 2010.

184. “Probiotics – What Works for IBS?” AGA Clinical Symposium. Digestive Diseases Week,

New Orleans, LA, May 4, 2010.

185. “Emerging Diagnostic and Therapeutic Strategies for Functional Bowel Disorders: Insights

from DDW 2010” GI Grand Rounds. University of Michigan Health System, June 8, 2010.

186. “Diagnosis and Treatment of Small Intestinal Bacterial Overgrowth” GI Grand Rounds,

University of Michigan Health System, Ann Arbor, MI, June 8, 2010.

187. “Small Intestinal Bacterial Overgrowth” Difficult Clinical Problems in Gastroenterology,

University of Manitoba, Winnipeg, Canada, June 11, 2010.

188. Participant and Course Director, Northern MI DDW Wrap-Up, University of Michigan

Medical Center, Mackinac Island, MI, July 16-18, 2010.

189. “Perianal Inspection and Digital Rectal Examination” GI Fellows Teaching Series,

University of Michigan Health System, Ann Arbor, MI, August 24, 2010.

190. “Meet the Professor” ANMS 5th Biennial Postgraduate Course on GI Motility &

Neurogastroenterology in Clinical Practice, Boston, MA, August 26, 2010.

191. “Workshop: Testing for Bacterial Overgrowth, IBS and Carbohydrate Malabsorption”

ANMS 5th Biennial Postgraduate Course on GI Motility & Neurogastroenterology in

Clinical Practice, Boston, MA, August 26, 2010.

192. Moderator: Plenary Session: IBS-IBD Overlap, International Neurogastroenterology &

Motility Meeting, Boston, MA, August 28, 2010.

193. “Diagnosis and Treatment of GERD” GI Fellows Teaching Series, University of Michigan

Health System, Ann Arbor, MI, September 29, 2010.


194. “Plenary Presentation: Erosive vs. Nonerosive GERD: The many faces of heartburn”

Annual Meeting of the Gastroenterological Society of Taiwan, Taipei, Taiwan, October 3,

2010.

195. “Recertification preparation and update course” Faculty Member, Annual Meeting of the

American College of Gastroenterology, San Antonio, TX, October 15, 2010.

196. “Treatment of IBS” Learning Luncheon, Postgraduate Course, Annual Meeting of the

American College of Gastroenterology, San Antonio, TX, October 16, 2010.

197. “Celiac disease and IBS: How far should you go?” Annual Meeting of the American

College of Gastroenterology, San Antonio, TX, October 18, 2010.

198. Moderator: Plenary Session: Functional GI Disorders/Inflammatory Bowel Disease,

Annual Meeting of the American College of Gastroenterology, San Antonio, TX, October

20, 2010.

199. “Management of chronic constipation” Balloon Training, Manual Techniques and

Exercises for Bowel Dysfunction sponsored by the Department of Physical Therapy,

University of Michigan Health System, Ann Arbor, MI, November 6, 2010.

200. “Critical review and rational for the use of prokinetics for GERD” as part of the

symposium “GERD & dyspepsia share motility disorders that affect diagnosis & treatment”

at 2010 Gastroenterology Mexican Week, Acapulco, Mexico, November 16, 2010.

201. “Manipulation of intestinal microbiota in the treatment of IBS”, 2010 Gastroenterology

Mexican Week, Acapulco, Mexico, November 16, 2010.

202. “Overlap between IBS and celiac disease” Michigan Bowel Control Program Grand

Rounds, Ann Arbor, MI, December 8, 2010.

203. “PPI safety: What are the concerns” and “Evidence-based management of IBS” AGA

Clinical Congress of Gastroenterology & Hepatology, Miami, FL, January 14-15, 2011.

204. “Management of the difficult IBS patient” ACG Western Region Postgraduate Course, Las

Vegas, January 28-30, 2011.

205. “Management of IBS”, Update on GERD & Motility Disorders, Emory University School

of Medicine, Atlanta, GA, March 19, 2011.

206. “New and emerging treatments of the gut”. 9th International Symposium on Functional GI

Disorders, Milwaukee, WI, April 8, 2011.

Audio-Digest Gastroenterology, Volume 25, Issue 16, August 21, 2011.

207. “Challenging cases at the referral center”. 9th International Symposium on Functional GI

Disorders, Milwaukee, WI, April 9, 2011.

208. “Role of small intestinal bacterial overgrowth in the Irritable Bowel Syndrome” Digestive

Diseases Week, Chicago, IL, May 8, 2011.

Audio-Digest Gastroenterology, Volume 25, Issue 20, October 21, 2011.

209. “Management of the patient with IBS-C” Satellite Symposium – GI Health Foundation,

Digestive Diseases Week, Chicago, IL, May 8, 2011.

210. “First-line and salvage treatments for H. pylori infection” First Beijing Helicobacter pylori

Summit Symposium. Beijing, China, May 15, 2011.

211. “Management of Gastroesophageal Reflux Disease in 2011”. Shanghai, China, May 17,

2011.

212. “Management of Acute Peptic Ulcer Bleeding” Medan, Indonesia, May 19, 2011.

213. Participant and Course Director, Northern MI DDW Wrap-Up, University of Michigan

Medical Center, Mackinac Island, MI, August 19-21, 2011.


214. “Functional Disorders and IBS – New Therapies” ACG/Virginia GI Society Regional

Postgraduate Course, Williamsburg, VA, September 10, 2011.

215. “Testing of colonic function: Wireless Motility Capsule” and “Meet the Professor” ANMS

6th Biennial Postgraduate Course on GI Motility & Neurogastroenterology in Clinical

Practice, St Louis, MO, September 16, 2011.

216. “The role of food in functional GI disorders” Dr. Timothy T. Nostrant Retirement CME

Program, University of Michigan Health System, Ann Arbor, MI, September 23, 2011.

217. “Emerging therapies for IBS and Chronic Constipation” Chicago Gut Club, Oakbrook, IL,

September 27, 2011.

218. “IBS: Evidence-based diagnosis and management”, “Learning Luncheon: Refractory

Abdominal Pain: Management Considerations”, ACG Postgraduate Course, Washington,

DC, October 30, 2011.

219. “Strategies for effective management of IBS-C and Chronic Constipation: Expert

Perspectives” CME Satellite Symposium: Annual Meeting of the American College of

Gastroenterology 2011, Washington, DC, October 30, 2011.

220. “Current Management of H. pylori Infection” Annual Meeting of the American College of

Gastroenterology 2011, Washington, DC, November 1, 2011.

221. “The role of food in the irritable bowel syndrome” 5th Annual Japan & US Collaboration in

Gastroenterology, Tokyo, Japan, November 10, 2011

222. “Evidence-based management strategies for IBS” and “Role of probiotics for IBS and

IBD” Clinical Congress of Gastroenterology & Hepatology, Miami, FL, January 20-21,

2012.

223. “Evidence-based management of the patient with dyspepsia” and “Management of H.

pylori infection”, Best Practices in Gastroenterology & Hepatology, Huntington Beach,

CA, January 27-28, 2012.

224. “Emerging therapies for IBS-C and Chronic Constipation” and “Star articles from the GI

journals” Canadian Digestive Diseases Week, Montreal, CA, February 27, 2012.

225. “Management of IBS in 2012” University of Michigan Health Service CME Lecture Series.

Ann Arbor, MI, March 29, 2012.

226. “Dietary strategies for patients with IBS” Advocate Christ Medical Center, Oak Lawn, IL,

May 3, 2012.

227. “Management of H. pylori infection” Fellow’s Conference, Division of Gastroenterology,

University of Michigan Health System, May 9, 2012.

228. “Clinical Challenge Session: Managing the Difficult IBS Patient” AGA Postgraduate

Course, Digestive Diseases Week 2012, San Diego, May 19, 2012.

229. “Microbiome and Irritable Bowel Syndrome” AGA Postgraduate Course. Digestive

Diseases Week 2012, San Diego, May 20, 2012.

230. “Clinical Symposium: Everything You Need to Know about IBS Treatment” Digestive


231. “Clinical Symposium: Celiac disease or gluten sensitivity: What's the difference and how

to evaluate and treat?” Digestive Diseases Week 2012, San Diego, May 21, 2012.

232. “Committee Sponsored Symposium: Diets and Irritable Bowel Syndrome” Digestive


233. “Evidence-based treatment strategies for IBS-C and Chronic Constipation” Pacific

Northwest GI Society, Seattle, WA, May 31, 2012.


234. “Diagnostic evaluation of IBS” and “Treatments directed at the bowel for IBS”, Small

group and facilitated role play moderator. Rome Foundation/AGA Workshop: Improving

the Medical Interview and the Physician Patient Relationship with Patients Having

Functional GI Disorders, Chapel Hill, NC, June 8-9, 2012.

http://theromefoundation.org/meetings_events/communication_workshop_agenda.cfm 235. “Slow colon transit: Why it matters and how to treat it” and “Diet and IBS: Food for

thought” UNC Patient Symposium, Chapel Hill, NC, June 23-24, 2012.

236. Participant and Course Director, Northern MI GI-Liver Wrap-Up, University of Michigan

Medical Center, Mackinac Island, MI, July 20-22, 2012.

237. “Cases in colorectal disorders”, “Meet the Professor”, “Evaluation and Treatment of

Constipation”. ANMS 7th Annual Postgraduate Course on GI Motility &

Neurogastroenterology in Clinical Practice, Chicago, IL, July 28-30, 2012.

238. “Moderator: Functional Bowel Disorders” and “Constipation and Pelvic Floor Disorders”

ACG Midwest Region Postgraduate Course, Indianapolis, IN, August 25-26, 2012.

239. “Discussant: Large Bowel: Clinical Session”, “Functional Constipation”, “Chair:

Pharmacotherapy, pharmacology and alternative therapies” Joint International

Neurogastroenterology & Motility Meeting, Bologna, Italy, September 6-8, 2012.

240. “New developments in the management of IBS” North California Society of

Gastroenterology, San Francisco, CA, September 20, 2012.

241. “Management of chronic constipation.” Sanya Festival of Gastroenterology and

Endoscopy, Hainan Island, China, October 10, 2012,

242. ACG Postgraduate Course Learning Luncheon "Current treatment of H. pylori", Las

Vegas, NV, October 20, 2012.

243. ACG Postgraduate Course - Moderator – “Motility and FGIDs”, speaker: “Management of

Chronic Constipation”, Las Vegas, NV, October 21, 2012.

244. Moderator: “Food and GI Diseases: Where's the Beef?”, speaker: “Food: The Forgotten

Factor in IBS”, Annual Meeting of the American College of Gastroenterology, Las Vegas,

NV, October 23, 2012.

245. Rome Foundation Symposium: “The role of diet in IBS”, Pan American Congress of

Gastroenterology, Panama City, Panama, November 10, 2012.

246. “Are Functional Constipation and IBS-C distinct conditions: Considerations for Rome IV”,

the role of the gut microbiota in IBS”, “Understanding the pathophysiology of bloating”,

Mexican Gastroenterology Week, Merida, Mexico, November 21, 2012.

247. “Rational management of GERD”, “Meet the Experts – How to publish in Western

Medical Journals”, Asian Pacific Digestive Week, Bangkok, Thailand, December 7, 2012.

248. “Up and Down the GI Tract: GERD, Celiac Disease, Fecal Incontinence” National Course

Co-Director, Regional Pri-Med CME Series, 2013

249. “Therapeutic challenges in the Functional GI Disorders” 9th Annual Meeting of the

Japanese Gastroenterology Association. Tokyo, Japan, January 25, 2013.

250. “Management of Chronic Constipation” Spring Conference for the MSGNA. Ypsilanti, MI,

February 9, 2013.

251. “Transforming the way that Patients and Doctors interact: My GI Health” Michigan Bowel

Control Program Education Hour. University of Michigan Health System, Ann Arbor, MI,

February 13, 2013.

252. “Morbidity and Mortality – Expert GI Commentator”, Internal Medicine Grand Rounds,

University of Michigan Health System, Ann Arbor, MI, February 22, 2013.

http://theromefoundation.org/meetings_events/communication_workshop_agenda.cfm


253. “The future of therapies for functional GI disorders” Through the Glass Darkly

Symposium, McMaster University, Hamilton, ON, February 23, 2013.

254. Biannual Meeting of the International Foundation of Functional GI Disorders: “Mini

Symposium: The Rome Working Group, Food & Functional Gastrointestinal Disorders:

Dietary Factors and Lower GI Symptoms”; “Workshop: Clinical Pearls for the Clinician:

Diagnostic Pearls”; “General Plenary Session: New and Emerging Treatments of the Gut”.

Milwaukee, WI, April 12-14, 2013.

Audio Digest Gastroenterology, Volume 27, Issue 20, October 21, 2013.

255. “The essentials to managing IBS” Department of Internal Medicine Spring Review:

University of Michigan, Ann Arbor, MI, May 10, 2013.

Audio-Digest Internal Medicine Volume 61, Issue 02, January 14, 2014, ISSN 0271-1303 256. “The role of food in the functional GI disorders: Report from a Rome Foundation Working

Group” Rome IV Orientation Meeting, Orlando, FL, May 16, 2013.

257. “The transformative role of patient portals in clinical practice” AGA Postgraduate Course,

Digestive Diseases Week 2013, Orlando, FL, May 19, 2013.

258. “Finding and Eradicating H. Pylori in 2013” AGA Postgraduate Course Luncheon

Breakout Session, Digestive Diseases Week 2013, Orlando, FL, May 19, 2013.

259. “State of the Art: Foods, Fads and FODMAPs” Research Forum, Digestive Diseases Week

2013, Orlando, FL, May 19, 2013.

260. “Research Forum: Irritable Bowel Syndrome” Moderator, Digestive Diseases Week 2013,

Orlando, FL, May 20, 2013.

261. “Clinical Conversations: Getting Patients with CC and IBS-C Back on Track” Satellite

Symposium, Digestive Diseases Week 2013, Orlando, FL, May 19, 2013.

262. “Management of GERD”, “Diagnosis and Treatment of H. pylori infection”, Evidence-

based management of chronic constipation”, “Dietary and lifestyle strategies for IBS”,

“Medical and complementary treatments for IBS”, Michigan Academy of Family Practice

Meeting 2013, Bellaire, MI, June 19-21, 2013.

Audio-Digest Family Practice, Volume 61, Issue 41, November 7, 2013, ISSN 0271-1362 Audio-Digest Family Practice, Volume 61, Issue 45, December 7, 2013, ISSN 0271-1362

263. “DDW 2013 Review: Motility and Functional GI disorders” GI & Liver Association of the

Americas – First Annual Conference. Austin, TX, June 21, 2013.

264. “Evidence-based treatment of IBS”, Management strategies for chronic constipation” 21st

Annual Primary Care Conference, Kiawah Island, SC, July 4-6, 2013.

265. “Diet & lifestyle interventions for IBS” University of Florida: 7th Annual GI/Liver

Meeting, Clearwater, FL, July 27, 2013.

266. “Evidence-based approach to IBS”, “What’s new in Celiac Disease and non-celiac Wheat

Intolerance” ACG 2013 Midwest Regional Postgraduate Course, St. Louis, MO, August

24-25, 2013.

267. “Current and emerging therapies for IBS-C and chronic constipation” ANMS Clinical

Course, Huntington Beach, CA, September 20, 2013.

268. “Diet as a primary treatment strategy for IBS” Rome Foundation Symposium, ANMS

Scientific Meeting, Huntington Beach, CA, September 20, 2013.

269. “Bloating: Blowing up old myths” and “The changing face of Helicobacter pylori”

American College of Gastroenterology Postgraduate Course, San Diego, CA, October 13,

2013.

270. “Traditional medical treatments for IBS” and course moderator, UNC Center for

Functional GI and Motility Disorders. Chapel Hill, NC, November 2, 2013.


271. “Management of constipation” and course planning committee, Practical Solutions to

Common GI Problems. Division of Gastroenterology, University of Michigan Health

System, Plymouth, MI, November 16, 2013.

272. “Clinical approach to the patient with dyspepsia” and “Complementary and Alternative

Medicine for GI Disorders” American College of Gastroenterology Governor’s Course, Las

Vegas, NV, January 24, 2014.

273. “Update on the Functional GI Disorders” ACG Lecturer, Meeting of the Japanese

Gastroenterological Association, Fukushima, Japan, February 14-15, 2014.

274. “Primary and Salvage Treatments for H. pylori infection” GI Pow-Wow, Denver, CO,

April 12, 2014.

275. “Incontinence: the scope of the problem and treatment options” AGA Postgraduate Course,

Chicago, IL, May 3, 2014.

276. “The overlap between inflammatory bowel diseases, microscopic colitis and IBS”

Digestive Diseases Week, Chicago, IL, May 6, 2014.

277. “Management of IBS – What’s New?” American College of Gastroenterology East

Regional Course, Washington, DC, June 7, 2014.

278. ”Update on Celiac Disease” & “Patient Portals – How to use them in your practice”

Michigan Association of Family Practice Annual Meeting, Bellaire, MI, June 18-19, 2014.

279. Expert Panel Discussant. Young Investigator’s Forum. American Neurogastroenterology &

Motility Society. Baltimore, MD, July 25, 2014.

280. “Medical therapies for IBS” & “Dietary recommendations for patients with FGIDs” ANMS

Post-graduate Course, Baltimore, MD, July 26-27, 2014.

281. “Evidence-based treatment strategies for IBS” & “Management of chronic constipation”

5th Annual Essentials in Primary Care Conference, Big Island, HI, July 31, 2014.

282. “Update on irritable bowel syndrome” ACG Virginia GI Society Meeting, Williamsburg,

VA, September 6-7, 2014.

283. “Treatment approach to the patient with IBS” & “Best of DDW 2014: FGID & Motility”

Gastroenterology International Frontier, Beijing, China, September. 26, 2014.

284. “Treatment approach to the patient with IBS” 1st AGA Professional Conference in China,

9th SRRSH International Academic Week, 7th Zhejiang Digestive Disease Academic

Conference, Hangzhou, China, September. 27, 2014.

285. “The role of food in functional GI disorders” Rome Symposium, Latin American Digestive

Diseases Week, Buenos Aires, Argentina, October 8, 2014.

286. “Management of H. pylori infection” ACG Postgraduate Course, Philadelphia, PA, October

19, 2014.

287. “The role of inflammation in IBS” Annual Meeting of the ACG, Philadelphia, PA, October

20, 2014.

288. “Anorectal dysfunction: definitions, clinical presentation, features on defecography and

anorectal function testing” & “IBS-C and chronic constipation: Differences in clinical

presentation, pathophysiological mechanisms” Rome Foundation Symposium: Recent

Advances in FGIDs. Dubai, UAE, October 31-November 1, 2014.

289. “The role of food in FGIDs”, “Manipulating gut microbiome in FGIDs: probiotics,

antibiotics and fecal transplant”. Clinical Practice in Neurogastroenterology & Motility,

Cancun, Mexico, November 15-16, 2014.

290. “Dyspepsia – Don’t’ test, just treat” AGA Clinical Congress in Gastroenterology &

Hepatology, Miami, FL, January 23-24, 2015.


http://www.hcplive.com/conferences/aga-2015/Debating-Testing-or-Treatment-for-Gastroparesis

291. “Diet as a primary treatment strategy for irritable bowel syndrome”. University of Toronto

City Wide Rounds, Toronto, Canada, March 11, 2015.

292. “New advances in the treatment of GERD” Changhua Christian Hospital, Changhua,

Taiwan, March 30, 2015.

293. “Manipulating the gut microbiome: Emerging treatment strategies for IBS” Kaohsiung

Medical University, Kaohsiung, Taiwan, March 31, 2015.

294. “Manipulating the microbiome to treat IBS” Arapahoe POW WOW, Denver, CO, April 18,

2015.

295. “Management of IBS in 2015” Bluegrass Gut Club, Lexington, KY, April 23, 2015.

296. “Current management options for patients with IBS and diarrhea” McGill Grand Rounds,

Montreal General Hospital, Montreal, CN, May 6, 2015.

297. “The emerging role of bile acids in the pathogenesis and treatment of IBS with diarrhea”

Medical Grand Rounds, Toronto General Hospital, Toronto, CN, May 7, 2015.

298. “Emerging diagnostic and treatment strategies for IBS with diarrhea” McMaster

University, St. Joseph’s Hospital-Charlton Campus, Hamilton, May 8, 2015.

299. “Learning Luncheon: Helicobacter pylori in the Modern Age: How to Find, How to Treat”

AGA Postgraduate Course, Washington DC, May16, 2015.

300. “2015 Rome Foundation Symposium: Use of Health Information Technology in Clinical

Practice” Digestive Diseases Week 2015, Washington DC, May 17, 2015.

301. “Breakfast with the expert: Antibiotic-Resistant H. pylori Infections: What to Do When

Standard Therapy Fails” Digestive Diseases Week 2015, Washington DC, May 18, 2015.

302. “Management of GERD in 2015” and “The emerging role of diet and lifestyle in IBS” 6th

Annual Essentials in Primary Care Conference, Kiawah Island, SC, July 3-6, 2015.

303. “Targeting the microbiome” and moderator – “Luminal factors affecting epithelial function

and symptoms in IBS” 2015 AGA James Freston Conference, Chicago, IL, August 29-30,

2015.

304. “Emerging therapeutic options for chronic constipation/anorectal disorders” ANMS 10th

Postgraduate Course, Chicago, IL, August 28, 2015.

305. “Food – at the intersection of GI wellness and illness” Georgia GI Society Annual Meeting,

Atlanta, GA, September 12, 2015.

306. “Emerging role of lifestyle and diet for IBS” and “Evidence-based medical management of

IBS” Oregon Gut Club, Portland, OR, September 19. 2015.

307. “Advances in the management of functional GI disorders” University of Washington,

Seattle, WA, September 21, 2015.

308. “FGID Update” Chicago Gut Club, Chicago, IL September 24, 2015.

309. “First and second line therapies for H. pylori infection” Gastroenterology Update: A case-

based approach to common GI problems. UMHS, Dearborn, MI, October 2, 2015.

310. “David Sun Lecture: Food – the main course to GI wellness and disease” ACG

Postgraduate Course, Honolulu, HI, October 17, 2015.

311. “Evolving concepts in the treatment of IBS” “Diet- what should you choose for IBS?”

Annual Meeting of the American College of Gastroenterology, Honolulu, HI, October 20,

2015.

312. “Hotspot Clinical Trial Discussion: Naloxegol”, “Bridging guidelines into practice:

Pharmacological agents for IBS”, “Expert roundtable discussion on chronic diarrhea: Bile




acid diarrhea”, “Managing the GI side effects of opioids”, United European

Gastroenterology Week, Barcelona, Spain, October 26-28, 2015.

313. “Keynote Address: The emergence of diet as a therapy for irritable bowel syndrome” Prato

International FODMAP Congress, Monash University, Prato, Italy, November 2-3, 2015.

314. “The emerging role of diet in human health and gastrointestinal diseases” School of Public

Health, University of Michigan, Ann Arbor, MI, November 11, 2015.

315. “The emerging role of Diet & Lifestyle in IBS” Ob-Gyn Grand Rounds, University of

Michigan Health System, Ann Arbor, MI, January 7, 2016.

316. “Management of IBS-D in 2016” Edmonton Citywide Gut Club, Edmonton, Canada,

January 12, 2016.

317. “The emerging role of the gut microenvironment in the pathogenesis of IBS” University of

British Columbia Gut Club, Vancouver, Canada, January 13, 2016.

318. “Do bile acids play a role in the pathogenesis and treatment of IBS?” University of Calgary

GI faculty dinner conference, January 14, 2016.

319. “The role of the gut microbiome on functional bowel symptoms” 2016 ACG Board of

Governors Postgraduate Course, Scottsdale, AZ, January 30, 2016.

320. “My GI Health” Pelvic Floor Research Group Day, University of Michigan Health System,

February 3, 2016.

321. “Food – the main course to wellness and disease” FODMAPs, SIBO, and the gut

microbiome, Boston, MA, February 26, 2016.

322. “Prebiotics, Probiotics, Synbiotics, and Antibiotics -- Role in IBS” & “Management of

visceral pain” ACG/Florida GI Society Regional Postgraduate Course, Bonita Springs, FL,

March 18-20, 2016.

323. “Rome III Criteria for Functional Gastrointestinal Disorders: Is There a Need for Better

Definition?” & “How Best to Publish in Scientific Journals” 6th Asian Postgraduate Course

on Neurogastroenterology & Motility, Seoul, Korea, April 2-4, 2016.

324. “State of the Art Lecture: Microbiota, FODMAP Diet & IBS” Digestive Diseases Week

2016, San Diego, CA. May 22, 2016.

325. “Treatment of functional GI disorders: Current challenges, future opportunities” NIH

Functional Bowel Disorders Workshop, June 24, 2016.

326. “The new way to diagnose FGIDs: Rome IV”, “The new drug revolution for IBS”, “Why

does food cause GI symptoms?” The Multidisciplinary Treatment of IBS. Alfred Hospital.

Melbourne, Australia, July 16, 2016.

327. “The probiotic scene for IBS in the US” PRO-GUT Meeting, Melbourne, Australia, July

17, 2016.

328. “Food: the main course to GI wellness and illness” Annual Meeting of the Florida

Academy of Nutrition & Dietetics. Tampa, FL, July 24, 2016.

329. “The emerging role of diet in the pathogenesis and treatment of IBS”, “Diagnosis of IBS in

the Rome IV era” Brazilian Congress of Functional Diseases of the Digestive System.

Gramado, Brazil, July 29-31, 2016.

330. Course Co-Director: Food: the main course to GI Health – Nutrition Management for GI

Diseases. Ann Arbor, MI, August 20-24, 2016.

331. “Dietary management of the lower gut” American Neurogastroenterology & Motility

Society. San Francisco, CA, August 25-26, 2016.

332. “Management of functional dyspepsia” ACG Midwest Regional Course, Minneapolis, MN,

August 27-28, 2016.

https://www.conferenceharvester.com/harvester2/Tasks/DisclosureForm.asp?PresentationID=250466


333. “Food in GI Health & Disease”, Case Western Reserve Cleveland IDEAS Symposium

2016, Cleveland, OH, September 9, 2016.

334. “The Low-FODMAP diet - what is it and who is it for?” Ohio Gastroenterology Society,

Columbus, OH, September 17, 2016.

335. “Therapeutic nutrition: Food for thought” Division of Gastroenterology & Hepatology,

University of Michigan Health System. Ann Arbor, September 22-23, 2016.

336. Moderator: Esophagus and Stomach, Postgraduate Course, Annual Meeting of the

American College of Gastroenterology, Las Vegas, NV, October 16, 2016.

337. “Resistant Helicobacter pylori infection – what now?” Postgraduate Course, Annual

Meeting of the American College of Gastroenterology, Las Vegas, NV, October 16, 2016.

338. Moderator: Rome IV symposium, Speaker: “Bowel Disorders”, Annual Meeting of the

American College of Gastroenterology, Las Vegas, NV, October 18, 2016.

339. Moderator: Colon Controversies, Speaker: “New tricks for an old problem: Opioid induced

constipation” Annual Meeting of the American College of Gastroenterology, Las Vegas,

NV, October 17, 2016.

340. “Microbiome-based treatment strategies for IBS.” Canadian Digestive Health Foundation

Discover the World Within Symposium, Toronto, ON, November 7, 2016.

341. “The emerging role of food in the management of IBS” University Health Service, UMHS,

Ann Arbor, MI, November 10, 2017.

342. “Treatment of H. pylori infection in 2017” Loma Linda University Medical Center, Loma

Linda, CA, December 16, 2016.

343. “Rome IV criteria for IBS: Notable Changes” 2017 ACG/LGS Regional Postgraduate

Course, New Orleans, March 4, 2017.

344. “Management of H. pylori infection: ACG Practice Guidelines” GI Grand Rounds,

Division of Gastroenterology, Michigan Medicine, March 7, 2017.

345. “Evaluation of chronic constipation”, “The future of Gastroenterology in 2017” 2017 ACG

Western Regional Postgraduate Course, Las Vegas, NV, March 11-12, 2017.

346. “Gut microbiota in chronic constipation” “Rome IV criteria: Bowel Disorders” APNM-

JSNM joint meeting 2017, Osaka, Japan, March 22-24, 2017.

347. “Keynote address: You are what you eat – the role of food in gut health and disease”,

“Update on Celiac disease”, 2017 ACG Eastern Regional Postgraduate Course.

Washington, DC, April 8, 2017.

348. “Update on the Rome IV criteria for the diagnosis of functional GI disorders” GI Grand

Rounds, Division of Gastroenterology, Michigan Medicine, April 11, 2017.

349. “Rome IV criteria for IBS: Notable Changes”, “Utility of biomarkers in the diagnosis of

IBS”, “State of the art management of IBS” SAGE Autumn Symposium, Buenos Aires,

Argentina, April 20-21, 2017.

350. Planning Committee and speaker: Falk Symposium “Mucosal Microbiome and Mucosal or

Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions” Brisbane,

AU, May 19-20, 2017.

351. “Current Diagnosis of IBS-D” and “Salvage therapy for Helicobacter pylori infection”

Digestive Diseases Week, Chicago, IL, May 6-9, 2017.

352. “New diagnostic and therapeutic approaches to IBS” 37th Annual Advances in

Gastroenterology Conference, Thomas Jefferson University, Atlantic City, NJ, June 17,

2017.


353. “Update on functional GI disorders for primary care physicians” and “Celiac disease”

25th Annual Primary Care Summer Conference Session, Kiawah Island, SC, June 30 to

July 3, 2017.

354. “Pain assessment in clinical trials: Pelvic pain and IBS”. IMMPACT Meeting. Washington

DC, July 13, 2017.

355. “Novel therapies for IBS” and “Functional dyspepsia” AGA NP PA GI Course, Chicago,

IL, August 11, 2017.

356. “Bloating and Distention: The Role of Diet and the Microbiome” ACG Midwest Regional

CME Course. St. Louis, MO, August 25, 2017.

357. “Updates in the treatment of IBS” Mastering concepts in IBD and IBS: St Louis University.

St Louis, MO, September 9, 2017.

358. “Microbiome-Gut-Brain Interactions” Chinese GI Association Annual Meeting, Xian,

China, September 16, 2017.

359. Course Director and Speaker, Food: the main course to digestive health. Michigan

Medicine, Ann Arbor, MI, September 22-24, 2017.

360. “Update on the management of H. pylori infection” Third Annual GI Update, Michigan

Medicine, Dearborn, MI, September 29, 2017.

361. “Learning luncheon: H. pylori: Who to treat and how” ACG Postgraduate Course. Orlando,

Fla, October 15, 2017.

362. “Diagnostic challenges in H. pylori” and “Rome IV vs. Biomarkers: How accurate are our

diagnostic tools?” Annual Meeting of the ACG/WCOG. Orlando, FL, October 16-17, 2017.

363. “Should dietary trials have different rules to drug trials?” and “Sucrase-isomaltase

deficiency: Hiding in plain sight”. Gastrodiet 2017. Monash University. November 3-5,

2017.

364. “Fecal incontinence: How to fix it” and “Efficacious care of the functional bowel

disorders” 43rd Annual Topics in GI and Hepatobiliary Update, Johns Hopkins University,

Baltimore, MD, November 10, 2017.

365. Panel participant. AGA Regional Practice Skills Workshop, UCLA, Los Angeles, CA,

December 9, 2017.

366. “Upper GI Disorders” Rome Foundation Webcast, New York, NY, January 19, 2018.

367. “Managing the bloated patient: role of diet, probiotics, antibiotics” ACG/ASGE Best

Practices Course. Las Vegas, NV, January 27-28, 2018.

368. “Irritable bowel syndrome” Canadian Digestive Diseases Week 2018. Toronto, Ontario,

February 9-10, 2018.

369. “Dietary therapies for IBS” and “Update on the management of H. pylori infection” Annual

Educational Meeting in Gastroenterology, Cedars Sinai, Los Angeles, CA, March 2-3,

2018.

370. “Small intestinal bacterial overgrowth” and “New options for the medical management of

IBS” ACG/Florida Gastroenterology Society Annual Spring Postgraduate Course. Bonita

Springs, FL, March 17-18, 2018.

371. “Functional dyspepsia”. Annual Arapahoe GI course. Denver, CO, April 14-15, 2018.

372. “Update on the management of IBS-D” Kansas City Live Course and Update in

Gastroenterology. Kansas University, Kansas City, April 20-21, 2018.

373. AGA Postgraduate Course – “Case-based sessions - Breath testing: Role in Diagnosis and

Prediction of Treatment Response”, Washington, DC, June 2, 2018.


374. AGA Postgraduate Course – “Irritable Bowel Syndrome – What’s new?” Washington, DC,

June 3, 2018.

375. “How to get your functional GI patient functioning again”. Digestive Diseases Week 2018,

Washington, DC, June 3, 2018.

376. “Meet the Professor: Dietary interventions for IBS” Digestive Diseases Week 2018,

Washington, DC, June 4, 2018.

377. Moderator: “Chronic Diarrhea and Irritable Bowel Syndrome: Current Knowledge and

Update on Management Strategies” Digestive Diseases Week 2018, Washington, DC, June

5, 2018.

378. “Efficacy and Safety of Tenapanor in Patients with Constipation Predominant Irritable

Bowel Syndrome: A 6-month, Double-Blind, Placebo-Controlled Phase 3 Trial (T3MPO-

2)” Digestive Diseases Week 2018, Washington, DC, June 5, 2018.

379. “Dietary modifications for lower GI disorders” ANMS Clinical Postgraduate Course,

Milwaukee, WI, July 26, 2018.

380. “Getting CIC patients to effective therapy through phenotype and specialized care” ANMS

Clinical Postgraduate Course, Milwaukee, WI, July 26, 2018.

381. Session Chair: “Therapeutic advances in FGIDs” Functional Neurogastroenterology

Motility Meeting, Amsterdam, NE, August 31, 2018.

382. “FODMAPs” Functional Neurogastroenterology Motility Meeting, Amsterdam, NE,

August 31, 2018.

383. “Management of ulcer disease in the upper GI tract” VGS/ACG Regional Postgraduate

Course, Williamsburg, VA, September 8, 2018.

384. “Management of IBS in 2018” Chicago Gut Club, Oakbrook, IL, September 12, 2018.

385. “Chronic idiopathic constipation and opioid-induced constipation: The same but

different...” GI GALA, San Diego, CA, September 21, 2018.

386. Course Director and Speaker, Food: the main course to digestive health. Michigan

Medicine, Ann Arbor, MI, September 28-30, 2018.

387. Course Co-Director and Speaker, ACG Pharmacology Course, Annual Meeting of the

American College of Gastroenterology, Philadelphia, PA, October 5, 2018.

388. “Non-pharmacologic therapies for IBS” ACG Postgraduate Course, Philadelphia, PA,

October 6, 2018.

389. “Presidential Plenary: A Low FODMAP Diet May Reduce Symptoms in Patients with

Fecal Incontinence” Best FBD Research Award, Annual Meeting of the American College

of Gastroenterology, Philadelphia, PA, October 8, 2018.

390. “Non-celiac gluten sensitivity” Annual Meeting of the American College of

Gastroenterology, Philadelphia, PA, October 9, 2018.

391. “Plenary Session: Avoidant/Restrictive Food Intake Disorder in the Adult Gastroenterology

Population: An Under-Recognized Diagnosis?” Annual Meeting of the American College

of Gastroenterology, Philadelphia, PA, October 10, 2018.

392. “Functional esophageal disorders” and “Functional gastroduodenal disorders” Rome

Foundation CME course. Santa Fe, NM, October 13-14, 2018.

393. “Role of the gut microbiome in IBS”, Diagnosis of IBS and functional constipation in the

Rome IV era”, “Diet therapies for IBS”. Peking University Medical Center Hospital

Symposium of FGIDs and Psychological Disorders. Beijing, China, October 26-27, 2018.

394. “Chronic Constipation” Colorado Society for Parenteral & Enteral Nutrition, Denver, CO,

November 9, 2018.


395. “Management of H. pylori infection” Phoenix GI Society, Scottsdale, AZ, November 15,

2018.

396. “What are the key differences between Rome III and Rome IV” Rome Foundation- Thail

GI Thought Leader Summit, Chiang Mail, Thailand, December 6, 2018.

397. “Management of visceral pain” ACG/FGS Postgraduate Course, Naples, FL, March 3,

2019.

398. “Manipulation of the gut microbiota in IBS and other GI conditions” ACG/LGS

Postgraduate Course, New Orleans, LA, March 9, 2019.

399. “Management of IBS in 2019” GI GALA Conference, Dallas, TX, March 29, 2019.

400. “Practical diagnosis and management of IBS” Focus on GI Motility and IBD. Brooke

Army Medical Center, San Antonio, April 6, 2019.

401. “Is it IBS, SIBO or both?” 2019 Integrative SIBO Conference, Seattle, WA, April 13,

2019.

402. “Evidence-based treatment of H. pylori” Evening with the expert, Baltimore, MD, May 2,

2019.

403. “Food and IBS” Clinical Symposium, Digestive Diseases Week 2019, San Diego, CA, May

18, 2019.

404. “SIBO: fact or fiction” AGA Postgraduate Course, Digestive Diseases Week 2019, San

Diego, CA, May 18, 2019.

405. “Keeping to time and keeping the patient happy” Clinical Symposium, Digestive Diseases

Week 2019, San Diego, CA, May 19, 2019.

406. “Overlap between food intolerances and IBS” Clinical Symposium, Digestive Diseases

Week 2019, San Diego, CA, May 21, 2019.

407. “Emerging role of the microbiome in IBS” Newcastle Gut Club, Newcastle, AU, July 25,

2019.

408. “Evidence-Based Diet Therapies for IBS: Which Ones for Which Patients?” AGA

Freston Conference: Food at the intersection of gut health and disease. Course Co-

Director, Chicago, IL, August 8, 2019.

409. “Emerging capsule technologies for functional gastrointestinal and motility

disorders: The future is now!”, “Diet therapies for IBS: Where are we going?”

Course Co-director, ANMS Post-Graduate Course. Chicago, IL, August 16-17,

2019.

410. “IBS and small intestinal bacterial overgrowth” ANMS Annual Patient Education

Conference, Chicago, IL, August 18, 2019.

411. “Non-medical therapies for IBS: Soup to nuts”, “Microbiome-based therapies for

IBS”, “The inspired digital rectal examination”. ACG Functional GI Disorders

School. Course Co-Director, Williamsburg, VA, September 6, 2019.

412. “Functional dyspepsia: Getting to the right diagnosis and treatment” ACG/VGS

Regional Postgraduate Course, Williamsburg, VA, September 7-8, 2019.

413. “Microbiome-based treatments for IBS” Food, the Main Course to Gut Health,

Course Co-director, Michigan Medicine, Ypsilanti, MI, September 20-22, 2019.

414. “Primary and salvage treatment for H. pylori infection” ACG What’s New in GI

Pharmacology, Course Co-Director, San Antonio, TX, October 25, 2019.

415. “Non-celiac Wheat Intolerance” ACG Annual Postgraduate Course, San Antonio,

TX, October 26, 2019.


416. “Presidential Plenary: Avoidant restrictive food intake disorder amongst GI

behavioral health patients: comparison of ARFID vs non-ARFID patients” Best FBD

Research Award, Annual Meeting of the American College of Gastroenterology, San

Antonio, TX, October 27, 2019.

417. “Update on the management of IBS” San Diego Gut Club, San Diego, CA,

November 14, 2019.

418. “Is IBS a diagnosis of exclusion”, “Management strategies for chronic constipation”,

“Exclusion diets for IBS” Mexican Digestive Diseases Week, Cancun, Mexico,

November 17-20, 2019.

419. “Keynote Address: Understanding the overlap between IBS and IBD” AIBD

Meeting, Orlando, FL, December 12, 2019.

420. “IBS Masqueraders: Focus on sucrase-isomaltase deficiency” NYSGE Meeting, New

York, NY, December 20, 2019.

421. “IBS as a gut microbiome disorder”, “Non-pharmacological therapies for IBS”, “The

inspired digital rectal exam”. ACG Functional Bowel Disorders School, Course Co-

director, San Diego, CA, Januaary 10, 2020.

422. “Tips for Writing a Manuscript That Editors Want to Publish” ACG Bridging the

Leadership Gap. San Diego, CA, January 11, 2020.

423. “How do we help the patient with chronic bloating” ACG Governor’s Course, Las

Vegas, NV, January 26, 2020.

424. “Refractory constipation”, “Treatment of H. pylori” University of Michigan Winter

GI and Hepatology Update. Bonita Springs, FL, February 7-9, 2020.

Bibliography

Peer-Reviewed Publications

1. Chey WD, Hasler WL, and Bockenstedt P. Angiodysplasia and vonWillebrand's Disease

type IIB treated with Estrogen/Progesterone therapy. Am J Hematology 1992; 41:276-

79.

2. Chey WD, Kochman ML, Traber PG, and Gumucio JJ. Nizatidine-induced subfulminent

hepatic failure: Report of a case and review of the literature. J Clin Gastroenterol 1995;

20:164-7.

3. Sims M, Hasler W, Chey WD, Kim M, and Owyang C. Acute hyperglycemia inhibits

gastrocolonic and colonic peristaltic reflexes measured by an electronic barostat in

healthy humans. Gastroenterol 1995; 108:350-9.

4. Hasler WL, Kim MS, Chey WD, Stevenson V, Stein B, Owyang C. Central cholinergic

and alpha-adrenergic mediation of gastric slow wave dysrhythmias evoked during motion

sickness. Am J Physiol 1995; 268: G539-G547.

5. Chey WD, Kim ML, Hasler WL, Owyang C. Acute hyperglycemia alters perception of

rectal distention and blunts the rectoanal inhibitory reflex in healthy volunteers.

Gastroenterol 1995; 108:1700-8.

6. Chey WD, Beydoun A, Roberts D, Hasler W, and Owyang C. Somatostatin analog

educes perception of rectal electrical stimulation by spinal afferent pathway inhibition.

Am J Physiol 1995; 269 (Gastrointest. Liver Physiol. 32): G821-6.


7. Chey WD, Carpenter S, Spybrook M, Nostrant T, Elta G, Scheiman J. Prolonged effect

of omeprazole on the 14

C-urea breath test. Am J Gastroenterol 1996; 91:89-92.

8. Kohagen KR, Kim MS, McDonnell M, Chey WD, Owyang C, Hasler WL. Nicotine

effects on prostaglandin-dependent gastric slow wave rhythmicity and antral motility in

non-smokers and smokers. Gastroenterol 1996; 110:3-11.

9. Scheiman JM, Chey WD, Behler EM, Crause I, Elta GH. One-week therapy for H.

pylori: A randomized trial of two treatment regimens. J Clin Gastroenterol 1996; 23:170-

3.

10. Chey WD, Fey D, Woods M, Scheiman J, Del Valle J, Nostrant T. Lansoprazole and

ranitidine effect the accuracy of the 14C-urea breath test by a pH dependent mechanism.

Am J Gastroenterol 1997; 92:446-50.

11. Kim MS, Chey WD, Owyang C, Hasler WL. Role of plasma vasopressin as a mediator

of nausea and gastric slow wave dysrhythmias in motion sickness. Am J Physiol 1997;

272(4 Pt 1): G853-62.

12. Marinella MA, Chey WD. The syndrome of inappropriate antidiuretic hormone secretion

in a patient with Whipple’s disease. Am J Med Sci 1997; 313:247-8.

13. Chey WD, Fisher L, Elta GH, Barnett J, Nostrant T, Del Valle J, Scheiman J. Bismuth

subsalicylate instead of metronidazole with lansoprazole and clarithromycin for H. pylori

infection: a randomized trial. Am J Gastroenterol 1997; 92:1483-6.

14. Elta GH, Barnett JL, Wille RT, Brown KA, Chey WD, Scheiman JM. Pure cut

electrocautery current for sphincterotomy causes less post-procedure pancreatitis than

blended current. Gastrointest Endosc 1998; 47:149-53.

15. Chey WD, Murthy U, Linscheer W, Barish C, Riff R, Rubin H, Safdi M, Schwartz H,

Shah H, Wruble L, El-Zamaity, HMT. The ChemTrak Hp ChekTM fingerstick, whole

blood serology test for the detection of H. pylori infection. Am J Gastroenterol 1998;

93:16-19.

16. Fendrick AM, Chey WD. Approach to the patient with Helicobacter pylori-associated

epigastric pain. J Clin Outcomes Med 1998; 5:41-8.

17. Stern MA, Chey WD. Pneumatosis coli and colonic intussusception. N Engl J Med 2001;

345:964.

18. Bjornsson ES, Chey WD, Ladabaum U, Hooper FG, Woods ML, Owyang C, Hasler WL.

Differential 5-HT3 mediation of the human gastrocolonic response and colonic peristaltic

reflex. Am J Physiol 1998; 275: G498-505.

19. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential

effects of amitriptyline on perception of somatic and visceral stimulation in healthy

volunteers. Am J Physiol 1998; 275: G460-6.

20. Chey WD, Fisher L, Barnett J, Delvalle J, Elta GH, Nostrant T, Palaniappan J, Scheiman

J. Triple therapy with low versus high dose azithromycin to treat H. pylori infection.

Aliment Pharm Ther 1998; 12:1263-7.

21. Fendrick AM, Chey WD, Fennerty MB. Estimating the demand for H. pylori

confirmatory testing after eradication treatment. Am J Med 1999; 107:133-6.

22. Chey WD, Murthy U, Shaw S, Zawadski A, Linscheer W, Laine L. A comparison of 3

fingerstick, whole blood antibody tests for H. pylori infection: a US multi-center trial.



23. Chey WD, Murthy U, Toskes P, Carpenter S, Laine L. The 13C-urea blood test accurately

detects active H. pylori infection: a US, multicenter trial. Am J Gastroenterol 1999;

94:1522-4.

24. Pop-Busui, R, Chey W, Stevens MJ. Severe Hypertension Induced by the Long-Acting

Somatostatin Analogue Sandostatin LAR in a Patient with Diabetic Autonomic

Neuropathy. Journal of Clinical Endocrinology & Metabolism 2000; 85:943-946.

25. Mao HV, Lak BV, Long T, Chung NQ, Thang DM, Hop TV, Chien NN, Hoan PQ,

Henley KS, Connor BA, Stone CD, Chey WD. Omeprazole or ranitidine bismuth citrate

with clarithromycin and amoxicillin for 10 days to treat H. pylori infection: A

randomized, controlled trial in Vietnamese patients with duodenal ulcer. Aliment

Pharmacol Ther 2000; 14:97-101.

26. Chey WD, Metz DC, Shaw S, Kearney D, Montague J, Murthy U. Appropriate timing of

the 14C-urea breath test to establish eradication of H. pylori infection. Am J Gastroenterol

2000; 95:1171-4.

27. Wille RT, Barnett JL, Chey WD, Scheiman JM, Elta GH. Routine droperidol pre-

medication improves sedation for ERCP. Gastrointest Endosc 2000; 52:362-6.

28. Stern MA, Fendrick AM, McDonnell WM, Gunaratnam N, Moseley RH, Chey WD. A

randomized, controlled trial to assess a novel colorectal cancer screening strategy: the

conversion strategy. Am J Gastroenterol 2000; 95:2074-9.

29. Hirsh G, Chey WD. Case of the Month: ruptured pseudoaneurysm. Am J Med 2000;

109:65.

30. Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C. Localization of

human cortical and subcortical responses to gastric distention using positron emission

tomography. Gastroenterol 2001; 120:369-76.

31. Chey WD, Shapiro B, Zawadski A, Goodman K. Gastric emptying characteristics of a

novel 13C-octanoate-labelled muffin meal. J Clin Gastroenterol 2001; 32:394-99.

32. Chey WD, Chathadi K, Montague J, Ahmed F, Murthy U. Intragastric acidification

reduces the occurrence of false negative urea breath test results in patients taking a proton

pump inhibitor. Am J Gastroenterol 2001; 96:1028-32.

33. Chey WD, Fendrick M. Non-invasive H. pylori testing for the test and treat strategy: a decision

analysis to assess the impact of past infection on test choice. Arch Intern Med 2001; 161:2129-

32.

34. Chey WD. Diagnosis of Helicobacter pylori. Practic Gastroenterol 2001; 25:28-41.

35. Scheiman JM, Carlos R, Barnett JL, Elta GH, Nostrant TT, Chey WD, Francis I, Nandi P. Can

endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in

patients with suspected biliary disease? Am J Gastroenterol 2001; 96:2900-4.

36. Quallich LG, Stern MA, Rich M, Chey WD, Barnett JL, Elta GH. Bile duct crystals do

not contribute to post-cholecystectomy syndrome. Gastrointestinal Endoscopy 2002;

55:163-6.

37. Lake J, Chey WD. Diagnosis of H. pylori in the clinical setting. Frontiers in Bioscience

2001; 6: e129-e136.

38. Gonlachanvit S, Chey WD, Goodman KJ, Parkman HP. Effect of meal size and test

duration on gastric emptying and gastric myoelectrical activity as determined with

simultaneous EGG and 13C-octanoate breath test in normal subjects using a muffin meal.

Dig Dis Sci 2001; 46:2643-50.


39. Bjornsson E, Chey WD, Hooper F, Woods M, Owyang C, Hasler W. Impaired

gastrocolonic response and peristaltic reflex in slow transit constipation: Role of 5-HT3

pathway. Am J Physiol 2002; 283: (Gastrointest Liver Physiol) G400-G407.

40. Gorelick A, Cannon M, Barnett J, Chey W, Scheiman J, Elta G. First cut, then blend: an

electrocautery technique affecting bleeding at sphincterotomy. Endoscopy 2001; 33:976-

80.

41. Ladabaum U, Chey WD, Scheiman J, Fendrick M. Empiric therapy may be cost-effective

compared to H. pylori testing and treatment in some populations with uninvestigated

dyspepsia. Aliment Pharmacol Ther 2002; 16:1491-1501.

42. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and

Rome II criteria for IBS in US women. Am J Gastroenterol 2002; 97:2803-11.

43. Cash BD, Chey WD. Diagnosis of the Irritable Bowel Syndrome. Practical Gastroenterol

2002; 26:24-38.

44. Cash BD, Chey WD. Irritable Bowel Syndrome: Diagnosis and Management. J Clin

Outcomes Med 2002; 9:409-18.

45. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel

syndrome patients: a systematic review. Am J Gastroenterol 2002; 97:2812-19.

46. Brown WH, Chey WD, Elta GH. Number of Responses on a Review of Systems

Questionnaire Predicts the Diagnosis of Functional GI Disorders. J Clin Gastroenterol

2003; 36:222-27.

47. Koshy SS, Bansal R, Scheiman J, Barnett J, Chey WD, Nostrant TT. Intrasphincteric

botulinum toxin versus Witzel pneumatic balloon dilatation for treatment of primary

achalasia. J Clin Gastroenterol 2003; 36:209-214.

48. Chey WD, Huang B, Lukasik N, Jackson RL. Lansoprazole vs. Esomeprazole in

symptomatic gastro-esophageal reflux disease: A double-blind, radomised, multicentre

trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003; 23:69-

84.

49. Hasler WL, Chey WD. Clinical management of nausea and vomiting. Gastroenterol

2003; 125:1860-7.

50. Schoenfeld P, Chey WD. An evidence based approach to clinical practice guidelines –

diagnosis and treatment of Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2003;

1:322-7.

51. Cash BD, Chey WD. Irritable Bowel Syndrome: An evidence based approach to

diagnosis. Aliment Pharmacol Ther 2004; 19:1235-45.

52. Gorelick A. Barnett J. Chey W. Anderson M. Elta G. Botulinum toxin injection after

biliary sphincterotomy. Endoscopy 2004; 36(2):170-3.

53. Cash BD, Chey WD. Irritable Bowel Syndrome: A systematic review. Fam Med Clin N

Am 2004; 6:647-70.

54. Rubenstein J, Sherif A, Appelman H, Chey WD. Ulcerative colitis associated enteritis. J

Clin Gastroenterol 2004; 38:46-51.

55. Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ. Long-

term efficacy and safety of Alosetron in women with severe diarrhea-predominant

Irritable Bowel Syndrome. Am J Gastroenterol 2004; 99:2195-2203.

56. Fischer R, Thistle J, Lembo A, Novick J, O’Kane P, Chey WD, Beglinger C, Rueegg P,

Shi V, Dogra A, Luo D, Earnest D. Tegserod does not alter fasting or meal-induced

biliary tract motility. Am J Gastroenterol 2004; 99:1342-9.


57. Chey WD. Erosive esophagitis and NERD: Can we really classify patients with heartburn

using endoscopic findings? Clin Gastroenterol Hepatol, 2004; 2:654-5.

58. Evans LT, Chey WD. Clostridial aortitis and colon cancer. Gastrointest Endosc 2004;

60:803.

59. Johanson JF, Wald A, Tougas G, Chey WD, Novick J, Lembo A, Fordham F, Guella M,

Nault B. Tegaserod is effective and well tolerated in patients with chronic constipation:

Findings from a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol

Hepatol 2004; 2:796-805.

60. Saad R, Chey WD. A clinician’s guide to the diagnosis and treatment of H. pylori. Clin J

Med 2005; 72:109-126.

61. Gonlachanvit S, Rhee J, Sun WM, Chey WD. Effect of acute acoustic stress on anorectal

function and sensation in healthy humans. Neurogastroenterol Motil 2005; 17:222-8.

62. Chey WD, Inadomi, JM, Booher A, Sharma VK, Fendrick AM, Howden CW. Primary

care physicians perceptions and practices on the management of GERD: Results of a

national survey, Am J Gastroenterol 2005; 100:1243-50.

63. Chey WD, Cash BD. Cilansetron: A new serotonergic agent for the irritable bowel

syndrome and diarrhea. Expert Opinions on Investigational Drugs, 14:185-93; 2005.

64. Talley NJ, Vakil N, Practice Parameters Committee of the ACG. Guidelines for the

management of dyspepsia. Am J Gastroenterol 2005; 100:2324-37.

65. Schmeidlin-Ren P, Kesisoglou F, Mapili JA, Sabek ME, Chey WD, Roessler B,

Zimmermann EM. Increased transduction of human intestinal epithelial cells by

adenoviral vectors in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:464-72.

66. Cash BD, Chey WD. Role of serotonergic agents in the treatment of patients with

primary chronic constipation. Aliment Pharmacol Ther 2005; 22:1047-60.

67. Ahmed F, Chey WD, Murthy U. Evaluation of the Ez-HBT Helicobacter blood test to

establish Helicobacter pylori eradication, Aliment Pharm Ther 2005; 22:875-80.

68. Dickman R, Green C, Chey WD, Jones MP, Eisen GM, Ramirez F, Briseno M, Garewal

HS, Fass R. Clinical predictors of Barrett’s esophagus length. Gastrointest Endosc 2005;

62:675-81.

69. Saad R, Chey WD. What is the most effective treatment for patients with dyspepsia who

are negative for Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol

2006; 3:20-21.

70. Chey WD, Eswaran S, Howden CW, Inadomi J, Fendrick AM, Scheiman J. Primary care

physicians perceptions of NSAID and aspirin-associated toxicity: Results of a national

survey. Aliment Pharm Ther 2006; 23:655-68.

71. Saad R, Chey WD. Tegaserod in the treatment of irritable bowel syndrome with

constipation. Women’s Health 2006; 2:29-42.

72. Saad R, Schoenfeld P, Chey WD. Levofloxacin triple or PPI quadruple salvage therapy

for persistent Helicobacter pylori infection: Results of a meta-analysis. Am J


73. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic

colitis and serious complications of constipation among patients using alosetron:

systematic review of clinical trials and post-marketing surveillance data. Am J


74. Longstreth G, Thompson WG, Chey WD, Houghton L, Mearin F, Spiller R. Rome III:

Functional Bowel Disorders. Gastroenterol 2006; 130:1480-91.


75. Irvine EJ, Whitehead W, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldehuyzen van

Zanten S. Rome III: Design of treatment trials. Gastroenterol 2006; 130:1538-51.

76. Saad R, Chey WD. Current and emerging therapies for functional dyspepsia. Aliment

Pharmacol Ther 2006; 24;475-92.

77. Saad R, Chey WD. Treatment of H. pylori infection in 2006. Gastroenterol Hepatol

Annual Review 2006; 1:30-35.

78. Chey WD, Wong B. American College of Gastroenterology Practice Guidelines:

Management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808-25.

79. Elnachef N, McMorris M, Chey WD. Successful treatment of Common Variable

Immunodeficiency Disorder Associated Diarrhea with Budesonide: A Case Report. Am J


80. Rubenstein JH, Nojkov B, Korsnes S, Adlis SA, Shaw MJ, Inadomi JM, Chey WD.

Esophageal hypersensitivity is associated with features of psychiatric disorders and the

irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:443-52.

81. Saad R, Chey WD. The role of breath tests in clinical GI practice. Gastroenterol 2007;

133:1763-6.

82. Portlock CS, Hamlin P, Noy A, Chey WD (4/12) Markowitz A. Infectious disease

associations in advanced stage, indolent lymphoma (Follicular and Non-Follicular):

Developing a lymphoma prevention strategy. Ann Oncology 2008; 19:254-258. [I

contributed by helping with the study design, providing breath testing analysis and

interpretation and reviewing and revising the manuscript]

83. Portlock CS, Hamlin P, Noy A, Chey WD (4/12) Markowitz A. Infectious disease

associations in advanced stage, indolent lymphoma (Follicular and Non-Follicular):

Developing a lymphoma prevention strategy. Ann Oncology 2008; 19:254-258. [I

contributed by helping with the study design, providing breath testing analysis and

interpretation and reviewing and revising the manuscript]

84. Kuo B, McCallum RW, Koch KL…Chey WD (6/12)…Parkman HP. Comparison of

gastric emptying of a non-digestible capsule to a radiolabeled meal in healthy and

gastroparetic subjects. Aliment Pharmacol Ther 2008; 27:186-96. [I contributed by

helping to design the study, interpret the data and by reviewing and revising the

manuscript]

85. Saad R, Chey WD. Recent developments in the treatment of the irritable bowel

syndrome. Expert Opinion Invest Drugs 2008; 17:117-30.

86. Nojkov B, Saad R, Adlis S, Shaw M, Chey WD. Predictors of response to PPI therapy in

patients with GERD: the influence of co-morbid IBS and psychological disease. Aliment


87. Chey WD, Paré P , Viegas A, Ligozio G, Shetzline MA. Tegaserod for females suffering

from IBS with mixed bowel habits or constipation: A randomized controlled trial. Am J


88. Saad R, Chey WD. Treatment of persistent H. pylori infection. Clin Gastroenterol

Hepatol 2008; 6(10):1086-1090.

89. Saad R, Chey WD. Lubiprostone in the treatment of chronic idiopathic constipation and

irritable bowel syndrome and constipation. Exp Rev Gastroenterol Hepatol 2008;

2(4):497-508.

90. Vakil N, Laine L, Talley NJ…Chey WD (6/10), Cohard-Radice M. Tegaserod treatment

for dysmotility-like functional dyspepsia: Results of two randomized, controlled trials.


Am J Gastroenterol 2008 103(8):1906-19. [contributed by helping to design the study,

interpret the data and by reviewing and revising the manuscript]

91. Elnachef N, Scheiman JS, Fendrick M, Howden C, Chey WD. Changing perceptions and

practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2

selective nonsteroidal anti-inflammatory drugs among US primary care providers.

Aliment Pharmacol Ther 2008; 28:1249-58.

92. Lewicky-Gaupp C, Morgan D, Chey WD (3/6), Fenner DE. Does physical therapy for

constipation related to puborectalis dyssynergia improve symptom severity and quality of

life? Dis Colon Rectum 2008; 51:1686-91.

93. Lacy B, Chey WD. Lubiprostone: Chronic constipation and irritable bowel syndrome

with constipation. Expert Opinion Pharmacol 2009; 10:143-52.

94. Drossman D, Chey WD, Johanson JF, Fass R, Panas R, Ueno R. Lubiprostone in patients

with constipation-associated irritable bowel syndrome: results of two randomized,

placebo-controlled trials. Aliment Pharmacol Ther 2009; 29:329-41. [contributed by

helping to design the study, interpret the data and by reviewing and revising the

manuscript]

95. Maneerattanaporn M, Chey WD. Sleep and functional gastrointestinal disorders: The

chicken or the egg? Neurogastroenterol Motil 2009; 2:97-99.

96. Brenner D, Moeller MJ, Chey WD, Schoenfeld P. The role of probiotics in the treatment

of irritable bowel syndrome: a systematic review. Am J Gastronterol 2009; 104:1033-49.

[contributed by helping to design the study and by writing, reviewing and revising the

manuscript]

97. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BMR, Moayyedi P. Utility of

diagnostic tests for celiac disease in Irritable Bowel Syndrome: Systematic review and

meta-analysis. Arch Int Med 2009; 169:651-8.

98. ACG IBS Task Force. An evidence-based review of the management of irritable bowel

syndrome. Am J Gastroenterol 2009; 104 (supplement 1): S1-S35. [contributed by

interpreting the data used to make management recommendations and by writing,

reviewing and revising the manuscript]

99. Sharma P, Chey WD, Hunt R, Laine L, Malferheiner P, Wani S. Endoscopy of the

esophagus in gastroesophageal reflux disease – Are we losing sight of symptoms?

Another perspective. Dis Esophagus 2009; 22:461-6. [contributed by helping to write,

review and revise the manuscript]

100. Rao SSC, Kuo B, McCallum RW, Chey WD, DiBaise JK, Hasler WL, Koch KL,

Lackner JL, Miller C, Saad R, Semler JR, Sitrin, MD, Wilding GE, Parkman HP.

Investigation of Wireless Manometry Capsule for Colonic and Whole Gut Transit: A

Comparative Study with Radiopaque Markers in Health and Constipation. Clin

Gastroenterol Hepatol 2090; 7:537-44. [contributed by helping to design the study,

interpret the data and by reviewing and revising the manuscript]

101. Spiegel B, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Estrailian E, Chey WD,

Lembo A, Karsan H, Tillisch K, Dulai G, Tally J, Chang L. Developing valid and reliable

health utilities in IBS: Results from the IBS Proof Cohort. Am J Gastroenterol 2009;

104:1984-91.

102. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein A, Moayyedi P. Efficacy of 5-

HT3 Antagonists and 5-HT

4 Agonists in Irritable Bowel Syndrome: Systematic Review

and Meta-analysis. Am J Gastroenterol 2009; 104:1831-43.


103. Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN.

The effects of the proton pump inhibitor TAK 390MR on daytime and nighttime

heartburn in patients with nonerosive gastroesophageal reflux disease: A double-blind,

randomized, placebo-controlled trial. Aliment Pharmacol Ther 2009; 29:1261-72.

104. Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N. Treatment

patterns and symptom control in patients with gastroesophageal reflux disease – A US

Community-based Survey. Curr Medical Res Opin 2009; 8:1869-78.

105. Hasler WL, Saad RJ, Rao SS, Wilding GE, Parkman HP, Koch KL, McCallum RW, Kuo

B, Sarosiek I, Sitrin MD, Semler JR, Chey WD. Heightened colon motor activity

measured by wireless capsule in patients with constipation: relation to colon transit and

IBS. Am J Physiol – GI and Liver Physiology 297: 2009; G1107-14.

106. Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley

NJ, Whitehead WE. Psychometric evaluation of endpoints in IBS randomized controlled

trials: A Rome Foundation Working Group Report. Gastroenterol 2009; 137:1944-53.

107. Spiegel B, Bolus R, Harris LA, Lucak S, Mayer E, Naliboff B, Esrailian E, Chey WD,

Lembo A, Karsan H, Tillisch K, Talley J, Chang L. Measuring IBS Patient Reported

Outcomes with an Abdominal Pain Numeric Rating Scale: Results from the PROOF

Cohort. Aliment Pharmacol Ther 2009; 30:1159-70.

108. Sarosiek I, Selover KH, Katz LA, Semler JR, Wildings GE, Lackner JM, Sitrin MD, Kuo

B, Chey WD, Hasler WL, Koch KL, Parkman H, Sarosiek J, McCallum R. Assessment of

Regional Gut Transit Times in Healthy Controls and Patients with Gastroparesis using

Wireless Motility Technology. Aliment Pharmacol Ther 2010; 31:313-22.

109. Luther J, Higgins P, Moayyedi P, Vakil N, Chey WD. Clarithromycin-based triple

therapy vs. Bismuth-based quadruple therapy for H. pylori infection: A meta-analysis.


110. Saad R, Rao S; Hasler WL; Katz LA; Koch K; Kuo B; Lackner JM; Parkman HP;

McCallum R; Miller C; Sarosiak I; Semler J; Sitrin MD; Wilding GE; Chey WD. How

well do stool form or stool frequency correlate with colonic transit: Results from a multi-

center study using the SmartPill Wireless pH/Pressure Capsule & radio-opaque

Sitzmarker test in healthy controls and constipated patients. Am J Gastroenterol 2010;

105:403-11.

111. Chey WD, Howden CW, Tack J, Ligozio G, Earnest D. Long-Term Tegaserod Treatment

for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort

Studies. Dig Dis Sci 2010; 55:684-97.

112. Chey WD, Mody RR, Izat E. Patient and Physician Satisfaction with Proton Pump

Inhibitors: Are There Opportunities for Improvement? Dig Dis Sci 2010; 55:3415-22.

113. Chey WD, Nojkov B, Cash BD. The yield of colonoscopy in patients with nonconstipated

IBS: Results from a prospective, controlled US multicenter trial. Am J Gastroenterol

2010; 105:859-65.

114. Nojkov B, Rubenstein J, Chey WD, Hoogerwerf W. The effect of shift work on the

prevalence and clinical impact of Functional Bowel Disorders in nurses. Am J


115. Kloetzer L, Chey WD, McCallum RW, Koch KL, Wo JM, Sitrin M, Katz LA, Lackner

JM, Parkman HP, Wilding GE, Semler JR, Hasler WL, Kuo B. Motility of the

antroduodenum in healthy and gastroparetics characterized by wireless motility capsule.

Neurogastroenterol Motil 2010; 22:527-e117.


116. Spiegel B, Bolus R, Harris LA, Lucak S, Mayer E, Naliboff B, Esrailian E, Chey WD,

Lembo A, Karsan H, Tillisch K, Talley J, Chang L. Characterizing Abdominal Pain in

IBS: Guidance for Study Inclusion Criteria, Outcome Measurement, and Clinical

Practice. Aliment Pharmacol Ther 2010; 32:1192-1202.

117. Spiegel B, Bolus R, Agarwal N, Harris LA, Lucak S, Esrailian E, Chey WD, Lembo A,

Karsan H, Tillisch K, Talley J, Sayuk G, Chang L. Measuring Symptoms in Irritable

Bowel Syndrome: Development of a Framework for Clinical Trials. Aliment Pharmacol

Ther 2010; 32:1275-91.

118. Mullady DK, Yadav D, Amann ST, O'Connell MR, Barmada MM, Elta GH, Scheiman

JM, Wamsteker EJ, Chey WD, Korneffel M, Weinman BM, Slivka A, Sherman S, Hawes

RH, Brand RE, Burton FR, Lewis MD, Gardner TB, Gelrud A, DiSario JA, Baillie J,

Banks PA, Whitcomb DC, Anderson MA. Type of pain, pain-associated complications,

quality of life, disability and resource utilization in chronic pancreatitis: a prospective

cohort study. Gut 2011; 60:77-84.

119. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya S, Shaw AL, Bortey

E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without

constipation. New Engl J Med 2011; 364:22-32.

120. Chey WD, Maneerattanaporn M, Saad R. Pharmacologic and complementary and

alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011; 5:253-66.

121. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-

controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic

constipation. Am J Gastroenterol 2011; 106:1803-12.

122. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez

RL, Ferreccio C, Herrero R, Lazcano-Ponce E, Meza-Montenegro MM, Peña R, Peña

EM, Salazar-Martinez E, Correa P, Martinez ME, Valdivieso M, Goodman GE, Crowley

JJ, Baker LM. 14-day triple, 5-day concomitant, and 10-day sequential therapies for

Helicobacter pylori infection in seven Latin American sites: a randomized trial. Lancet

2011; 378:507-14.

123. Cash BD, Rubenstein JH, Young PE, Gentry A, Nojkov B, Lee D, Andrews AH, Dobhan

R, Chey WD. The prevalence of celiac disease among patients with nonconstipated

irritable bowel syndrome is similar to controls. Gastroenterol 2011; 141:1187-93.

124. Kuo B, Maneerattanaporn M, Lee AA, Baker JR, Weiner SM, Chey WD, Wilding GE,

Hasler WL. Generalized transit delay on wireless motility capsule testing in patients with

clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit

constipation. Dig Dis Sci 2011; 56:2928-38.

125. Menees SB, Maneerattanaporn M, Kim HM, Chey WD. The efficacy and safety of

rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J

Gastroenterol 2012; 107:28-35. PMID 22045120

126. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient

outcomes with lubiprostone for up to 52 weeks in patients with Irritable Bowel Syndrome

with Constipation. Aliment Pharmacol Ther 2012; 35(5):587-99. PMID 22251419

127. Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, Muller-Lissner S,

Quigley EMM, Schuurkes J, DeMaeyer JH, Stanghellini V. Systematic Review:

Cardiovascular safety profile of 5-HT4 agonists developed for GI disorders. Aliment

Pharmacol Ther 2012; 35:745-67. PMID 22356640

128. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia


XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM. Linaclotide for Irritable

Bowel Syndrome with Constipation: A 26-week, Randomized, Double-blind, Placebo-

controlled Trial to Evaluate Efficacy and Safety. Am J Gastroenterol 2012;

107(11):1702-12. PMID 22986437

129. Menees S, Saad R, Chey WD. Agents that act luminally to change diarrhea and

constipation. Nature Rev Gastroenterol Hepatol 2012, 9:661-74. PMID 22945441

130. Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shif SJ, Currie

MG, Johnston JM. Randomised clinical trials: linaclotide phase 3 studies in IBS-C – a

prespecified further analysis based on European Medicines Agency-specified endpoints.

Aliment Pharmacol Ther 2013; 37:49-61. PMID 23116208

131. Smith TM, Menees SB, Xu X, Saad RJ, Chey WD, Fenner DE. Factors associated with

quality of life among women with fecal incontinence. Int Urogynecol J 2013; 24:493-9.

PMID 22806489

132. Greenberg ER, Chey WD. Defining the role of sequential therapy for H. pylori infection.

Lancet 2013; 381:180-2. PMID: 23158881

133. Menees SB, Smith TM, Xu X, Chey WD, Saad RJ, Fenner DE. Factors associated with

symptom severity in women presenting with fecal incontinence. Dis Colon Rectum.

2013; 56(1):97-102. PMID: 23222286

134. Morgan DR, Torres J, Sexton R, Herrrero R, Salazar-Martinez E, Greenberg ER, Bravo

LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Pena EM,

Pena R, Correa P, Martinez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE,

Crowley JJ, Baker LH. Risk of recurrent Helicobacter pylori infection 1 year after initial

eradication therapy in 7 Latin American communities. JAMA 2013; 309:578-86. PMID

23403682

135. Eswaran S, Goel A, Chey WD. What role does wheat play in the symptoms of Irritable

Bowel Syndrome? Gastroenterol Hepatol 2013; 9:85-91. PMID 23983652

136. Chey WD. The role of food in the functional gastrointestinal disorders: introduction to a

manuscript series. Am J Gastroenterol 2013; 108:694-7. PMID 23545712

137. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am J

Gastroenterol 2013; 108:718-27. PMID 23545709

138. Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in

the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol 2013; 25:700-706.

PMID 24047604

139. Rubenstein JH, Morgenstern H, Chey WD, Murray J, Scheiman JM, Schoenfeld P,

Appelman HD, McMahon L, Metko V, Kellenberg J, Kalish T, Baker J, Inadomi JM.

Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett’s esophagus.

Gut 2013 Mar 5 [Epub ahead of print]. PMID 23461896

140. Saad R, Chey WD. Breath testing for small intestinal bacterial overgrowth: maximizing

test accuracy. Clin Gastroenterol Hepatol 2014;12(12):1964-1972. PMID 24095975

141. Jones MP, Chey WD, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley NJ. A

biomarker panel and psychological morbidity differentiate the irritable bowel syndrome

from health and provide novel pathophysiological leads. Aliment Pharmacol Ther 2014;

39:426-437.

142. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for

Opioid-induced Constipation in Patients with Noncancer Pain. N Engl J Med 2014;25:

2387-2396. PMID: 24896818

http://www.ncbi.nlm.nih.gov/pubmed/23222286

http://www.ncbi.nlm.nih.gov/pubmed/23222286


143. Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E,

Forbes WP. Safety and tolerability of rifaximin for the treatment of IBS with diarrhea; a

pooled analysis of randomized, placebo-controlled trials. Aliment Pharmacol Ther 2014;

39:1161-8.

144. Webster L, Chey WD, Tack J, et al. Randomised clinical trial: long-term safety and

tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment


145. Almario C, Chey WD, Kuang A, et al. Computer Algorithm Vs Physician-Documented

History of Presenting Illness (HPI): Results of a Blinded Comparison. Am J

Gastroenterol 2015; 110:170–179. PMID: 25461620

146. Menees S, Powell C, Kurlander J, Goel A, Chey WD. A Meta-analysis of the Utility of

C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin

to exclude inflammatory bowel disease in Adults with IBS. Am J Gastroenterol 2015:

110:1243-44. PMID: 25732419

147. Chey WD, Eswaran S, Kurlander J. Management of Irritable Bowel Syndrome. JAMA

2015; 313(9):949-958. PMID: 25734736

148. Heidelbaugh JJ, Stelwagon MA, Miller SA, Shea EP, Chey WD. The Spectrum of

Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic

Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden. Am J

Gastroenterol 2015; 110:580-7. PMID: 25781368

149. Baker JR, Eswaran S, Saad R, Menees S, Fenner D, Chey WD. Improvement in

Abdominal Symptoms After Biofeedback Therapy in Patients with Dyssynergic

Defecation. Clin Translational Gastroenterol 2015; 6: e105. PMID: 26225863

150. Menees S, Guentner A, Chey SW, Saad R, Chey WD. How Do US Gastroenterologists

use Over-the-Counter and Prescription Medications in Patients with Gastroesophageal

Reflux and Chronic Constipation? Am J Gastroenterol 2015; 110:1516-25. PMID:

26054623

151. Almario CV, Chey WD, Iriana S, Dailey F, Robbins K, Patel AV, Reid M, Whitman C,

Fuller G, Bolus R, Dennis B, Encarnacion R, Martinez B, Soares J, Modi R, Agarwal N,

Lee A, Kubomoto S, Sharma G, Bolus S, Chang L, Spiegel BMR. Computer versus

physician identification of gastrointestinal alarm features. Int J Med Inform 2015;

84:1111-17. PMID: 26254875

152. Kulkami HS, Chey WD, Mookherjee S, Saint S, Bump GM. Taking the detour. J Hosp

Med 2015; 10:686-90. PMID: 26178589

153. Mearin F, Lacy B, Chang L, Chey WD, Lembo A, Simren M, Spiller R. Rome IV: The

Functional Bowel Disorders. Gastroenterol 2016; 150:1393-1407.

154. Palsson OS, Whitehead WE, van Tilburg MAL, Chang L, Chey WD, Crowell MD,

Keefer L, Lembo AJ, Parkman HP, Rao SSC, Sperber A, Spiegel B, Tack J, Vanner S,

Walker LS, Whorwell P, Yang Y. Development and validation of the Rome IV diagnostic

questionnaire for adults. Gastroenterol 2016; 150:1481-91.

155. Almario C, Chey WD, Spiegel BS. Impact of National Institutes of Health

Gastrointestinal PROMIS® Measures in Clinical Practice: Results of a Multicenter

Controlled Trial. Am J Gastroenterol 2016; 111:1546-56. PMID: 27481311

156. Eswaran S, Chey WD, Han-Markey T, Ball K, Jackson K. US, randomized, controlled

trial comparing the low FODMAP diet vs. modified NICE guidelines in adults with IBS-

D. Am J Gastroenterol 2016; 111:1824-32. PMID: 27725652


157. Chang L, Chey WD, Drossman D, Losch-Beridon T, Wang M, Lichtlen P, Mareya S.

Effects of Baseline Abdominal Pain and Bloating on Response to Lubiprostone in

Patients with Irritable Bowel Syndrome with Constipation. Aliment Pharmacol Ther

2016; 44:1114-22. PMID: 27669680

158. McRorie J, Chey WD. Fermented Fiber Supplements Are No Better Than Placebo for a

Laxative Effect. Dig Dis Sci 2016; 61:3140-46. PMID: 27680987

159. Chey WD, Leontiadis G, Howden C, Moss S. American College of Gastroenterology

Practice Guideline: Management of Helicobacter pylori infection. Am J Gastroenterol

2017; 112:211-38.

160. Ford AC, Chey WD. Screening for Celiac Disease in Irritable Bowel Syndrome: An

Updated Systematic Review and Meta-analysis. Am J Gastroenterol 2017; 112:65-76.

PMID: 27753436

161. Chey WY, Chang V, Hoellrich CM, Lubkin M, Corcoran D, Chang TM, Chey WD.

Mega-cecum: An unrecognized cause of symptoms in some female patients with uro-

gynecological symptoms and severe slow-transit constipation. Dig Dis Sci 2017; 62:217-

23. PMID: 27913997

162. Chey WD, Lembo AJ, Phillips JA, Rosenbaum DP. Tenapanor Treatment of Patients

with Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized,

Placebo-Controlled Efficacy and Safety Trial. Am J Gastroenterol 2017; 112:763-74.

PMID: 28244495

163. Lacy BE, Chey WD, Cash BD, et al. Eluxadoline efficacy in IBS-D patients who report

prior loperamide use. Am J Gastroenterol 2017; 112:924-32. PMID: 28417992

164. Eswaran S, Chey WD, Jackson K, Pilai S, Chey SW, Han-Markey T. A Low FODMAP

Diet improves quality of life, reduces activity impairment, and improves sleep quality in

patients with Irritable Bowel Syndrome and Diarrhea: Results from a US Randomized

Controlled trial. Clin Gastroenterol Hepatol 2017; 15:1890-9. PMID: 28668539

165. Chey WD, Dove LS, Andrae A, Covington PS. Early response predicts a sustained

response to eluxadoline in patients with irritable bowel syndrome with diarrhea in two

Phase 3 studies. Aliment Pharmacol Ther 2017; 45:1319-28. PMID: 28326568

166. Lenhart A, Chey WD. A Systematic Review of the Effects of Polyols in Gastrointestinal

Health and Irritable Bowel Syndrome. Adv Nutrition 2017; 8:587-96. PMID: 28710145

167. Guivatchian T, Koeppe ES, Baker JR, Moisa C, Demerath M, Foor-Passin C, Chey WD,

Eswaran SL, Kolars JC, Menees SB. Family history in colonoscopy patients: feasibility

and performance of electronic and paper-based surveys for colorectal cancer risk

assessment in the outpatient setting. Gastrointest Endoscopy 2017; 86:684-91. PMID:

28174125

168. Kurlander J, Chey WD, Morris C, Drossman D, et al. Development and Validation of the

Patient-Physician Relationship Scale (PPRS) among Patients with Irritable Bowel

Syndrome. Neurogastroenterol Motil 2017; 28: e13106. PMID: 28544094

169. Chey SW, Chey WD, Saini SD, Weissman A, Harris L, Menees S. US Primary Care

Providers use of Over-the-Counter Medications for Gastroesophageal Reflux Disease and

Chronic Constipation. Am J Pharm Ben 2017; 9:116-21.

170. Cryer B, Drossman DA, Chey WD, Webster L, Habibi S, Wang M. Analysis of nausea in

clinical studies of lubiprostone for the treatment of constipation disorders. Dig Dis Sci

2017; 62:3568–3578. PMID: 28849329

171. Camilleri M, Ford AC, Mawe G, Dinning PG, Rao S, Chey WD, Lembo A, Fadok T,


Chang L. Chronic Constipation. Nat Rev Dis Primers 2017; 3: article number 17095.

PMID: 29239347

172. Eswaran S, Farida J, Green J, Miller JD, Chey WD. Nutrition in the management of GI

diseases and disorders: the evidence for the low FODMAP diet. Curr Op Pharmacol

2017; 37:151-7.

173. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, et al. Low dose (72 mcg)

Linaclotide for Chronic Idiopathic Constipation: A 12 week randomized, double-blind,

placebo-controlled trial. Am J Gastroenterol 2018; 113:105-14. PMID: 29091082

174. Lenhart A, Ferch C, Shaw M, Chey WD. Use of Dietary Management in Irritable Bowel

Syndrome: Results of a Survey of over 1500 U.S. Gastroenterologists. J

Neurogastroenterol Motil 2018; 24:437-51. PMID: 29886578

175. Shah E, Almario CV, Spiegel BMR, Chey WD. Lower and upper gastrointestinal

symptoms differ between individuals with IBS with constipation or chronic idiopathic

constipation. J Neurogastroenterol Motil 2018; 24:299-306. PMID: 29605985

176. Menees S, Almario CV, Spiegel BMR, Chey WD. Prevalence and Predictors of Bowel

Incontinence: Results from a Population-Based Survey of Over 71,000 Americans.


177. Garcia-Etxebarria K, Zheng T, Bongfiglio F, Chey WD, et al. Increased prevalence of

rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients.

Clin Gastroenterol Hepatol 2018; 16:1673-6. PMID: 29408290

178. Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM.

American College of Gastroenterology Monograph on the Management of IBS. Am J


179. Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Quigley EMM, Moayyedi P. A

systematic review and meta-analysis evaluating the efficacy of a gluten free diet and a

low FODMAP diet in treating symptoms of IBS. Am J Gastroenterol 2018; 113:1290-

1300. PMID: 30046155

180. Brenner D, Dove LS, Andrae DA, Covington PS, Gutman C, Chey WD. Radar plots: a

novel modality for displaying disparate data on the efficacy of eluxadoline for the

treatment of irritable bowel syndrome with diarrhea. Neurogastroenterol Motil 2018; 30:

e13331. PMID: 29575372

181. Auesomwang C, Maneerattanaporn, M, Chey, WD, Kiratisin P, Leelakusolwong S. Ten-

day high-dose proton pump inhibitor triple therapy versus sequential therapy for

Helicobacter pylori eradication. J Gastroenterol Hepatol 2018; 33:1822-8. PMID:

29804294

182. Menees S, Chey WD. The gut microbiome and irritable bowel syndrome. F1000

Research 2018: https://f1000research.com/articles/7-1029/v1 .

183. Shah ED, Farida JD, Menees S, Chey WD. Examining balloon expulsion testing as an

office-based, screening test for dyssynergic defecation: A systematic review and meta-

analysis. Am J Gastroenterol 2018; 113:1613-20. PMID: 30171220

184. Almario C, Chey WD, Spiegel BMR. Burden of Gastrointestinal Symptoms in the United

States: Results of a Nationally Representative Survey of Over 71,000 Americans. Am J


185. Fodor A, Pimentel M, Chey WD, Lembo A, Golden PL, Israel RJ, Carroll IM. Rifaximin

is associated with modest, transient decreases in multiple taxa in the gut microbiota of

patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes 2019;1022-

https://f1000research.com/articles/7-1029/v1


33. PMID: 29708822

186. Eswaran S, Dolan R, Ball S, Jackson K, Chey WD. The impact of a 4 week low

FODMAP diet on nutrient intake in a sample of US adults with IBS-D. J Acad Nutrition

Dietetics. 2019, in press.

187. Chey WD, Lacy BE, Cash BD, Epstein M, Corsino PE, Shah SM. A novel duodenal-

release formulation of a combination of caraway oil and L-menthol for the treatment of

functional dyspepsia: an RCT. Clin Translational Gastroenterol 2019;10: UNSP e-00021.

188. Olden KW, Chey WD, Shringarpure R, Nicandro JP, Chuang E, Earnest DL. Alosetron

versus traditional pharmacotherapy in clinical practice: effects on resource use, health-

related quality of life, safety and symptom improvement in women with severe diarrhea-

predominant irritable bowel syndrome. Current Medical Research and Opinion 2019;

35(3):461-472. PMID: 30293448

189. Ahmed S, Almario CV, Chey WD, Robbins LA, Chang B, Ahn J, Ko J, Gu P, Siu A,

Spiegel BMR. Electronic patient agenda form: comparing agreement between the reason

for specialty consultation reported by referring providers and patients. Inform Health Soc

Care 2019; 44:105-13. PMID: 29509054

190. Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, Chey WD. American

Gastroenterology Association Institute Technical Review on the Evaluation of functional

diarrhea and Diarrhea Predominant Irritable Bowel Disease in adults (IBS-D).

Gastroenterol 2019;157:859-80.

191. Riehl M, Kinnucan J, Chey WD, Stidham R. Nuances of the psychogastroenterology

patient: A predictive model for gastrointestinal quality of life improvement.

Neurogastroenterol Motil 2019,31:e13663.

192. Taylor DCA, Abel JL, Doshi JA, Hunter AG, Essoi B, Korrer S, Reasner DS, Carson RT,

Chey WD. The impact of stool consistency on bowel movement satisfaction in patients

with IBS-C or CIC treated with linaclotide or other medications: Real world evidence

from the CONTOR study. J Clin Gastroenterol 2019, in press.

193. Liu J, Chey WD, Haller E, Eswaran S. Low FODMAP Diet for Irritable Bowel

Syndrome: What we know and what we have yet to learn. Ann Rev Med 2019, in press.

194. Menees S, Chandhrasekhar D, Liew EA, Chey WD. A Low FODMAP Diet May Reduce

Symptoms in Patients with Fecal Incontinence. Clin Translation Gastroenterol 2019;10:e-

00060.

195. Spechler SJ, Hunter JG, Jones KM…Chey WD, et al. Randomized trial of medical and

surgical treatments for patients with heartburn that is refractory to PPIs: A VA

Cooperative Study. N Engl J Med 2019; in press.

196. Carrington EV, Heinrich H, Knowles CH, Fox M, Rao S, Altomare DF, Bharucha AE,

Burgell R, Chey WD, Chiarioni G, Dinning P, Emmanuel A, Farouk R, Felt-Bersma RJF,

Jung KW, Lembo A, Malcolm A, Mittal R, Mion F, Myung SJ, O’Connell PR, Pehl C,

Remes Troche JM, Reveille RM, Vaizey CJ, Vitton V, Whitehead WE, Wong RK, Scott

SM. The international anorectal physiology working group recommendations:

Standardized testing protocol and the London Classification for disorders of anorectal

function. Neurogastroenterol Motil 2019, e13679.

197. Nojkov B, Baker JRB, Menees S, Saad R, Chey WD. Is dyssynergic defecation an

unrecognized cause of chronic constipation in patients using opioids? Am J Gastroenterol

2019, in press.

198. Chey WD, Lembo AL, Rosenbaum D. Efficacy of Tenapanor in Treating Patients with


Irritable Bowel Syndrome with Constipation: A 12-Week, Placebo-Controlled Phase 3

Trial. Am J Gastroenterol 2019, in press.

199. Sadowski DC, Camilleri M, Chey WD, Leontiadis GL, Marshall JK, Shaffner EA, Tse F,

Walters JRF. Canadian Association of Gastroenterology Clinical Practice Guideline on

the management of bile acid diarrhea. Clin Gastroenterol Hepatol 2019, in press.

200. Chey WD, Shah E, Dupont H. Mechanism of action of rifaximin and therapeutic effects

in IBS. Ther Adv Gastroenterol. 2019, in press.

201. Almario CV, Chey WD, Spiegel BR. Prevalence and predictors of GERD and PPI-

refractory GERD symptoms in the US: Results from a population-based survey.

Gastroenterol, 2020, in press.

202. Shah ED, Suresh S, Jou J, Chey WD, Stidham RW. Evaluating when and why patients

discontinue chronic therapy for irritable bowel syndrome with constipation and chronic

idiopathic constipation. Am J Gastroenterol 2019, in press.

203. Shah ED, Almario CV, Spiegel BM, Chey WD. Presentation and characteristics of

abdominal pain vary by IBS subtype: results of a nationwide population-based study. Am

J Gastroenterol 2019, in press.

Non-Peer-Reviewed Publications

1. Chey WD and Elta GH. Selected Summary: Natural history of gastric varices.


2. Mayer E, Chey WD. The role of visceral hyperalgesia in the irritable bowel syndrome.

The Regulatory Peptide Letter 1996; 7:22-6.

3. Chey WD. The diagnosis of Helicobacter pylori. Hospital Physician 1997; 33:11-22.

4. Chey WD. Treating Helicobacter pylori: candidate and regimen selection. Contemporary

Internal Medicine 1997; 9:52-61.

5. Peura DA, Chey WD. Helicobacter pylori and peptic ulcer disease. The Regulatory

Peptide Letter, in press.

6. Fendrick AM, Chey WD. Approach to the patient with Helicobacter pylori-associated

epigastric pain. Hospital Physician 1998; 34:36-44.

7. Chey WD. Therapy for nonulcer dyspepsia: a new application for an old drug? Adv

Gastroenterology, Hepatology & Clin Nutrition 1998; 3:157-59.

8. Chey WD. H. pylori and nonulcer dyspepsia: an unaccommodating relationship? Adv

Gastroenterology, Hepatology & Clin Nutrition 1998; 3:265-7.

9. Chey WD. Case Report: anti-TNF antibody case study and discussion. The Regulatory

Peptide Letter 1999; 8:1-2.

10. Chey WD. Accurate diagnosis of H. pylori: breath tests. Gastroenterology Clinics of

North America 2000; 29:895-901.

11. Chey WD. Treatment of H. pylori. Current Treatment Options in Gastroenterology 1999;

2:171-81.

12. Rhee J, Chey WD. Antibody testing for H. pylori. LabMedica International 2000; 17:16-

17.

13. Chey WD, Murthy U, Shaw S, Zawadski A, Linscheer W, Laine L. A comparison of 3

fingerstick, whole blood antibody tests for H. pylori infection: a US multi-center trial.

ACP Journal Club 2000; 132:34.


14. Chey WD, Murthy U, Toskes P, Carpenter S, Laine L. The 13C-urea blood test accurately

detects active H. pylori infection: a US, multicenter trial. ACP Journal Club 2000;

132:35.

15. Chey WD. Comment on meta-analysis of smooth muscle relaxants in the treatment of

Irritable Bowel Syndrome. ACP Journal Club 2001; 135:53.

16. Chey WD. Review: Smooth muscle relaxants improve symptoms and reduce pain in

irritable bowel syndrome. Evidence-Based Medicine 2001; 6:153.

17. Cutler A, Chey WD. Update on the treatment of H. pylori. Gastroenterology and

Endoscopy News, November, 2001, pages 25-6.

18. Ladabaum U, Chey WD. Management of uninvestigated dyspepsia. Current Treatment

Options in Gastroenterology 2002; 5:125-31.

19. Cutler A, Chey WD. Update on the treatment of Helicobacter pylori: Initial options and

salvage therapy. Gastroenterology and Endoscopy News, pages 21-3, November 2002.

20. Rubenstein J, Chey WD. Review: Tegaserod or alosetron are effective for the irritable

bowel syndrome. ACP Journal Club 2003; 138;50.

21. Howden CW, Chey WD. Clinical Update: Gastroesophageal reflux disease. J Family

Practice 2003; 52:1-8.

22. Chey WD. Tegaserod and other serotonergic agents: What is the evidence? Reviews in

Gastroenterological Disorders 2003; 3: S35-40.

23. Cash BD, Chey WD. Diagnostic testing in IBS patients. Digestive Health Matters 2003;

12:4-7.

24. Cash BD, Chey WD. Advances in IBS management. Current Gastroenterology Reports

2003; 5:468-75.

25. Chey WD, Saad R. Helicobacter pylori eradication had no effect on heartburn or

gastroesophageal reflux in patients with H. pylori infection. ACP Journal Club 2004;

141:75.

26. Chey WD, Moayyedi P. Uninvestigated dyspepsia and non-ulcer dyspepsia – the use of

endoscopy and the roles of H. pylori eradication and antisecretory therapy. Aliment

Pharmacol Ther 2004; 19(suppl 1):1-8.

27. Chey WD. Endoscopy negative reflux disease: Concepts and clinical practice. Am J Med

2004; 117:5A-36S-43S.

28. Bhuket T, Chey WD. Hypnotherapy for irritable bowel syndrome: effectively expanding

the arsenal? Evidence-Based Gastroenterology 2004; 5(2):54-55.

29. Chey WD. Tegaserod: The global experience. Aliment Pharmacol Ther 2004; 20 (suppl

7):15-19.

30. Cash BD, Chey WD. Update on the management of chronic constipation: What

differentiates chronic constipation from IBS with constipation? Medscape

Gastroenterology, posted 8/26/04, http://www.medscape.com/viewprogram/3375_pnt .

31. Cash BD, Chey WD. Diagnosis of the Irritable Bowel Syndrome. Gastroenterol Clin N

Am 2005; 34:205-20.

32. Chey WD. Update on the pathophysiology and treatment of the irritable bowel syndrome.

Korean J Neurogastroenterol Motil 2005; 11:29-43.

33. Chey WD. Implications for treatment: pH, Helicobacter pylori, or alternative

approaches? Aliment Pharmacol Ther 2005; 21(Suppl 1):17-18.

34. Cash BD, Chey WD. Irritable bowel syndrome: update on colonic neuromuscular

dysfunction and treatment. Curr Gastroenterol Reports 2006; 8:273-81.


35. Chey WD, Richter JE, Kane SV, Siegel JH, Zein N. Meeting Coverage: Highlights from

Digestive Diseases Week and the 107th Annual Meeting of the American

Gastroenterological Association Institute. Gastroenterol Hepatol 2006; 2:515-7.

36. Saad R, Chey WD. Irritable bowel syndrome with constipation in the elderly. Geriatrics

& Aging 2007; 10:84-90.

37. Cash BD, Chey WD. Update on the irritable bowel syndrome. US Gastroenterol, in press.

38. Chey WD. Presentations in IBS from DDW 2007. Gastroenterol Hepatol 2007; 3:629-33.

39. Rangnekar A, Chey WD. Commentary: tTG is almost as accurate as EMA antibody test

for diagnosis of celiac disease. Evidence-Based Medicine 2007; 12:24.

40. Saad R, Chey WD. Review: Prokinetics, histamine 2 receptor antagonists,

antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer

dyspepsia. Evidence-Based Medicine 2007; 12:79.

41. Rangnekar, AS, Chey WD. Review: tissue transglutaminase test is almost as accurate as

endomysial antibody test for diagnosis of coeliac disease. Archives of Disease in

Childhood Education & Practice 2007; 92(1): e32.

42. Spiegel B, Chang L, Chey WD. Irritable bowel syndrome and bacterial overgrowth:

Unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J


43. Chey WD. Presentations in IBS from DDW 2008. Gastroenterol Hepatol 2008 134:(4

suppl 1).

44. Rangnekar A, Chey WD. Selected Summary: Methylnaltrexone: A new treatment for an

old problem. Gastroenterol 2008; 135:1792-4.

45. Chey WD. Antibiotics for IBS: Paradigm shift or the Emperor’s new clothes? AGA

Perspectives 2009; 4:5-8.

46. Luther J, Chey WD. Selected Summary: Sequential Therapy for H. pylori: A two for one

deal that’s worth the extra effort? Gastroenterol 2009; 136:720-721.

47. Chey WD. A patient with constipation-predominant IBS. Gastroenterol Hepatol 2009; 5

(suppl 1):6-8.

48. Brenner D, Chey WD. Bifidobacterium infantis 35624: A Novel Probiotic for the

Treatment of Irritable Bowel Syndrome. Rev Gastroenterol Disorders 2009; 9:7-15.

49. Rangnekar A, Chey WD. Selected Summary: The FODMAP diet for IBS: Food fad or

roadmap to a new treatment paradigm? Gastroenterol 2009; 137:383-6.

50. Rude MK, Chey WD. Selected Summary: Proton Pump Inhibitors, Clopidogrel, and

Cardiovascular Adverse Events: Fact, Fiction, or Something In Between? Gastroenterol

2009; 137:1168-71.

51. Chey WD. IBS diagnosis and confirmation. Gastroenterol Hepatol 2009; 5 (supplement

20):6-9.

52. Chey WD, Moayyedi P. Passing the torch: The American Journal of Gastroenterology

2010 Introduction. Am J Gastroenterol 2010; 105:4-7.

53. Luther J, Chey WD. Psyllium increased symptom relief in patients with the irritable

bowel syndrome more than bran or placebo. ACP Journal Club 2010; 152: J1.

54. Moayyedi P, Ford AC, Quigley EMM, Foxx-Orenstein AE, Chey WD, Talley NJ, Brandt

L. The American College of Gastroenterology IBS Monograph: Translating systematic

review data to clinical practice. Gastroenterol 2010; 138:789-90.

55. Maneerattanaporn M, Chey WD. Book review: Understanding the Irritable Gut.

Gastroenterol 2010; 138:786.


56. Maneeratannaporn M, Chey WD. Selected Summary: Acupuncture for IBS: Sham or the

Real Deal? Gastroenterol 2010; 139:348-51.

57. Chey WD, Spiegel BS. PPIs, IBS, and Small Intestinal Bacterial Overgrowth:

Coincidence or Newton’s Third Law Revisited? Clin Gastroenterol Hepatol 2010; 8:480-

482.

58. Moayyedi, P; Chey, WD. Is Lumping Peer-Reviewed Case Reports Together With Non-

Peer-Reviewed Comments for Publication as Letters to the Editor Appropriate? Response


59. Vakil N, Malferheiner P, Chey WD. Bismuth and H. pylori. New Engl J Med 2010;

363:595.

60. Chey WD. Efficacy and safety of probiotics in the treatment of Irritable Bowel

Syndrome. US Gastroenterology & Hepatology Review 2010; 6:48-53.

(http://www.touchbriefings.com/ebooks/A1q1ey/usgastro6/).

61. Brenner D, Chey WD. Selected Summary: St. John’s Wort and Irritable Bowel

Syndrome: Reminders of the Hippocratic Oath. Gastroenterol 2010; 139:1788-90.

62. Adams M, Chey WD. Selected Summary: Biofeedback training for dyssynergic

defecation: an approach whose time has come. Gastroenterol 2011; 140:1682-5.

63. Luther J, Chey WD, Saad RJ. A clinician's guide to salvage therapy for persistent

Helicobacter pylori infection. Hosp Pract 2011; 39:133-40.

64. Chey WD. Preface: Irritable Bowel Syndrome. Gastroenterol Clin North Am 2011; 40:

XII-XIV.

65. Eswaran S, Tack J, Chey WD. Food: The forgotten factor in IBS. Gastroenterol Clin

North Am 2011; 40:141-62.

66. Maneeratannaporn M, Chang L, Chey WD. Emerging therapies for IBS. Gastroenterol

Clin North Am 2011; 40:223-43.

67. Chey WD, Rai J. Exercise and IBS: no pain, no gain. Gastroenterology 2011; 141:1941-

3.

68. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD. Treatment of

Helicobacter pylori in Latin America – Author’s reply. Lancet 2012; 379:4-10.

69. Schmulson M, Chey WD. Editorial: Abnormal immune regulation and low-grade

inflammation in IBS: Does one size fit all? Am J Gastroenterol 2012; 107:273-5.

70. Ferch C, Chey WD. IBS and gluten sensitivity without celiac disease: Separating the

wheat from the chafe. Gastroenterol 2012; 142:664-6.

71. Foxx-Orenstein A, Chey WD. Manipulation of the gut microbiota as a novel treatment

strategy for gastrointestinal disorders. Am J Gastroenterol Suppl 2012; 1:34-40.

72. Chey WD. Current Consensus and Remaining Questions Regarding the Diagnosis and

Treatment of Helicobacter pylori Infection. Gastroenterol Hepatol 2012; 8:621-5.

73. Moayyedi P, Chey WD. Stoking the Flame: American Journal of Gastroenterology 2013.

Am J Gastroenterol 2013; 108:162-5. PMID: 23381063

74. Chey WY, Chang V, Lubukin M, Lee KY, Hoellrich CM, Chey WD. Mega-cecum: A

novel clinical entity which explains overlapping gastrointestinal and urogynecologic

symptoms in women with chronic constipation. Am J Gastroenterol 2013 Oct 1 [Epub

ahead of print]. PMID 24091519

75. Eswaran S, Guenther A, Chey WD. Emerging therapies for chronic constipation and IBS-

C. J Neurogastroenterol Motil 2014; 20:141-51.

http://apps.isiknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=4&SID=4FIBc9Nbjl5BFPB1FfB&page=1&doc=4&colname=WOS&cacheurlFromRightClick=no

http://apps.isiknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=4&SID=4FIBc9Nbjl5BFPB1FfB&page=1&doc=4&colname=WOS&cacheurlFromRightClick=no


76. Lacy BE, Chey WD, Chang L. An evidence-based look at misconceptions in the

treatment of patients with IBS-D. Gastroenterology & Hepatology 2013; 9 (supplement

5): 3-19.

77. Saad R, Chey WD. First-line treatment of H. pylori infection in 2014. Gastroenterology

& Endoscopy News 2014; 65(2):1-8.

78. Chey WD, Howden C, Vakil N. Clinical rational for confirmation testing after H. pylori

treatment: Implications of rising antibiotic resistance. Gastroenterol & Hepatol 2014; 10

(7, supplement 3):3-18.

79. Brenner DB, Chey WD. An evidence based review of novel and emerging therapies for

opiate induced constipation. Am J Gastroenterol Suppl 2014; 2 (issue1):38-46.

80. Chey WD. The effect of probiotics on functional constipation in adults: a systematic

review and meta-analysis of randomized, controlled trials. PracticeUpdate website.

Available at: http://www.practiceupdate.com. Accessed August 2014.

81. Spencer M, Chey WD, Eswaran S. Dietary renaissance in IBS: Has food replaced

medications as a primary treatment strategy? Curr Treatment Op Gastroenterol 2014;

12:424-40.

82. Chey WD, Eswaran S, Kurlander J. Irritable Bowel Syndrome Patient Page. JAMA 2015;

313:982.

83. Chey WD. Current insights into the pathophysiology of IBS. Gastroenterol Hepatol 2015;

11:2-5, supplement 2.

84. Chey WD, Lacy BE, Lembo AL. New and emerging treatment options for IBS: Q&A.

Gastroenterol Hepatol 2015; 11:16-8, supplement 2.

85. VanDam L, Chey WD. The low-FODMAP diet and IBS. Whole Foods Magazine 2015;

http://www.wholefoodsmagazine.com/blog/low-fodmap-diet-and-ibs

86. Chey WD. Dietary Interventions in Patients with Irritable Bowel Syndrome.

PracticeUpdate website. Available at: http://www.practiceupdate.com/c/23013/48/9.

Accessed April 21, 2015.

87. Menees S, Powell C, Chey WD. Response to Dai et al. Am J Gastroenterol 2015;

110:1243-4.

88. Moayyedi P, Chey WD. The light shines on: American Journal of Gastroenterology 2015.


89. Chey WD, Owyang C. Timothy T. Nostrant, MD, MACG, October 20, 1947-October 2,

2015. Gastroenterol 2016; 150:289-90.

90. Chey WD. David Sun Lecture: Food - The main course to wellness and illness in patients

with IBS. Am J Gastroenterol 2016; 111:366-71.

91. Gupta A, Chey WD. Breath Testing for Small Intestinal Bacterial Overgrowth:

A means to enrich rifaximin responders in IBS patients? Am J Gastroenterol 2016;

111:305-6.

92. Spencer M, Gutpta A, Van Dam L, Shannon C, Menees S, Chey WD. Artificial

sweeteners: A systematic review and primer for gastroenterologists. J Neurogastroenterol

Motil 2016; 22:168-80.

93. Chey WD, Whelan K. Dietary guidelines for irritable bowel syndrome are important for

gastroenterologists, dietitians and people with irritable bowel syndrome. J Human

Nutrition Dietetics 2016; 29:547-8.

94. Kerdsirichairat T, Choi EYK, Chey WD. An atypical coincidence of colon ischemia and

bilateral distal ureteral strictures. Gastroenterol 2017; 153: E13-E16.

http://www.wholefoodsmagazine.com/blog/low-fodmap-diet-and-ibs

http://www.practiceupdate.com/c/23013/48/9


95. Chey WD. An evidence-based approach to IBS and CIC: Applying new advances to daily

practice. Gastroenterol Hepatol 2017; 13 (supplement 1):3-14.

96. Chey WD, Leontiadis GI, Howden CW, Moss SF, Which Regimens Should Be Used and

Which Rejected for the Treatment of Helicobacter pylori? Response. Am J Gastroenterol

2017; 112:1169-70.

97. Chey WD. Introduction. J Gastroenterol Hepatol 2017;32 (suppl 1):3-4.

98. Chey WD. Treatment of H. pylori infection: What the clinician needs to know. ACG

Magazine. 2017; 1:20-21.

99. Eswaran S, Farida J, Green J, Miller JD, Chey WD. Nutrition in the management of GI

diseases and disorders: the evidence for the low FODMAP diet. Curr Opin Pharmacol

2017; 37:151-7.

100. Chey WD, Leontiadis G, Moss S, Howeden C. Response to Hsu et al. Am J Gastroenterol

2018; 113:143.

101. Shah E, Chey WD. Editorial: recurrence of Helicobacter pylori infection - still the same

after all these years… Aliment Pharmacol Ther 2018;47:131-132.

102. Chey WD. Sucrase isomaltase deficiency: hiding in plain sight? J Gastroenterol Hepatol,

2018, in press.

103. Staudacher H, Chey WD. Design of clinical trials assessing the efficacy of diet

interventions for GI diseases. J Gastroenterol Hepatol 2018, in press.

104. Dolan R, Chey WD, Eswaran S. The role of diet in the management of IBS: a focus on

FODMAPs. Exp Rev Gastroenterol Hepatol 2018; 12:607-15.

105. Chey WD, Howden CW, Leontiadis G. Houston H. pylori Clarifying the Houston

Consensus on Helicobacter pylori (Letter to the Editor). Clin Gastroenterol Hepatol

2018;16:2003-4.

106. Chey WD. Editorial: Elimination diets for IBS: Approaching the end of the beginning.

Am J Gastroenterol 2019;114:201-3.

107. Zheng T, Eswaran S, Chey WD, Merchant J, D’Amato M. Reduced efficacy of low

FODMAP diet in patients with IBS-D carrying sucrase-isolmaltase hypomorphic

variants. Gut 2019, in press.

108. Chey WD. Treatment of Helicobacter pylori: When we should… Am J Gastroenterol

2019, in press.

109. Chey WD. Microbiome-based treatment strategies for IBS. Gastroenterol Hepatol 2019;

15:164-6.

110. Ginnebaugh B, Chey WD, Saad R. Small intestinal bacterial overgrowth. Gastroenterol

Cl North Am. 2019, in press.

111. Chey WD. Highlights from the AGA Technical Review on value of diagnostic tests in

functional diarrhea and IBS-D. Gastroenterol Hepatol 2019;15:488-92.

112. Chey WD. Highlights in Neurogastroenterology & Motility from DDW 2019.

Gastroenterol Endo News 2019, in press.

113. Chey WD. Oral FMT with antibiotics does not improve symptoms of IBS-D: Perspective.

Healio Gastroenterol Liv Dis 2019;5:28.

Articles Submitted for Publication

1. Shah E, Almario CV, Spiegel BM, Chey WD. Presentation and characteristics of


abdominal pain vary by IBS subtype: Results of a national population-based study. Am J

Gastroenterol, in revision.

2. Shah E, Chey WD. Determining the comparative value of pharmacologic, dietary, and

psychological treatments for irritable bowel syndrome with diarrhea: cost-effectiveness

and budget-impact analysis. Gastroenterol, in revision 8/19.

3. Baker JR, Marratt JK, Maneerattaporn M, Nojkov B, Menees S, Eswaran S, Saad R,

Chey WD. Do symptoms reliably predict the presence of dyssynergic defecation in

patients with chronic constipation. Aliment Pharmacol Ther, In prep.

4. Chey WD, Baker JR, Attari A, Ashton-Miller J. Digital Manometry – A disposable, point

of service device to diagnose dyssynergic defecation. Neurogastroenterol Motil. in prep.

Chapters in Books

1. Contributor of questions to Textbook of Gastroenterology: Self -Assessment Review,

First Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 1993.

2. Chey WD. "Chapter 1: The esophagus" and "Chapter 5: The pancreas" for Textbook of

Gastroenterology: Self -Assessment Review. 2nd Edition. Ed: T Yamada. JB Lippincott

Co. Philadelphia, PA, 1995.

3. Chey WD. “Chapter 4: The Pathophysiology of Nausea and Vomiting” in

Gastrointestinal Pathophysiology, First Edition. Ed: J Henderson. JB Lippincott Co.

Philadelphia, PA, 1996.

4. Chey WD, Hasler WL. “Chapter 26: Gastroduodenal Motility Disorders and

Gastroparesis” in Clinical Practice of Gastroenterology, First Edition. Ed: L Brandt.

Current Medicine. Philadelphia, PA, 1999.

5. Chey WD, Chey WY. “Chapter 132: Tests of Gastric and Exocrine Pancreatic Function

and Absorption” in Textbook of Gastroenterology, Third Edition. Ed: T Yamada. JB

Lippincott Co. Philadelphia, PA, 1999.

6. Chey WD, Chey WY. “Chapter 8.7: Colonic diseases in elderly people” in Oxford

Textbook of Geriatric Medicine, Second Edition. Ed: JG Evans. Oxford University

Press. Oxford, UK, 2000.

7. Chey WD, Fendrick MA. “Non-invasive Helicobacter pylori diagnostic tests: recent

innovations” in Harrison’s Textbook of Internal Medicine Online, 1999.

8. Chey WD, Kim HR. “Chapter 2: Stomach” in Textbook of Gastroenterology: Self -

Assessment Review. 3rd Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA,

2000.

9. Section Editor, Stomach and Duodenum, Current Treatment Options in Gastroenterology,

5:125-160, 2002.

10. Editor for “Chapter 121: Peptic acid disorders” and “Chapter 123: Hiatus hernia, bezoars,

and foreign bodies” in Merck Manual of Medical Information – Home Edition, 2nd

Edition. Ed: MH Beers. Merck Research Laboratories, Whitehouse Station, NJ, 2003.

11. Chey WD, Chey WY. “Chapter 151: Evaluation of secretion and absorption functions of

the GI tract” in Textbook of Gastroenterology, Fourth Edition. Ed: T Yamada. JB

Lippincott Co. Philadelphia, PA, 2003.


12. Delvalle J, Chey WD, Scheiman JM, “Chapter 66: Acid-peptic disorders” in Textbook of

Gastroenterology, Fourth Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA,

2003.

13. Chey WD, Scheiman JM. “Chapter 20: Peptic ulcer disease” in Current diagnosis and

treatment in Gastroenterology: Second Edition, Ed: McQuaid KR. McGraw-Hill. New

York, NY, 2003.

14. Cash BD, Chey WD. “Chapter 22: Dyspepsia – Current treatments” in Hot Topics in

GERD and Dyspepsia, Ed: Fass R. Hanley & Belfus, Inc. Philadelphia, PA, 2003.

15. Rubenstein JH, Chey WD. “Chapter 2: A case of refractory heartburn” in Acid-related

Disorders, Ed: Howden CW. McMahon Publishing Group, New York, NY, 2003.

16. Chey WD, Saad R. “Chapter 4c - Female patient with severe, persistent GI symptoms.”

In Functional Gastrointestinal Disorders, Ed: Carol Burke, McMahon Publishing Group,

New York, NY, 2005.

17. Editor for “Bezoars and Foreign Bodies” in Merck Manual of Medical Information, 18nd

Edition. Ed: MH Beers. Merck Research Laboratories, Whitehouse Station, NJ, 2006.

18. Longstreth G, Thompson WG, Chey WD, Houghton L, Mearin F, Spiller R, Wang WA.

“Chapter 9: Functional Bowel Disorders” in Rome III: The functional gastrointestinal

disorders, Third Edition, Ed: Drossman D, et al. Degnon Associates, 2007.

19. Irvine EJ, Whitehead W, Chey WD, Matsueda K, Shaw M, Talley NJ, van Zanten S.

“Chapter 15: Design of treatment trials for Functional Gastrointestinal Disorders” in

Rome III: The functional gastrointestinal disorders, Ed: Drossman D, et al. Degnon

Associates, 2007.

20. Chey WD, DiMagno MJ, Chey WY. “Tests of gastric and exocrine pancreatic function

and absorption” in Textbook of Gastroenterology, Fifth Edition. Ed: T Yamada.

Blackwell Publishing Co. Malden, MA, 2008.

21. Bhuket T, Chey WD. “Evaluation and management of the Irritable Bowel Syndrome” in

Functional GI Disorders, Ed: MP Jones, McMahon Group, in press.

22. Saad R, Chey WD. Chapter 32: Functional Dyspepsia. GI Motility Testing: A Laboratory

and Office Handbook, First Edition, SLACK Inc., Thorofare, NJ, Ed: HP Parkman, S

Rao, R McCallum, 2010.

23. Maneerattanaporn M, Chey WD. Chapter 35: Small Intestinal Bacterial Overgrowth.

Practical Gastroenterology and Hepatology: Small and Large Intestine and Pancreas, First

Edition, Ed: NJ Talley. Wiley-Blackwell, West Sussex, UK, 2010.

24. Saad R, Chey WD. Functional Dyspepsia. Gut instincts – A Clinician’s Handbook of

Digestive and Liver Diseases, Ed: E Estralian. SLACK Incorporated, 2012.

25. Chey WD. Foreword: The Complete low-FODMAP Diet. Shepherd & Gibson. The

Experiment, New York, New York, 2013.

26. Mearin F, Lacy B, Chang L, Chey WD, Lembo A, Simren M, Spiller R. Rome IV:

Functional Gastrointestinal Disorders. Disorders of Gut-Brain Interaction. 4th Edition,

2016.

27. Chey WD. Foreword: A Teen’s Guide to Gut Health. Meltzer Warren R. The

Experiment, New York, NY, 2017.

28. Chey WD. Foreword: The IBS elimination diet and cookbook. Catsos P. Harmony

Books, New York, 2017.

29. Chey WD. Endorsement: The Low FODMAP Diet: Step by step. Kate Scarlata, Dede

Wilson. 2018.


Books

1. Special Editor and contributor, Textbook of Gastroenterology: Self -Assessment Review.

3rd Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 2000.

2. Guest Editor and contributor, Irritable Bowel Syndrome. Gastroenterology Clinics of

North America, WB Saunders, Philadelphia, PA, 2011;40:1.

3. Contributing Editor, Multi-Dimensional Clinical Profile for the Functional

Gastrointestinal Disorders. 1st Edition. Ed: Rome Foundation, Raleigh, NC, 2014.

4. Contributing Editor, Rome IV: Functional Gastrointestinal Disorders. Disorders of Gut-

Brain Interaction. 4th Edition, 2016

5. Contributing Editor, Rome IV: Functional Gastrointestinal Disorders. Disorders of Gut-

Brain Interaction. 4th Vol 2, Edition, 2016

6. Contributing Editor, Multi-Dimensional Clinical Profile for the Functional

Gastrointestinal Disoders. 2nd Edition. Ed: Rome Foundation, Raleigh, NC, 2016.

7. Contributing Editor, Functional Gastrointestinal Disorders: Disorders of Gut-Brain

Interaction. Special Issue Gastroenterology; Vol 150, Number 6, May 2016

8. Contributing Editor, Rome IV: Diagnostic Algorithms for Common GI Symptoms. 2nd

Edition, 2016

9. Contributing Editor, Rome IV: Pediatric Functional Gastrointestinal Disorders: Disorders

for Gut-Brain Interaction, 1st Edition, 2016

10. Contributing Editor, Rome IV: Functional Gastrointestinal Disorders for Primary Care

and Non-GI Clinicians. 1st Edition, 2016

11. Contributing Editor, Rome IV: Diagnostic Questionnaires and Tables for Investigators

and Clinicians, 1st Edition, 2016

Other Media

1. Chey WD. Proton pump inhibitors and the urea breath test: how long is long enough? Am

J Gastroenterol. 92:720-1, 1997 (letter).

2. Chey WD. Response to Dr. Stermer, et al. Am J Gastroenterol. 92:1575, 1997.

3. Chey WD. The channel occlusion technique: a novel method of retrieving polyps

following snare resection. Am J Gastroenterol 95:1608-9,2000 (letter).

4. Drossman DA, Clouse RE, Chey WD, Koch KL, Lembo T, Locke R, Longstreth GF,

Mertz H, Norton N, Toner B, Whitehead WE, Wilson JAP. Irritable Bowel Syndrome:

New Visions (part 1) Nosology, Epidemiology, and Pathophysiology. Monograph of the

Digestive Health Initiative, 1999.

5. Drossman DA, Clouse RE, Camilleri M, Chey WD, Lebovitz PJ, Lembo T, Longstreth

GF, Mertz H, Naliboff BD, Thompson G, Toner B, Whitehead WE. Irritable Bowel

Syndrome: New Visions (part 2): Diagnosis and Treatment. Monograph of the Digestive

Health Initiative, 2000. (Award of excellence in education from the American Society of

Association Executives in the outstanding print-based education program category)

6. Chey WD. Medical Simulations in the Diagnosis and Management of Acid-Related

Disorders. CME Monograph accredited by Albert Einstein College of Medicine, 10/2000.


7. Chey WD. Testing for H. pylori infection: which test should you use? SCOPE Issue 1,

May 2002, pages 17-20.

8. Chey WD. Non-erosive esophageal disorders. SCOPE Issue 2, July 2002, pages 14-17.

9. Cash BD, Chey WD. Irritable bowel syndrome. Northwestern University, Feinberg

School of Medicine Reports on Digestive Disorders. 1:4, 2002.

10. Chey WD. Critical analysis of current therapy of IBS and anticipating future

improvements. CME supplement to Gastroenterology and Endoscopy News pg 5-7,

February 2003.

11. Chey WD. Long-term management of GERD: PPI vs. newer endoscopic interventions vs.

surgery. Advanced Studies in Medicine. 3:S123-7, 2003.

12. Cash BD, Chey WD. The role of endoscopy in irritable bowel syndrome. ASGE Clinical

Update. 11:1-4, January 2004.

13. Chang L, Chey WD, Prather C. Coping with the complexities of IBS: Practical aspects of

patient management. CME supplement to Gastreonterology and Endoscopy News,

February 2004.

14. Chang L, Chey WD. Translating Science into Clinical Outcomes: New Advances

in the Management of Irritable Bowel Syndrome, CME Monograph, Rush University

Medical Center, April 2004.

15. Cash BD, Chey WD. A clinical and safety update on serotonergic agents for irritable

bowel syndrome and chronic constipation. Family Practice Recertification Supplement,

September 2004.

16. Cash BD, Chey WD. Book Review: Neuro-Gastroenterology. Gastroenterology. 27:1858-

9, 2004.

17. Chey WD, Saad R. Case 4c: Female with severe, persistent GI symptoms.

Gastroenterology and Endoscopy News, October 2004.

18. Saad R, Chey WD. Book Review: Digestion, diet, and disease. Gastroenterology,

128:2175, 2005.

19. Cash BD, Chey WD. Irritable bowel syndrome and chronic constipation: The latest

serotonergic agents. Family Practice Recertification Supplement, January 2005.

20. Saad R, Chey WD. Peptic ulcer disease in patients with chronic liver disease: Looking

beyond bugs and drugs. Gastrointest Endosc 62:357-9, 2005.

21. Chey WD. Clinical perspectives in chronic constipation. Medscape Gastroenterology,

posted 5/27/05, http://www.medscape.com/viewarticle/505146 .

22. Chey WD. New insights in IBS-C and chronic constipation. Medscape Gastroenterology,

poseted 5/31/06, http://www.medscape.com/viewarticle/532440 .

23. Saad R, Chey WD. What is the optimal therapy for patients with Helicobacter pylori-

negative dyspepsia? Gastroenterology Today. X:135-6, 2006.

24. Chey WD, Rao S. Update on chronic constipation. Clinical Symposia, 2006.

25. Chey WD. Examining the issues in Functional Bowel Disorders. Medscape

Gastroenterology, posted 10/23/07, http://www.medscape.com/viewarticle/563731.

26. Chey WD. Update on gastroparesis. Reach MD.

http://www.reachmd.com/xmsegment.aspx?sid=1870

27. Chey WD. Newer thoughts on irritable bowel syndrome. Reach MD.


28. University of Michigan Health System Press Release: Phase III lubiprostone trials for

IBS, 5/19/08: http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=307

http://www.medscape.com/viewarticle/505146





http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=307


29. University of Michigan Health System Press Release: IBS guideline, 12/18/08:


30. University of Michigan Health System Press Release: Celiac disease, 2/2/09:


31. Chey WD, Chang L. Providing patient centered care for individuals with IBS. Reach

MD. February 2009. http://www.reachmd.com/cmedetails.aspx?sid=4112

32. Chey WD. Chang L. Nonpharmacologic vs. pharmacologic treatments options for

chronic constipation and IBS-C. Reach MD. February 2009.

http://www.reachmd.com/cmedetails.aspx?sid=4113

33. Chey WD, Chang L. IBS and abuse in women. Reach MD. February 2009.


34. Chey WD. Pimentel M. The role of antibiotic therapy in IBS. Reach MD. August 2009.

35. Chey WD, Rubenstein J. The Evolving Landscape in GERD and Acid-Related Disorders:

What Are the Issues/Unmet Needs and Solutions? Medscape CME Gastroenterology,

September 2009, http://cme.medscape.com/viewarticle/707669

36. Johnson DA, Chey WD, Rangarajan M. Managing Challenging Patient Populations With

GERD: Common Clinical Challenges and Evidence-Based Solutions. Medscape CME

Gastroenterology November 2009, http://cme.medscape.com/viewarticle/712073

37. University of Michigan Health System Press Release: Shift workers at more risk for IBS,

a UM study says, 3/18/10:


38. University of Michigan Health System Press Release: IBS patients not at more risk of

colon cancer, 3/9/10:


39. Chey WD, Heidelbaugh J, Vaezi M. Contemporary Issues in GERD: The Economic and

Clinical Burden of Disease. Medscape CME Gastroenterology, May 2010,

http://cme.medscape.com/viewarticle/722389

40. University of Michigan Health System Press Release: Rifaximin for IBS, 1/5/11:


41. Chey WD, Johnson D. Expert to expert interview on IBS. Medscape Gastroenterology,

May 2011.

42. Chey WD, Saad R. The Management of Constipation – Related Functional GI Disorders:

An Update on Recent Advances. Medscape Gastroenterology, 2012.

http://www.medscape.org/viewarticle/765791

43. Chey WD, Rex D. Update from San Diego 2012: Therapies on the horizon for

constipation. Medscape Gastroenterology, 2012.

http://www.medscape.org/viewprogram/32497

44. Chey WD. Treatments for Chronic Constipation. Medscape Gastroenterology, 2012.

45. University of Michigan Health System Press Release: Drug may relieve IBS symptoms,

UM study finds, 9/18/12: http://umhsheadlines.org/19/drug-may-relieve-irritable-bowel-

syndrome-symptoms-u-m-study-finds/

46. AJG Podcasts: Monthly discussions between the Editors and lead authors of interesting

articles from the American Journal of Gastroenterology,

http://www.nature.com/ajg/index.html

47. Expert Perspectives from ACG: Reporting on IBS. GI Health Foundation. November

2012,













http://www.medscape.org/viewprogram/32497

http://umhsheadlines.org/19/drug-may-relieve-irritable-bowel-syndrome-symptoms-u-m-study-finds/

http://umhsheadlines.org/19/drug-may-relieve-irritable-bowel-syndrome-symptoms-u-m-study-finds/

http://www.nature.com/ajg/index.html


http://www.ibscme.tv/programming_guide/topics/xpert_acg2012/index.cfm?cme_proj_id

=40

48. Chey WD; Curtiss C; Kamdar MM; Peppin JF. Medscape CME Roundtable - Making A

Difference in Opioid-Induced Constipation: Adding Targeted Therapies to the Treatment

Regimen. January 4, 2013. http://www.medscape.org/viewarticle/779122

49. Chey WD, Dorn S. Medscape Education: Curbside Consult on IBS-C. May 20, 2013.

50. GERD and Obesity: What’s the Connection? Healthy Body, Healthy Mind – Episode

1401, Public Broadcasting System.

http://www.itvisus.com/programs/hbhm/episode_1401_Gerd.asp

51. Talking About Your GI Health: Improving the Dialogue with Your Doctor. Healty Body,

Healthy Mind - Episode 1501, Public Broadcasting System.

http://www.itvisus.com/programs/hbhm/episode_1501_GI_health.asp

52. Controlling Irritable Bowel Syndrome. Healthy Body, Healthy Mind – Episode 2504,

Public Broadcasting System. http://www.itvisus.com/programs/hbhm/episode_2504.asp

53. New and emerging therapies for FGIDs. Audio-Digest Gastroenterology, Volume 27,

Issue 20, October 21, 2013, ISSN 0892-9386 http://www.audio-

digest.org/pages/htmlos/15251.3.1051358327615669202

54. Topics in Otolaryngology: GERD. Audio-Digest Family Practice, Volume 61, Issue 41,

November 7, 2013, ISSN 0271-1362.

55. Treatment of H. pylori infection. Audio-Digest Family Practice, Volume 61, Issue 45,

December 7, 2013, ISSN 0271-1362.

56. Chronic Constipation – Episode 2901, Public Broadcasting System.

http://www.itvisus.com/programs/hbhm/episode_

57. Gastroenterology Update: Managing IBS. Audio-Digest Internal Medicine, Volume 61,

Issue 2, January 14, 2014, ISSN 0271-1303.

58. Chey WD, Eswaran S, Cash BD. Advances in probiotic therapy for diarrhea-associated

illnesses. CME Monograph, Gastroenterology & Endoscopy News, 2014.

59. IBS: Current Medical Management Options. Audio Digest Family Practice, Volume 62,

Issue 13, April 7, 2014, ISSN 0271-1362.

60. Lacy BE, Chey WD. Medscape CME discussions on IBS and Chronic Constipation from

DDW 2014. May 4, 2014.

61. University of Michigan Health System Press Release: Doctors miss the chance to

recommend equally effective generics, May 3, 2014,

http://www.uofmhealth.org/news/archive/201405/doctors-miss-chance-recommend-

equally-effective-generics

62. University of Michigan Health System Press release on NEJM article on naloxegol for

opiate induced constipation, June 4, 2014:

http://www.uofmhealth.org/news/archive/201406/drug-trial-shows-promise-treating-

constipation-caused-pain

63. University of Michigan Health System Press release: U-M home to nation’s most trusted

sources for GI research, September 3, 2014.

https://www.umhsheadlines.org/2014/09/u-m-home-to-nations-most-trusted-sources-for-

gi-research/

64. What is gluten? TED-ed video, January 2015. http://ed.ted.com/lessons/what-s-the-big-

deal-with-gluten-william-d-chey

http://www.ibscme.tv/programming_guide/topics/xpert_acg2012/index.cfm?cme_proj_id=40

http://www.ibscme.tv/programming_guide/topics/xpert_acg2012/index.cfm?cme_proj_id=40


http://www.itvisus.com/programs/hbhm/episode_1401_Gerd.asp

http://www.itvisus.com/programs/hbhm/episode_1501_GI_health.asp

http://www.itvisus.com/programs/hbhm/episode_2504.asp

http://www.audio-digest.org/pages/htmlos/15251.3.1051358327615669202

http://www.audio-digest.org/pages/htmlos/15251.3.1051358327615669202

http://www.itvisus.com/programs/hbhm/episode_2504.asp

http://www.uofmhealth.org/news/archive/201405/doctors-miss-chance-recommend-equally-effective-generics

http://www.uofmhealth.org/news/archive/201405/doctors-miss-chance-recommend-equally-effective-generics

http://www.uofmhealth.org/news/archive/201406/drug-trial-shows-promise-treating-constipation-caused-pain

http://www.uofmhealth.org/news/archive/201406/drug-trial-shows-promise-treating-constipation-caused-pain

https://www.umhsheadlines.org/2014/09/u-m-home-to-nations-most-trusted-sources-for-gi-research/

https://www.umhsheadlines.org/2014/09/u-m-home-to-nations-most-trusted-sources-for-gi-research/

http://ed.ted.com/lessons/what-s-the-big-deal-with-gluten-william-d-chey

http://ed.ted.com/lessons/what-s-the-big-deal-with-gluten-william-d-chey


65. Chey W. FODMAPs Alter Symptoms and the Metabolome of Patients With IBS: A

Randomised Controlled Trial. PracticeUpdate website. Available

at: http://www.practiceupdate.com/content/fodmaps-and-symptoms-in-patients-with-

irritable-bowel-syndrome/36735/65/9/1. Accessed April 15, 2016.

66. Chey WD, Lacy B, Cash B. IBS-D: From Diagnosis to Management. Medscape.

February 24, 2017: http://www.medscape.org/viewarticle/872892.

67. Chey WD. FDgard demonstrated rapid relief of symptoms in functional dyspepsia.

Medicalresearch.com, June 5, 2017, https://medicalresearch.com/author-

interviews/fdgard-demonstrated-rapid-relief-of-symptoms-in-functional-

dyspepsia/35035/#more-35035.

68. Chey WD, Lembo AL. Optimizing management of patients with IBS-D, AGA & Med-

IQ, May 12, 2017 https://www.med-iq.com/family-medicine/gastroenterology/internal-

medicine/free-cme-course/optimizing-the-management-of-patients-with-ibs-today.html

69. Chey WD. Individualized IBS diets reduce symptoms better than placebo: Perspective.

Helio Gastroenterol, September 21, 2017

https://www.healio.com/gastroenterology/irritable-bowel-

syndrome/news/online/%7Ba6f4365c-92a2-4926-abee-

38550bc2bcf4%7D/individualized-ibs-diets-reduce-symptoms-better-than-

placebo?utm_source=selligent&utm_medium=email&utm_campaign=gastroenterology%

20news&m_bt=129297058195

70. Chey WD. Expert Picks from 2017 WCOG/ACG: Part 2. Gastroenterology & Endoscopy

News, January 22, 2018.

71. UM Health Blog: Irritable Bowel Syndrome: Symptoms, Treatments, Effects.

https://healthblog.uofmhealth.org/digestive-health/physical-and-financial-toll-of-irritable-

bowel-syndrome

72. Chey WD. Most GIs believe IBS diets ‘as good or better’ than medical therapy. Healio

GI, June 21, 2018. https://www.healio.com/gastroenterology/irritable-bowel-

syndrome/news/online/%7Bc3f69219-fb1f-4bc9-8901-5df500e015a4%7D/most-gis-

believe-ibs-diets-as-good-or-better-than-medical-therapy

73. Chey WD. Data highlights diet, nutrition impact on GI disorders. Healio GI, October 11,

2018. https://www.healio.com/gastroenterology/nutrition/news/online/%7B9ca5f287-

806c-4e28-8df9-19f48dc06c7d%7D/video-data-highlights-diet-nutrition-impact-on-gi-

disorders

74. Chey WD. How to bridge the patient education gap in chronic constipation. Healio GI,

November 27, 2018.

https://www.healio.com/gastroenterology/motility/news/online/%7Bfaedf629-8f37-4052-

9371-57ec8fc0215f%7D/video-how-to-bridge-the-patient-education-gap-in-chronic-

constipation

75. Chey WD. Podcast: Managing Constipation, April 5, 2019.

https://www.breastcancer.org/community/podcasts/constipation-20190412

76. Chey WD. Physicians’ words guide patients from hopeless to hopeful. Healio GI, May

23, 2019. https://www.healio.com/gastroenterology/practice-

management/news/online/%7Bc1e38310-a030-4a81-a36c-73dad8aa055a%7D/video-

physicians-words-guide-patients-from-hopeless-to-hopeful

http://www.practiceupdate.com/content/fodmaps-and-symptoms-in-patients-with-irritable-bowel-syndrome/36735/65/9/1

http://www.practiceupdate.com/content/fodmaps-and-symptoms-in-patients-with-irritable-bowel-syndrome/36735/65/9/1


https://medicalresearch.com/author-interviews/fdgard-demonstrated-rapid-relief-of-symptoms-in-functional-dyspepsia/35035/#more-35035



https://www.med-iq.com/family-medicine/gastroenterology/internal-medicine/free-cme-course/optimizing-the-management-of-patients-with-ibs-today.html

https://www.med-iq.com/family-medicine/gastroenterology/internal-medicine/free-cme-course/optimizing-the-management-of-patients-with-ibs-today.html

https://www.healio.com/gastroenterology/irritable-bowel-syndrome/news/online/%7Ba6f4365c-92a2-4926-abee-38550bc2bcf4%7D/individualized-ibs-diets-reduce-symptoms-better-than-placebo?utm_source=selligent&utm_medium=email&utm_campaign=gastroenterology%20news&m_bt=129297058195





https://healthblog.uofmhealth.org/digestive-health/physical-and-financial-toll-of-irritable-bowel-syndrome

https://healthblog.uofmhealth.org/digestive-health/physical-and-financial-toll-of-irritable-bowel-syndrome

https://www.healio.com/gastroenterology/irritable-bowel-syndrome/news/online/%7Bc3f69219-fb1f-4bc9-8901-5df500e015a4%7D/most-gis-believe-ibs-diets-as-good-or-better-than-medical-therapy



https://www.healio.com/gastroenterology/nutrition/news/online/%7B9ca5f287-806c-4e28-8df9-19f48dc06c7d%7D/video-data-highlights-diet-nutrition-impact-on-gi-disorders



https://www.healio.com/gastroenterology/motility/news/online/%7Bfaedf629-8f37-4052-9371-57ec8fc0215f%7D/video-how-to-bridge-the-patient-education-gap-in-chronic-constipation



https://www.breastcancer.org/community/podcasts/constipation-20190412

https://www.healio.com/gastroenterology/practice-management/news/online/%7Bc1e38310-a030-4a81-a36c-73dad8aa055a%7D/video-physicians-words-guide-patients-from-hopeless-to-hopeful




77. Chey WD. Opioids lead to dyssynergic defecation. Healio GI, June 14, 2019.

https://www.healio.com/gastroenterology/motility/news/online/%7Bf1d6979c-e837-

4c09-af15-5760a84c4514%7D/video-opioids-lead-to-dyssynergic-defecation

78. Multiple appearances on the Ira Breit Show, Sirius XM Radio,

https://doctorira.blogspot.com/2017/09/monday-september-18th-on-doctor-ira.html

79. Dr. Nandi Show, https://askdrnandi.com/ask-dr-nandi-show/. June 5, 2019 – show to be

aired later in 2019.

80. Chey WD. Episode 3 Podcast on IBS, May 2019. https://www.ibspatient.org/podcasts/

Abstracts, Preliminary Communications, Panel Discussions

1. Chey WD and Owyang C. VIP has a selective relaxant effect on colonic myocytes

contracted by agonists that utilize an IP3 dependent pathway. Submitted to the 9th

International Symposium on GI Hormones, Leuven, Belgium. September, 1992 (Poster

presentation).

2. Chey WD, Patel A, and Owyang C. Galanin receptors in longitudinal and circular

colonic myocytes of guinea pig are coupled to different intracellular mediators:

Differential involvement of extracellular calcium and cyclic AMP pathways to mediate

contraction and relaxation. Gastroenterol 104: A489, 1993 (Oral presentation).

3. Roberts D, Chey WD, Hasler W, Soudah H, Beydoun A, and Owyang C. Somatostatin

analog reduces perception of rectal distention by specific inhibition of spinal afferent

pathways. Gastroenterol 1993; 104: A571 (Oral presentation).

4. Chey WD, Hasler W, Soudah H, and Owyang C. Intraduodenal lipid induces isobaric

gastric fundus relaxation, antral motor inhibition, and pyloric contraction: Role of

endogenous CCK. Gastroenterol 1993; 104: A817.

5. Chey WD, Beydoun A, Hasler W, Kim M, and Owyang C. Octreotide reduces spinal

afferent transmission in diarrhea-predominant Irritable Bowel Patients. Gastroenterol

1994; 106: A478 (Oral presentation).

6. Hasler W, Chey WD, Kim M, and Owyang C. Distinct mechanisms mediate tachygastria

evoked by acute hyperglycemia and experimental motion sickness: Roles of endogenous

prostaglandins and cholinergic pathways. Gastroenterol 1994; 106: A508 (Oral

presentation).

7. Sims M, Hasler W, Chey WD, Kim M, and Owyang C. Acute hyperglycemia inhibits

gastrocolonic and colonic peristaltic reflexes measured by an electronic barostat in

healthy humans. Gastroenterol 1994; 106: A566 (Oral presentation).

8. Kohagen K, Hasler W, Kim M, McDonnell M, Chey WD, and Owyang C. Transdermal

nicotine evokes gastric dysrhythmias via a prostaglandin-dependent pathway with

associated antral hypomotility: a model for decreased gastric motility with smoking.

Gastroenterol 1994; 106: A525 (Oral presentation).

9. Chey WD, Beydoun A, Hasler W, Kim M, and Owyang C. Octreotide reduces spinal

afferent transmission in diarrhea-predominant Irritable Bowel Patients. Dig Dis Sci 39:

1792, 1994 (10th International Symposium on Gastrointestinal Hormones, Santa Barbara,

CA. August 29, 1994, Oral Presentation).


rectal balloon distention and blunts the rectoanal inhibitory reflex in healthy volunteers:

implications for diabetic constipation. Gastroenterol 107: 1240, 1994 (American Motility

Society Biennial Symposium, Wintergreen, VA. October 1994, Oral Presentation).

https://www.healio.com/gastroenterology/motility/news/online/%7Bf1d6979c-e837-4c09-af15-5760a84c4514%7D/video-opioids-lead-to-dyssynergic-defecation

https://www.healio.com/gastroenterology/motility/news/online/%7Bf1d6979c-e837-4c09-af15-5760a84c4514%7D/video-opioids-lead-to-dyssynergic-defecation

https://doctorira.blogspot.com/2017/09/monday-september-18th-on-doctor-ira.html

https://askdrnandi.com/ask-dr-nandi-show/

https://www.ibspatient.org/podcasts/


11. Hasler WL, Kohagen K, Kim M, McDonnell M, Chey WD, Owyang C. Nicotine effects

of prostaglandin-dependent gastric slow wave rhythmicity and antral motility in non-

smokers and smokers. Gastroenterol 107: 1245, 1994 (American Motility Society

Biennial Symposium, Wintergreen, VA. October 1994, Poster presentation).

12. Chey WD, Beydoun A, Kim M, Hasler W, Spybrook M, Owyang C. Hyperglycemia

blunts perception of electrical rectal stimulation by effects on central processing of

afferent input. Gastroenterol 1995; 108: A582 (Oral Presentation).

13. Chey WD, Hasler W, Kim M, Owyang C. Suppression of gastric acid secretion corrects

the prolongation of migrating motor complex duration in patients with gastroesophageal

reflux. Gastroenterol 1995; 108: A582 (Poster Presentation).

14. Kim M, Chey WD, Owyang C, Hasler W. Role of plasma vasopressin as a possible

mediator of nausea and gastric slow wave dysrhythmias in experimental motion sickness.

Gastroenterol 1995; 108: A628 (Poster Presentation).

15. Carpenter S, Chey WD, Hasler W, Fey D, Kim M, Spybrook M, Owyang C. Modulation

of CCK and non-CCK dependent pancreatic enzyme secretion by inhibitory 5-HT3

pathways. Gastroenterol 1995; 108: A346 (Oral Presentation).


rectal balloon distention and blunts the rectoanal inhibitory reflex in healthy volunteers:

implications for diabetic constipation. Glaxo Institute for Digestive Health Research

Awards Alumni Symposium. Research Triangle Park, NC. January 28, 1995.

17. Kim M, Lu Y, Chey WD, Owyang C, Hasler W. Desensitization of the prostaglandin-

dependent slow wave dysrhythmic response to acute hyperglycemia in healthy chronic

smokers. Submitted to the Third International Workshop on EGG, May, 1995 (Trainee

Travel Award Winner).

18. Hasler W, Kim M, Chey WD, Owyang C. Correlation of tachygastria and EGG signal

power with plasma vasopressin levels and symptoms in response to distinct dysrhythmic

stimuli. Submitted to the Third International Workshop on EGG, May, 1995 (Walter

Alvarez Award for Excellence in Electrogastrography Research).

19. Chey WD, Beydoun A, Kim M, Hasler W, Spybrook M, Owyang C. Hyperglycemia

blunts perception of electrical rectal stimulation by effects on central processing of

afferent input. Third International Symposium on Brain-Gut Interactions, Cambridge,

UK, July 20-22, 1995 (Travel Scholarship Winner).

20. Kim M, Lu Y, Chey WD, Owyang C, Hasler W. Hyperglycemia induces gastric

dysrhythmias: mediation by prostaglandin-dependent pathways. Submitted to XV

International Symposium on Gastrointestinal Motility, Rome, Italy, November, 1995.

21. Hasler W, Kim M, Chey WD, Owyang C. Cholinergic blockade in the CNS prevents

gastric dysrhythmias and nausea during experimental motion sickness: mediation by

inhibition of release and action of vasopressin. Submitted to XV International

Symposium on Gastrointestinal Motility, Rome, Italy, November, 1995.

22. Chey WD, Stevens M, Hasler WL, Hooper F, Greene D, Owyang C. Hyperglycemia

blunts rectal afferent transmission and increases rectal compliance in diabetic patients: A

possible model of diabetic constipation. Gastroenterol 1996; 110: A647 (Presidential

plenary poster presentation at DDW ‘96).

23. Chey WD, Fey D, Scheiman J, Nostrant T, Del Valle. The role of acid suppression in the

effects of lansoprazole and ranitidine on the 14C-urea breath test. Gastroenterol 1996;

110: A80, (Poster presentation).


24. Chey WD, Murthy UK, Linscheer WG, Weisenfeld B, Bennett T, Barnett J, Elta G,

Hasler W, Nostrant T, Scheiman JM. A comparison between 4 different commercially

available serology tests for Helicobacter pylori. Gastroenterol 1996; 110: A80 (Poster

presentation).

25. Hasler W, Fey D, Woods M, Hooper F, Chey WD, Owyang C. Relative roles of gastric

mechanoreceptors and intestinal nutrient chemoreceptors in postprandial

electrogastrographic signal increases. Gastroenterol 1996; 110: A676.

26. Jednak M, Shadigian E, Hooper F, Woods M, Chey WD, Owyang C. Effects of nutrient

composition on symptoms and slow wave dysrhythmias in nausea of pregnancy.

Gastroenterol 1996; 110: A686.

27. Hasler W, Lu Y, Li Y, Fey D, Chey WD, Owyang C. Hyperglycemia induces gastric

dysrhythmias via endogenous prostaglandin production: mediation by cholinergic

pathways in the central nervous system. Gastroenterol 1996; 110: A1078.

28. Chey WD, Fey D, Scheiman J, Nostrant T, Del Valle. The role of acid suppression in the

effects of lansoprazole and ranitidine on the 14C-urea breath test. Developments in

Helicobacter Research: From the Basic Laboratory to the Patient, St. Petersburg, FL,

February 1996.

29. Chey WD, Fisher L, Elta GH, Barnett J, Nostrant T, Del Valle J, Scheiman J. One week,

BID therapy for H. pylori: A randomized comparison of 2 strategies. Gastroenterol 1997;

112: A87 (Poster presentation).

30. Chey WD, Murthy U, Barish C, Rapier R, Riff R, Rubin H, Safdi M, Schwartz H, Shah

H, Wruble L, Genta R. The ChemTrak AccuMeter whole blood serology test for the

detection of H. pylori infection. Gastroenterol 1997; 112: A87 (Poster presentation).

31. Fendrick WD, Fennerty MB, Chey WD. Estimating the demand for H. pylori

confirmatory testing after eradication treatment. Gastroenterol 1997; 112: A14 (Poster

presentation).

32. Bjornsson E, Chey WD, Ladabaum U, Hooper F, Woods M, Owyang C, Hasler W.

Mediation of both the mechano and chemoreceptor components of the gastrocolonic

response but not the colonic peristaltic reflex by seratonergic 5-HT3 pathways in healthy

humans. Gastroenterol 1997; 112: A700 (Oral presentation).

33. Wille RT, Barnett JL, Chey WD, Scheiman JM, Elta GH. Randomized controlled trial of

droperidol as routine premedication for ERCP. Gastrointest Endosc 1997; 45: AB152

(ASGE Plenary Session).

34. Ladabaum U, Chey WD. Eosinophilic gastroenteritis mimicking complicated peptic

ulcer disease. Submitted to the ACG National Fellows Forum, Colorado Springs, CO,

August, 1997 (Oral presentation).

35. Chey WD, Fisher L, Barnett J, Del Valle J, Elta GH, Nostrant T, Palaniappan J,

Scheiman J. The effectiveness of therapies with low and high dose azithromycin to treat

H. pylori infection. The Fourth International Conference on the Macrolides, Azilides,

Streptogramins & Ketolides, Barcelona, Spain, January 1998.

36. Rich M, Scheiman JM, Chey WD. Comparison of 14C-urea breath test utilization between

gastroenterologists and primary care physicians. Am J Gastroenterol 1997; 92:1663.

37. Chey WD, Murthy U, Toskes P, Carpenter S, Laine L. Validation of the 13C-urea blood

test for H. pylori infection: a US, multicenter trial. Gastroenterol 1998; 114: A371 (oral

presentation).


38. Chey WD, Fisher L, Barnett J, Delvalle J, Elta GH, Nostrant T, Palaniappan J, Scheiman

J. Triple therapy with low versus high dose azithromycin to treat H. pylori infection.

Gastroenterol 1998; 114: A370 (poster presentation).

39. Chey WD, Murthy U, Linscheer W, Barnett J, Delvalle J, Elta GH, Fisher L, Nostrant T,

Scheiman J, Zawadski A, Fayyad A. A comparison of 2 commercially available

fingerstick, whole blood antibody tests for H. pylori infection. Gastroenterol 1998; 114:

A369 (poster presentation).

40. Bjornsson E, Chey WD, Hooper F, Woods M, Owyang C, Hasler W. Selectively

enhanced phasic but not tonic gastro-colonic contractions in diarrhea-predominant

irritable bowel syndrome: role of serotonin 5-HT3 neural pathways. Gastroenterol 1998;

114: A2986 (oral presentation).

41. Stern MA, Gunaratnum N, Chey WD. Colonic intussusception from pneumatosis

cytoides intestinalis. Best case report winner - Michigan Society of Gastrointestinal

Endoscopy Fellows competition, May 6, 1998.

42. Chey WD, Murthy U, Toskes P, Carpenter S, Laine L. Validation of the 13C-urea blood

test for H. pylori infection: a US, multicenter trial. World Congress of Gastroenterology,

Vienna, Austria, September 1998 (President’s Plenary Poster selection).

43. Stern MA, McDonnell WM, Gunaratnum N, Moseley R, Chey WD. Interim analysis of a

randomized, controlled trial to assess technical and clnical outcomes of a novel colorectal

cancer screening strategy. Am J Gastroenterol 1998; 93: 1701 (Oral presentation, Astra

Merck Fellow Research Award).

44. Mao HV, Lak BV, Long T, Chung NQ, Thang DM, Hop TV, Chien NN, Hoan PQ,

Henley KS, Connor BA, Stone CD, Chey WD. Omeprazole or ranitidine bismuth citrate

with clarithromycin and amoxicillin for 10 days to treat H. pylori infection: A

randomized, controlled trial in Vietnamese patients with duodenal ulcer. Gastroenterol

1999; 116; A136 (Poster of Distinction - DDW ’99).

45. Chey WD, Shaw S, Montague J, Jones M, Murthy U. Appropriate timing of the 14C-urea

breath test to establish eradication of H. pylori infection: An interim analysis.

Gastroenterol 1999; 116; A136 (poster presentation).

46. Chey WD, Shapiro B, Zawadski A, Goodman K. Gastric emptying characteristics of a

novel muffin meal: Comparison of 13C-octanoate breath testing and scintigraphy.

Gastroenterol 1999; 116; A971 (poster presentation).

47. Stern MA, Fendrick AM, Gunaratnam N, McDonnell WM, Moseley RH, Chey WD.

Analysis of a randomized, controlled trial to assess clinical and economic outcomes of a

novel colorectal cancer screening strategy. Gastroenterol 1999; 116; A510 (oral

presentation).

48. Stern MA, Rhee JY, Chey WD. Pilot study of a novel use of oral fleets phosphasoda for

screening sigmoidoscopy preparation. Gastrointest Endosc 1999; 49: AB69 (poster

presentation).

49. Stern MA, Minoshima S, Montague J, Cross DJ, Ladabaum U, Hasler WL, Chey WD.

Differential cerebral activation in response to painful somatic thermal or visceral

esophageal stimulation in healthy volunteers. Gastroenterol 1999; 116; A1087 (poster

presentation).

50. Ladabaum U, Minoshima S, Hasler W, Cross D, Chey WD, Owyang C. Cerebral

representation of a distal gastric mechano-receptor activation. Gastroenterol 1999; 116;

A4444 (oral presentation).


51. Gorelick AB, Cannon ME, Barnett JL, Chey WD, Scheiman JM, Elta GH.

Sphincterotomy outcome with two different electrocautery currents. Gastrointest Endosc

1999; 49: AB179 (poster presentation).

52. Jednak MA, Barnett JL, Scheiman JM, Chey WD, Elta GH. A randomized trial of needle

knife fistulotomy versus needle knife precut sphincterotomy for biliary access.

Gastrointest Endosc 1999; 49: AB216 (poster presentation).

53. Nandi PS, Barnett JL, Nostrant TT, Chey WD, Francis IR, Prince MR, Carlos C,

Scheiman JM. A prospective, blinded comparison of EUS and MRCP with ERCP in

patients with suspected extrahepatic biliary disease. Gastrointest Endosc 1999; 49: AB95

(ASGE plenary session).

54. Cross DJ, Minoshima S, Ladabaum U, Hasler W, Chey W, Paulson PE, Morrow TJ,

Owyang C, Casey KL. Cerebral representation of somatic versus visceral pain as revealed

by PET. Submitted to Society for Neuroscience, Miami Beach, FLA, October 1999.

55. Chey WD, Stern MA, Montague J, Cross DJ, Ladabaum U, Hasler WL, Minoshima S.

Cerebral activation in response to painful visceral esophageal or somatic thermal

stimulation. Neurogastroenterol Motil 1999; 11:253.

56. Gonlachanvit S, Chey WD, Parkman HP, Goodman KJ. Effect of meal size and test

duration on gastric emptying as determined by breath test in normal subjects using a

muffin meal labeled with 13 C-sodium octanoate. Gastroenterol. 118: A143, 2000

(Alvarez Award for Best Scientific Paper at the International EGG Meeting).

57. Chathadi K, Murthy U, Montague J, Jones M, Chey WD. A modified 14C-urea breath test

eliminates false negative results in patients taking a proton pump inhibitor. Gastroenterol

2000; 118: A504 (Runner-up, Student Abstract Prize from the AGA).

58. Chey WD, Abrahmse P, Fendrick M. Active or antibody testing to diagnose H. pylori

infection? Examining the clinical and economical tradeoffs using decision analysis.

Gastroenterol 2000; 118: A504.

59. Brown WH, Chey WD, Elta, GH. The number of responses on a review of systems

questionnaire predicts the diagnosis of functional GI disorders. Gastroenterol 2001; 120;

A1205 (poster presentation).

60. Chang L, Olden KW, Carter EG, Boyle J, Chey, WD. Bowel habit predominance has a

significant impact on symptoms and daily activities in women with IBS. Gastroenterol

2001; 120; A3214 (poster presentation).

61. Olden K, Chey WD, Boyle J, Chang L. Health Related Quality of Life in Irritable Bowel

Syndrome: A Community Based Study. Gastroenterol 2001; 120; A3216 (poster

presentation).

62. Chey WD, Chang L, Carter E, Boyle J, Olden K. Do the Rome I and Rome II criteria

identify the same IBS pts? Gastroenterol 2001; 120; A3221 (poster presentation).

63. Gonlachanvit S, Chen YH, Sun WM, Chey WD. Effects of selective 5HT3 antagonist on

anorectal function in normal female subjects. Gastroenterol 2001; 120; A3258 (poster

presentation).

64. Chey WD, Ladabaum U, Fendrick AM, Scheiman JM. Cost-effectiveness of empiric PPI

therapy vs. test and treat in uninvestigated dyspepsia: impact of decreasing H. pylori

prevalence and increasing non-H. pylori ulcers. Am J Gastroenterol 2001; 96; A836.

65. Gorelick AB, Barnett JL, Chey WD, Anderson MA, Elta GH. A study of Botulinum toxin

injection into the residual pancreatic sphincter after biliary sphincterotomy in patients


with sphincter of oddi dysfunction. Gastrointest Endos 2001; 53; A3354 (poster

presentation).

66. Quallich LG, Stern MA, Rich M, Chey WD, Barnett JL, Elta GH. Bile duct crystals do

not contribute to post-cholecystectomy syndrome. Gastrointest Endosc 2001; 53; A3405

(poster presentation).

67. Gonlachanvit S, Kim H, Rhee J, Sun WM, Chey WD. Acute acoustic stress alters rectal

compliance in healthy humans. Gastroenterol 2002; 122; T1282 (poster presentation).

68. Schoenfeld PS, Chey WD, Drossman D, Kim HM, Thompson WG. Effectiveness and

safety of tegaserod in the treatment of Irritable Bowel Syndrome: a meta-analysis of

randomized controlled trials. Gastroenterol 2002; 122; T1486 (poster presentation).

69. Ahmed F, Murthy UK, Chey WD, Toskes P, Wagner DA. Evaluation of the Ez-HBT

Helicobacter blood test to establish Helicobacter pylori eradication. Gastroenterol 2002;

122; A386 (oral presentation).

70. Chey WD, Carr-Locke DL. Proton pump inhibitors do not affect the sensitivity of Urea

breath testing when using a citrate meal. Gastroenterol 2002; 122; S1322 (poster

presentation).

71. Chey WD, Inadomi J, Fendrick AM, Sharma VK, Howden C. Primary care physicians’

perceptions of Barrett’s esophagus, the relationship between GERD & H. pylori, and

treatment of nocturnal heartburn: results of a national survey. Am J Gastroenterol 2002;

97: S231-2 (oral presentation).

72. Cash BD, Schoenfeld PS, Chey WD. Value of diagnostic testing in Irritable Bowel

Syndrome: A systematic review. Am J Gastroenterol 2002; 97: S227 (poster

presentation).

73. Chey WD, Inadomi JM, Booher AK, Fendrick AM, Sharma VK, Howden CW. Primary

care physicians perceptions and practices on the management of GERD: results of a

national survey. Gastroenterol 2003; 124: A505 (poster presentation).

74. Chey WD, Inadomi JM, Booher AK, Fendrick AM, Sharma VK, Howden CW. What do

primary care physicians think about Barrett’s esophagus, the relationship between GERD

& H. pylori, and treatment of nocturnal heartburn? Gastroenterol 2003; 124: A108 (oral

presentation).

75. Chey WD, Shaw MJ, Inadomi JM, Popovski S, Adlis S, Nojkov B, Cleary MJ. Erosive

esophagitis, nonerosive esophageal disorders, and dyspepsia: population characteristics

and effectiveness of rabeprazole therapy. Gastroenterol 2003; 124: A227 (poster

presentation).

76. Green C, Chey WD, Jones MP, Eisen GM, Briseno M, Garewal HS, Fass R. Clinical

predictive factors for long-segment Barrett’s esophagus. Gastroenterol 2003; 124: A642


77. Wald A, Johanson JF, Tougas G, Chey WD, Novick J, Lembo A, Fordham F, Guella M,

Nault B. Safety and tolerability of Tegaserod in patients treated for chronic constipation

(CC): a 12 week, double blind, placebo controlled multicenter study performed in the

Americas. Gastroenterol 2003; 124: A573 (poster presentation).

78. Johanson JF, Tougas G, Chey WD, Novick J, Lembo A, Fordham F, Guella M, Nault B.

Tegaserod provides rapid and sustained relief of chronic constipation and associated

abnormal symptoms: An American double blind, placebo controlled multicenter study.

Gastroenterol 2003; 124: A47 (oral presentation).


79. Wagner DA, Bolt DB, Chey WD. Novel breath test detects fructose malabsorption in IBS

patients. Gastroenterol 2003; 124: A394 (poster presentation).

80. Kim B, Rhee J, Elta GH, Inadomi J, Chotisprashidhi P, Wamsteker E, Scheiman JM,

Chey WD, Anderson MA. Droperidol is superior to phenergen for sedation in patients

undergoing ERCP: Results of a randomized, double-blind trial. Gastrointest Endosc

2003; 57: AB79 (oral presentation).

81. Chey WD, Lukasik N, Huang B, Joseph-Ridge N. Lansoprazole provides symptom relief

in ulcer free patients who are taking chronic NSAIDs. Am J Gastroenterol 2003; 98:

S296 (oral presentation).

82. Fisher R, Thistle J, Lembo A, Novick J, O’Kane P, Chey W, Ruegg P, Shi V, Dogra A,

Luo D, Ernest D. What is the impact of tegaserod on gallbladder emptying? Am J

Gastroenterol 2003; 98: S270 (poster presentation).

83. Sherif A, Coleski R, Sun WM, Chey WD, Hasler WL. 5-HT4 receptor stimulation of

colonic peristaltic reflex and basal tonic colon activity by tegaserod in healthy humans:

possible mechanisms of its action in constipation. Gastroenterol 2004; 126: Ab109 (oral

presentation).

84. Fass R, Green, Chey WD, Jones MP, Eisen GM, Briseno M, Garewal HS, Ramirez FC.

Patients who presently do not smoke have longer lengths of Barrett's esophagus (BE) as

compared to those who actively smoke—a multi-center survey. Gastroenterol 2004; 126:

AbS1702 (poster presentation).

85. Nojkov B, Shaw MJ, Adlis S, Chey WD. Symptom severity, quality of life (QoL), and

psychological distress in patients with erosive esophagitis (EE) vs. nonerosive esophageal

disorders (NEED): are they really similar? Gastroenterol 2004; 126: AbW1263 (poster

presentation).

86. Mulhall B, Cash BD, Schoenfeld P, Chey WD. How do US gastroenterologists diagnose

irritable bowel syndrome? Gastroenterol 2004; 126: AbW1287 (poster presentation).

87. Chey WD, Nojkov B, Adlis S, Inadomi J, Shaw MJ. Does co-morbid irritable bowel

syndrome influence the effectiveness of PPI therapy for gastroesophageal reflux disease?

Gastroenterol 2004; 126: AbW1464 (poster presentation).

88. Chey WD, Eswaran S, Scheiman JM, Fendrick M, Inadomi JM, Howden C. Facts and

fantasies concerning aspirin: results of a US national survey of 1000 primary care

physicians. Am J Gastroenterol 2004; 99: Ab99 (oral presentation).

89. Howden CW, Metz DC, Chey WD, Triadafilopoulos G, Peura DA. Degree of conformity

between US gastroenterologists and experts concerning Barrett's esophagus (BE).

Gastroenterol 2005; 128: Ab912 (oral presentation).

90. Nojkov B, Chey WD, Adlis S, Shaw M. Predictors of response to PPI therapy in patients

with GERD: the influence of co-morbid IBS and psychological disease. Gastroenterol

2005; 128: Ab416 (oral presentation).

91. Saad R, Schoenfeld P, Kim HM, Chey WD. Levofloxacin triple or PPI quadruple salvage

therapy for persistent Helicobacter pylori infection: results of a systematic review.

Gastroenterol 2005; 128: Ab431 (oral presentation).

92. Chey WD, Chan L, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic

colitis in clinical trials and post-marketing surveillance amongst patients using alosetron

after blinded adjudication. Gastroenterol 2005; 128: AbT1139 (poster presentation).


93. Eswaran SL, Chey WD, Askari F, Lok AS, Fontana RJ, Marrero JA. Prevalence of

abnormal liver function chemistries in an American cohort of patients with celiac disease.

Am J Gastroenterol 2005; 100: Ab211 (poster presentation).

94. Chey WD, Novick J, Sherman J, Jones J, Cohard-Radice M. Patients improve on

tegaserod regardless of primary constipation complaint. Am J Gastroenterol 2005; 100:

Ab914, (poster presentation).

95. Lee DH, Andrews AH, Dobhan R, Kim CH, Cash BD, Chey WD. A prospective,

multicenter US trial to determine the yield of routine diagnostic testing in suspected

diarrhea-predominant and alternating IBS patients. Am J Gastroenterol 2005; 100: Ab918


96. Chey WD, Bottoli I, Walter V, Shetzline M, Cohard-Radice M. Tegaserod is superior to

placebo in normalizing stool consistency and in increasing frequency of complete

spontaneous bowel movements (CSBMs) in chronic constipation (CC) patients who

present with hard stools. Am J Gastroenterol 2005; 100: Ab929 (poster presentation).

97. Chey WD, Pare P, Viegas A, Ligozio G, Shetzline MA. Tegaserod improves symptoms

in women with mixed/alternating bowel habits as well as those with IBS-C. Gastroenterol

2006; 130: Ab135 (oral presentation).

98. Cash BD, Andrews AH, Lee DH, Smith JH, Kim CH, Saad R, Rai JK, Chey WD. Yield

of diagnostic testing in patients with suspected irritable bowel syndrome (IBS): a

prospective, US multi-center trial. Gastroenterol 2006; 130: Ab771 (oral presentation).

99. Bottoli I, Chey WD, Ddunger-Baldauf C, Kralstein J. Complete spontaneous bowel

movement (CSBM) correlates better than spontaneous bowel movement (SBM) to global

endpoints in chronic constipation (CC) trials. Gastroenterol 2006; 130: AbM1192 (poster

presentation).

100. Hasler WL, Parkman HP, Hutson A, Chey WD, Koch KL, McCallum RW, Wo JM, Kuo

B, Sitrin M, Stevens K, Landrigan B, Semler JR, Coleski R. Postprandial gastric acid

neutralization-reacidification measured with an ingested pH telemetry capsule:

correlation with emptying of digestible and indigestible solids. Gastroenterol 2006; 130:

AbM2076 (poster presentation).

101. Hasler WL, Coleski R, Chey WD, Koch KL, McCallum RW, Wo JM, Kuo B, Sitrin M.

Stevens K, Landrigan B, Semler JR, Parkman HP. Postprandial gastric acid neutralization

and reacidification in diabetic vs. idiopathic gastroparesis: relation to degree of gastric

stasis. Gastroenterol 2006; 130: AbM2201 (poster presentation).

102. Kuo B, McCallum R, Koch K, Chey WD, Wo JM, Sitrin M, Hasler W, Lackner J, Katz

L, Landrigan B, Selover K, Hutson A, Barthel D, Semler J, Parkman HP. Smartpill, a

novel ambulatory diagnostic test for measuring gastric emptying in health and disease.

Gastroenterol 2006; 130: AbM2205 (poster presentation).

103. Hatfield CD, Chey WD, Barthel D, Semler J, Harrel S, Wo J. Making a diagnosis of

gastroparesis reduces diagnostic cost and unnecessary surgeries in patients with recurrent

nausea and vomiting. Gastroenterol 2006; 130: AbS1136 (poster presentation).

104. Chey WD, Nojkov B, Saad R, Rai J, Adlis SA, Shaw MJ. Does the absence of erosive

esophagitis really predict a worse response to Proton Pump Inhibitor (PPI) therapy in

patients with Gastroesophageal Reflux Disease? Gastroenterol 2006; 130: AbS1219


105. Parkman HP, Hutson A, Maurer AH, Knight LC, Kuo B, Hasler WL, Chey WD,

McCallum RW, Wo JM, Koch KL, Sitrin M, Lackner JM, Semler J. Optimizing gastric


emptying scintigraphy for the detection of gastroparesis. Gastroenterol 2006; 130:

AbT1249 (poster presentation).

106. Sabbagh LC, Chey WD, Barton G, Viegas A, Ligozio G, Shetzline MA. Tegaserod is

proven safe in IBS-C patients and those with mixed/alternating bowel habits.

Gastroenterol 2006; 130: AbT2047 (poster presentation).

107. Rubenstein J, Nojkov B, Korsnes S, Weinman B, Inadomi JM, Chey WD. Patients with

successfully treated GERD are persistently hypersensitive to esophageal balloon

distension. Gastroenterol 2006; 130: AbW1794 (poster presentation).

108. Sarosiek I, Koch K, Selover K, Kuo B, Parkman H, Hasler W, Wo JM, Sitrin M, Chey

WD, Lackner J, D’Andrea D, McCallum RW. A new non-scintigraphic method for

measuring gastrointestinal transit in gastroparetic patients. Gastroenterol 2006; 130:

AbW1833 (poster presentation).

109. Sarosiek I, McCallum RW, Sitrin M, Wo J, Parkman H, Kuo B, Hasler W, Chey WD,

Hooker J, Landrigan B, Koch K. Smartpill as a novel-non scintigraphic, ambulatory

method for assessing GI transit: results in normal subjects. Gastroenterol 2006; 130:

AbW1844 (poster presentation).

110. Parkman HP, Hutson A, Sarosiek I, Kuo B, Chey WD, Katz L, Semler J, McCallum RW.

SmartPill capsule for assessment of gastric emptying—comparison with simultaneous

gastric emptying scintigraphy. Am J Gastroenterol 2006; 102: S99 (Ab#168).

111. Elnachef N, McMorris M, Chey WD. Treatment of diarrhea in Common Variable

Immunodeficiency: a novel use for budesonide. Am J Gastroenterol 2006; 102: S230

(Ab#549).

112. Andrews A, Cash BD, Lee DH, Saad R, Rai J, Maydonovitch C, Kim CH, Chey, WD.

The high false positive rate of inflammatory bowel disease serological markers in patients

with irritable bowel syndrome. Am J Gastroenterol 2006; 102: S475 (Ab#1226).

113. Chey WD, Andrews AH, Lee DH, Smith JH, Kim CH, Saad RJ, Rai JK, Cash BD. Are

anti-endomysial or anti-tissue transglutaminase antibodies alone sufficient to screen for

celiac sprue in patients with the Irritable Bowel Syndrome? Am J Gastroenterol 2006;

102: S477 (Ab#1232).

114. Chey WD, Whorwell PJ, Viegas A, Venezia M, Ligozio G, Shetzline MA. Differences in

clinical parameters between IBS with constipation and IBS with mixed bowel habits. Am

J Gastroenterol 2006; 102: S484 (Ab#1250).

115. Rao SS, McCallum R, Parkman HP, Kock K, Saad RJ, Chey WD, DiBaise JK, Hutson A,

Semler J, Sitrin MD, Lackner JM, Katz L, Kuo B. A comparative study of Smartpill®

and radiopaque markers for the assessment of colonic transit time in humans.

Gastroenterol 2007; 132: A458 (Ab#M2136).

116. Hasler WL, Coleski R, Sarosiek I, McCallum R, Kuo B, Parkman HP, Sitrin MD,

Lackner JM, Katz L, Koch K, Wo JM, Chey WD, Hutson A, Semler J. Colon transit and

regional colon motor activity in diabetics with gastroparesis compared to healthy

volunteers and diabetics with near normal gastric emptying. Gastroenterology 2007; 132:

A459 (Ab#M2143).

117. Talley NJ, Chey WD, Vakil N, Omar M, Ligozio G, Kralstein J. Baseline health-related

quality of life is correlated with baseline symptom severity and is improved by tegaserod

in patients with moderate to severe functional dyspepsia dysmotility symptoms.

Gastroenterol 2007; 132: A268 (Ab#S1870).


118. Chey WD, Tack J, Howden CW, Zakko SF, Rueegg PC, Demissie S, Earnest DL,

Kralstein J. Safety and tolerability of long-term therapy with tegaserod in patients with

functional dyspepsia and dysmotility symptoms: results of multicenter extension studies.

Gastroenterol 2007; 132: A266 (Ab#S1859).

119. Rubenstein JH, Nojkov B, Korsnes S, Adlis S, Shaw MJ, Weinman B, Inadomi JM, Chey

WD. Esophageal hypersensitivity is associated with features of psychiatric disorders and

the irritable bowel syndrome. Gastroenterol 2007; 132: A595 (Ab#T1976).

120. Cash BD, Kim C, Lee D, Andrews AH, Smith JH, Saad RJ, Rai J, Nojkov B, Chey WD.

Yield of diagnostic testing in patients with suspected irritable bowel syndrome (IBS): a

prospective, US multi-center trial. Gastroenterol 2007; 132: A678 (Ab#W1182).

121. Chey WD, Whorwell PJ, Viegas Andrea, Dolker M, Shetzline MA. Satisfactory relief of

overall IBS symptoms correlates strongly with improvements in patients individual

symptoms. Gastroenterol 2007;132: A679 (Ab#W1189).

122. Reddymasu S, Sarosiek I, Koch K, Hasler WL, Lackner J, Katz L, Sitrin MD, Parkman

HP, Wo JM, Chey WD, Semler J, Hwang J, Kuo B, McCallum R. Non-digestible capsule

technology to measure frequency of gastric contractions- comparison between healthy

and gastroparetic subjects. Gastroenterol 2007;132: A677 (Ab#W1179).

123. Chey WD, Nojkov B, Saad RJ, Rai J, Kim CH, Lee DH, Andrews AH, Cash BD.

Screening for celiac sprue in patients with suspected irritable bowel syndrome: results

from a prospective US multi-center trial. Gastroenterol 2007; 132: A147 (Ab#986).

124. Sarosiek I, Reddymasu S, Koch K, Hasler W, Lackner J, Katz L, Sitrin M, Parkman H,

Wo J, Sarosiek J, Chey W, Semler J, Kuo B, McCallum R. Relationship between the

frequency of gastric contractions and gastric emptying of a non-digestible solid in

controls and gastroparetics using Smartpill pressure recording capsule: its future clinical

potential. Gastroenterol 2007; 132: A379 (Ab#M1175).

125. Elnachef N, Scheiman J, Fendrick AM, Howden CW, Chey WD. Changing perceptions

and practices regarding aspirin, NSAIDs, and coxibs amongst US primary care providers

(Pcps): a tale of 2 surveys. Gastroenterol 2007; 132: A136 (Ab#921).

126. Vakil N, Chey WD, Howden CW, Earnest DL, Ligozio G, Kralstein J, Rueegg PC.

Tegaserod significantly improves moderate-sever dysmotility symptoms in patients with

functional dyspepsia. Gastroenterol 2007; 132: A93 (Ab#643).

127. Lembo AJ, Rosenbaum DP, Chey WD, Drossman DA. Safety and efficacy of crofelemer

in patients with diarrhea predominant Irritable Bowel Syndrome (D-IBS). Gastroenterol

2007; 132: A141 (Ab#944).

128. Menees SB, Chey WD, McLeod A, Marcum R, Fenner D. Patient-centered goals in

constipation. Gastroenterol 2007; 132: A350 (Ab#M1045).

129. Menees SB, Chey WD, McLeod A, Marcum R, Fenner D. Patient-centered goals in fecal

incontinence. Gastroenterol 2007; 132: A473 (Ab#T1131).

130. Zakko S, Vakil N, Chey WD, Earnest DL, Ligozio G, Kralstein J, Rueegg PC. Symptom

distribution and characteristics of patients with functional dyspepsia: data from two large

multicenter trials. Gastroenterol 2007; 132: A478 (Ab#T1152).

131. Gaman A, Hutson A, Hwang J, Stevens K, Koch K, Parkman H, McCallum R, Chey WD,

Katz L, Sitrin MD, Lackner JM, Hasler W, Wo JM, Semler J, Kuo B. A non-digestible

device discriminates motility patterns with a luminal acidic pH change within the distal

small bowel and proximal colon. Gastroenterol 2007; 132: A460 (Ab#M2148).


132. Kloetzer L, Gaman A, Nojkov B, Chey WD, Hwang J, Stevens K, Koch K, Parkman H,

McCallum R, Katz L, Sitrin MD, Lackner JM, Hasler W, Wo JM, Semler J, Kuo B.

Complete pH profiling of the gastrointestinal tract in health volunteers with an

ambulatory pH capsule. Gastroenterol 2007; 132: A461 (Ab#M2149).

133. Drossman DA, Chey WD, Panas R, Wahle A, Scott C, Ueno R. Lubisprostone

significantly improves symptom relief rates in adults with irritable bowel syndrome and

constipation (IBS-C): data from two, twelve-week, randomized, placebo-controled,

double-blind trials. Gastroenterol 2007; 132: P90 (Ab#639f).

134. Chey WD, Nojkov B, Rubenstein JR, Adlis S, Shaw MJ. Prevalence and impact of co-

morbid psychological distress on response to PPI therapy in patients with GERD.

Gastroenterol 2007; 102: S126-7 (Ab#23).

135. Kaur N, Coffing BN, Greenson J, Chey WD. Iron pill gastropathy: a case report and

review of the literature. Gastroenterol 2007; 102: S168 (Ab#138).

136. Sarosiek I, Sarosiek J, Rao S, et al. Comparisons of alimentary tract transit times among

normal subjects from two multicenter trials using SmartPill wireless pH/pressure

recording capsule: its clinical implication. Gastroenterol 2007; 102: S170 (Ab#145).

137. Rao S, Kuo B, Chey W, et al. Simultaneous assessment of colonic transit using wireless

capsule (SmartPill® ) and radiopaque markers in healthy subjects and effects of gender.

Gastroenterol Fehmi SA, Saini S, Chey W. Uncommon presentation of PTLD in the

esophagus. Gastroenterol 2007; 102: S372 (Ab#693). 2007; 102: S270 (Ab#423).

138. Brenner DM, Moeller M, Chey WD, Schoenfeld P. The utility of probiotics in the

treatment of irritable bowel syndrome: a systematic review. Gastroenterol 2007; 102:

S500 (Ab#1040).

139. Chey WD, Nojkov B, Rubenstein JR, Adlis SA, Shaw MJ. Prevalence and impact of co-

morbid psychological distress on response to PPI therapy in patients with GERD. Am J

Gastroenterol 2007; 102: S126 (Ab#23).

140. Kaur N, Coffing BN, Greenson J, Chey WD. Iron pill gastropathy: a case report and

review of the literature. Am J Gastroenterol 2007; 102: S168 (Ab#138).

141. Sarosiek I, Sarosiek J, Rao S, Parkman H, Kuo B, Lackner J, Katz L, Sitrin M, Chey WD,

142. Hasler W, DiBaise J, Wo J, Koch K, Semler J, McCallum R. Comparisons of alimentary

tract transit times among normal subjects from two multicenter trials using

SmartPillWireless pH/Pressure recording capsule: Its clinical implication. Am J


143. Rao S, Kuo B, Chey WD, Dibaise J, Katz L, Koch K, Lackner J, McCallum R, Saad R,

Selover K, Semler J, Sitrin M, Wilding G, Parkman H. Simultaneous assessment of

colonic transit using wireless capsule (SmartPill) and radiopaque markers in healthy

subjects and effects of gender. Am J Gastroenterol 2007; 102: S270 (Ab#423).

144. Fehmi SA, Saini S, Chey WD. Uncommon presentation of PTLD in the esophagus. Am J


145. Brenner DM, Moeller M, Chey WD, Schoenfeld P. The utility of probiotics in the

treatment of Irritable Bowel Syndrome: A systematic review. Am J Gastroenterol 2007;

102: S500 (Ab#1040).

146. Rao S, Kuo B, Chey WD, Dibaise J, Katz L, Koch K, Lackner J, McCallum R, Saad R,

Selover K, Semler J, Sitrin M, Wilding G, Parkman H. Investigation of wireless capsule

(SmartPill) for colonic transit: A comparative study with radiopaque markers in health

and constipation. Am J Gastroenterol 2007; 102: S512 (Ab#1075).


147. Spiegel BM, Harris LA, Lucak SL, Mayer EA, Naliboff BD, Bolus RE, Esrailian E, Chey

WD, et al. Measuring IBS patient reported outcomes with a single item numeric rating

scale: results from the PROOF cohort. Gastroenterol 2008; 134: A467 (Ab#T1026).

148. Rangnekar AS, Morgan D, Knechtges P, Saad RJ, Fenner D, Morris AM, Chey WD.

Complaints suggestive of Irritable Bowel Syndrome are common in patients with

Puborectalis Dyssynergia: An under-recognized overlap syndrome. Gastroenterol 2008;

134: A423 (Ab#M1806).

149. Drossman DA, Chey WD, Scott C, Panas RM, Ueno R. Health-related quality of life in

adults with Irritable Bowel Syndrome with Constipation: Results of a combined analysis

of two phase 3 studies with lubiprostone. Gastroenterol 2008; 134: A469 (Ab#T1036).

150. Chey WD, Drossman DA, Scott C, Panas RM, Ueno R. Lubiprostone is effective and

well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and

constipation. Gastroenterol 2008; 134: A215 (Ab#S1272).

151. Chey WD, Saad RJ, Panas RM, Wahle A, Ueno R. Discontinuation of lubiprostone

treatment for irritable bowel syndrome with constipation is not associated with symptom

increase or recurrence: Results from a randomized withdrawal study. Gastroenterol 2008;

134: A401 (Ab#M1706).

152. Kloetzer L, Gaman A, Napadow V, McCallum R, Koch KL, Sitrin MD, Chey WD, et al.

Spectral analysis of contractile frequency in the ileum and proximal colon:

characterization of motility patterns using an ambulatory capsule, SmartPill.

Gastroenterol 2008; 134: A676 (Ab#W1303).

153. Kloetzer L, Gaman A, McCallum R, Koch KL, Sitrin MD, Chey WD, et al.

Characterization of Pressure Patterns in Distal Colonic and Rectal Motility Activity

between Healthy Volunteers and Patients with Dyssynergic Defecation Using An

Ambulatory Capsule, SmartPill. Gastroenterol 2008; 134: A281 (Ab#S1838).

154. Chey WD, Mody R, Kothari S. et al. Are Proton Pump Inhibitors (PPIs) sufficient in

controlling symptoms of gastro-esophageal reflux disease (GERD)? A community-based

US survey study. Gastroenterol 2008; 134: A325 (Ab#M1041).

155. Chey WD, Mody R, Chen L, et al. Nighttime symptoms and sleep impairment among

patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton

pump inhibitors (PPIs). Gastroenterol 2008; 134: A323-4 (Ab#M1033).

156. Saad RJ, Chey WD, Rao SS, et al. How well does stool form and stool frequency

correlate with colonic and whole gut transit in healthy controls and constipated patients?

Gastroenterol 2008; 134: A420 (Ab#M1794).

157. Hasler WL, Saad RJ, Rao SS, Katz LA, Parkman HP, Koch

KL, McCallum R, Kuo B,

Sarosiek I, Sitrin MD, Lackner JM, Wilding GE, Miller C, Semler J, Chey WD.

Heightened motor activity measured by a wireless capsule in unprepared colons of

patients with complaints of constipation: relation to colon transit and IBS. Gastroenterol

2008; 134: A678 (Ab#W1312).

158. Hasler WL, Rao SS, Koch

KL, Sarosiek I, McCallum R, Lackner JM, Parkman HP, Chey

WD, et al. Wireless capsule quantification of region-specific gastrocolonic response and

sleep inhibition of colon motor activity in unprepared colons of humans with normal

colon transit. Gastroenterol 2008; 134: A678 (Ab#W1313).

159. Reddymasu S, Sarosiek I, Parkman HP, Koch KL, Sitrin MD, Wo JM, Hasler WL, Katz

LA, Chey WD, et al. Non-digestible capsule technology to measure gastric motility-


comparison between healthy controls and gastroparetic patients with a normal gastric

emptying study. Gastroenterol 2008; 134: A629 (Ab#W1081).

160. Chey WD, Nojkov B, Saad R, Adlis S, Shaw M. Differences in GERD patients evaluated

by primary care physicians and gastroenterologists. Am J Gastroenterol 2008; 103: S26

(Ab#65).

161. Rao S, Paulson J, Kuo B, et al. Assessment of inter-observer agreement of colonic transit

time (Ctt) with radiopaque markers. Am J Gastroenterol 2008; 103: S194 (Ab#502).

162. Sarosiek I, Rao S, Parkman H, et al. Comparison of GI transit parameters in

functional/idiopathic versus constipation predominant irritable bowel syndrome (IBS)

patients assessed by wireless pH/pressure recording capsule. Am J Gastroenterol 2008;

103: S202 (Ab#522).

163. Luther J, Faje A, Saad R, Chey WD. Anaplastic intra-abdominal lymphoma as a cause of

sclerosing mesenteritis: a case report. Am J Gastroenterol 2008;103: S305 (Ab#773).

164. Chey WD, Drossman D, Baum C, Ueno R. Influence of responder definition on placebo

response: insights gained from phase III clinical trials with lubiprostone for IBS-C. Am J


165. Chey WD, Mody R, Izat E. Patient and physician satisfaction with proton pump

inhibitors (PPI) for GERD symptoms – are there opportunities for improvement? Am J


166. Luther J, Schoenfeld P, Moayyedi P, Vakil N, George S, Chey WD. Triple versus

quadruple therapy as primary treatment for Heliobacter pylori infection: a meta-analysis

of efficacy and tolerability. Am J Gastroenterol 2008; 103: S397 (Ab#1015).

167. Chey W, Talley N, Lembo A, Yu J, Bortey E. Rifaximin significantly improves quality of

life versus placebo in patients with diarrhea-predominant irritable bowel syndrome. Am J


168. Cash B, Lee D, Riddle M, et al. Yield of diagnostic testing in patients with suspected

irritable bowel syndrome (IBS): a prospective, U.S. multi-center trial. Am J Gastroenterol

2008; 103: S462 (Ab#1184).

169. Ford A, Chey W, Talley N, et al. Utility of diagnostic tests for celiac disease in irritable

bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2008; 103:

S463 (Ab#1185).

170. Baker J, Saad R, Rubenstein J, Chey WD. Effects of age and gender on anorectal

function in chronic constipation. Am J Gastroenterol 2008; 103: S466 (Ab#1193).

171. Nojkov B, Rubenstein J, Hoogerwerf S, Chey WD. The effect of shift work on the

prevalence and clinical impact of functional bowel disorders in nurses. Am J


172. Rao S, Paulson J, Kuo B, et al. Relationship between the colonic transit of wireless

capsule (Smartpill® ) and radio opaque markers in constipation. Am J Gastroenterol

2008; 103: S475 (Ab#1215).

173. Ford A, Brandt L, Foxx-Orenstein A, Chey W, Schoenfeld P, Moayyedi P. Efficacy of

5HT3-antagonists in non-constipation predominant irritable bowel syndrome: systematic

review and meta-analysis. Am J Gastroenterol 2008; 103: S477 (Ab#1220).

174. Ford A, Brandt L, Foxx-Orenstein A, Chey W, Schoenfeld P, Moayyedi P. Efficacy of

5HT4-agonists in non-diarrhea predominant irritable bowel syndrome: systematic review

and meta-analysis. Am J Gastroenterol 2008; 103: S478 (Ab#1222).


175. Saad RJ, Chey WD (2/15), Rao SS…Wilding GE. Reduced stool frequency does not

predict colonic and whole gut transit in constipated patients. Gastroenterol 2009; 136:

A373 (Ab# M1209).

176. Rangnekar AS, Saad RJ, Morgan DM, Fenner D, Chey WD. Do abnormalities on testing

for dyssynergic defecation correlate with abdominal pain and bloating in constipated

patients? Gastroenterol 2009; 136: A217 (Ab# S1227).

177. Bucur MC, Michalek W, McCallum R… Chey WD (6/12)…Kuo B. The impact of using

different standardized meals in the assessment of motility of upper gastrointestinal tract.

Gastroenterol 2009; 136: A781 (Ab#W2053).

178. Michalek W, Bucur MC, McCallum R…Chey WD (6/11)…Kuo B. A comparison of

small bowel pH profiles in healthy subjects and patients with gastroparesis as measured

by a non-invasive wireless capsule. Gastroenterol 2009; 136: A683-A684 (Ab#W1234).

179. Michalek W, Bucur MC, McCallum R…Chey WD (6/11)…Kuo B. Impact of age on

upper gastrointestinal function in healthy and gastroparetic populations, as measured by a

non-invasive wireless capsule. Gastroenterol 2009; 136: A144 (Ab#949).

180. Rao SS, Paulson JA, Saad RJ…Chey WD (8/8). 950 Assessment of colonic, whole gut

and regional transit in elderly constipated and healthy subjects with a novel wireless

pH/pressure capsule (SmartPill® ). Gastroenterol 2009; 136: A144 (Ab#950).

181. Hasler WL, McCallum R, Rao SS…Chey WD (8/12)…Semler JR. Region-specific motor

patterns and pH profiles in unprepared human colon quantified by simultaneous

radiography and wireless capsule measurements. Gastroenterol 2009; 136: A225-A226

(Ab# S1268).

182. Hong S, Mann N, Chey WD, Chang L, Spiegel B. Do proton pump inhibitors (PPIs)

predispose to the development of SIBO in IBS versus non-IBS patients? Am J


183. Hong S, Mann N, Chey WD, Chang L, Spiegel B. Is IBS a predictor of SIBO as

identified by hydrogen/methane breath testing? Am J Gastroenterol 2009; 104: S110

(Ab#289).

184. Chey WD (1/8), Xu Y, Baum C…Dabbous O. Gender differences in primary care

management of chronic constipation: a study from the examination of chronic

constipation treatment and outcomes in everyday medical practice (EXCCEED) registry.

Am J Gastroenterol 2009; 104: S402 (Ab#1095).

185. Saad R, Baker J, Rubenstein J, Chey WD. Dyssynergic defecation is a common finding in

men with chronic constipation. Am J Gastroenterol 2009; 104: S490 (Ab#1313).

186. Pimentel M, Lembo A, Chey WD, Ringel Y, Zakko S, Mareya SM, Shaw AL, Yu J,

Bortey E, Forbes WP. Rifaximin treatment for 2 weeks provides acute and sustained

relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome:

results from 2 North American Phase 3 trials (Target 1 and Target 2). Gastroenterol 2010;

138: S64-65 (Ab#475i).

187. Spiegel BM, Bolus RE, Harris LA, Lucak SL, Esrailian E, Chey WD, Sayuk GS, Lembo

A, Karsan HA, Tillisch K, Talley J, Naliboff BD, Mayer EA, Chang L. Characterizing

abdominal pain attributes in IBS: guidance for study inclusion criteria and outcome

measurement. Gastroenterol 2010; 138: S99-S100 (Ab#733).

188. Spiegel BM, Bolus RE, Harris LA, Lucak SL, Esrailian E, Chey WD, Lembo A, Karsan

HA, Tillisch K, Talley J, Chang L. Patient-reported symptom relief from current therapy

is a robust marker of illness severity in IBS. Gastroenterology 2010;138: S119 (Ab#865).

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-254&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=1&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=bffd2f75a51bee5f6067314fbce7f9db

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-254&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=1&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=bffd2f75a51bee5f6067314fbce7f9db

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-16V&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=2&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=df0ade719bcbe642d6415733bf2bcd32



http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-4JX&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=3&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=58a2b45f70d0c4bd7241c0ddc31a16da

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-4JX&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=3&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=58a2b45f70d0c4bd7241c0ddc31a16da

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-40C&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=4&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=3b3794f0dbba3ff653f8d039db96510d



http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-T3&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=5&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=49753bda690f25109c6b983786480302



http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-T4&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=6&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=b4912b57cb185cc3fe1f52bfec568ad2



http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFX-4W92RV9-189&_user=99318&_coverDate=05%2F31%2F2009&_alid=1007354903&_rdoc=7&_fmt=high&_orig=search&_cdi=6806&_sort=r&_docanchor=&view=c&_ct=7&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=39adb119bd5ab99e84f2f0e4a8f138ca




189. Saad RJ, Semler JR, Wilding GE, Chey WD. The effect of age on regional and whole gut

transit times in healthy adults. Gastroenterol 2010; 138: S127 (Ab#896).

190. Jankowski M, Chey WD, Maneerattanaporn M, Hasler WL, Wilding GE, Semler JR,

Saad RJ. A comparison of two radio-opaque marker methodologies in the assessment of

colonic transit of adults with constipation. Gastroenterol 2010; 138: S231 (Ab#S1333).


HA, Tillisch K, Talley J, Chang L. Do IBS patients understand the difference between

abdominal pain vs. discomfort? Implications for clinical practice and clinical trial design.

Gastroenterol 2010; 138: S379 (Ab#M1319).


HA, Tillisch K, Talley J, Chang L. Characterizing “Bowel Urgency”: Guidance for

outcome assessment in patients with diarrhea predominant IBS. Gastroenterol 2010; 138:

S379 (Ab#M1320).

193. Mody R, Beaulieu N, Wu EQ, Dabbous F, McHale J, Chey WD. Impact of nighttime

symptoms (NTS) on treatment patterns and healthcare costs among gastroesophageal

reflux disease (GERD) patients. Gastroenterol 2010; 138: S480 (Ab#T1065).

194. Hasler WL, Rao SS, Parkman HP, Saad RJ, Chey WD, McCallum R, Kuo B, Koch KL,

Sitrin MD, DiBaise JK, Rohde B, Semler JR. Bristol stool form in slow transit

constipation correlates inversely with regional colon contractile activity measured by a

wireless motility capsule. Gastroenterol 2010; 138: S628 (Ab#T2081).

195. Chey WD, Nojkov B, Rubenstein JH, Greenson JK, Cash BD. The yield of colonoscopy

in patients with non-constipation irritable bowel syndrome (IBS): results from a

prospective, controlled United States Trial. Gastroenterol 2010; 639: S379 (Ab#W1044).

196. Sun S, Spiegel B, Mody R, Dabbous F, Dabbous O, Chey W. Economic and humanistic

burden of chronic constipation. Am J Gastroenterol 2010; 105: S391 (Ab#1081).

197. Chey W, Schoenfeld P, Sun S, Dabbous F, Baum C, Mody R. Management of chronic

constipation: results from the EXCCEED Registry. Am J Gastroenterol 2010; 105: S482

(Ab#1310).

198. Sun S, Lembo A, Mody R, Dabbous F, Baum C, Chey W. Characteristics of US Patients

with Chronic Constipation Encountered in Primary Care: Data from the Examination of

Chronic Constipation Treatment and Outcomes in Everyday Medical Practice

(EXCCEED) Registry. Am J Gastroenterol 2010; 105: S483 (Ab#1311).

199. Lembo A, Pimentel M, Chey W, Lacy B, Schoenfeld P, Yu J, Mareya S, Shaw A, Bortey

E, Forbes W. Rifaximin treatment consistently demonstrated relief across daily symptoms

in patients with non-constipation Irritable Bowel Syndrome: results from 2 phase 3 trials

(TARGET 1 and TARGET 2). Am J Gastroenterol 2010; 105: S483 (Ab#1312).

200. Maneerattanaporn M, Baker J, Saad R, Chey W. What are the key questions which aid in

the diagnosis of dyssynergic defecation? Am J Gastroenterol 2010; 105: S493

(Ab#1335).

201. Chey W, Pimentel M, Lembo A, Brown K, Yu J, Mareya S, Shaw A, Bortey E, Forbes

W. The responsiveness and validity of a binary weekly recall question and the proposed

FDA composite endpoint as measures of daily symptom severity in non-constipation

Irritable Bowel Syndrome: results of TARGET 1 and TARGET 2. Am J Gastroenterol

2010; 105: S494 (Ab#1337).

202. Kuo B, Maneerattanaporn M, Lee A, Baker J, Wiener S, Chey W, Wilding G, Hasler W.

Generalized transit delay on wireless motility capsule in patients with clinical suspicion


of gastroparesis, intestinal dysmotility, or slow transit constipation. Am J Gastroenterol

2010; 105: S501 (Ab#1356).

203. Chey WD, Lembo A, MacDougall JE, Lavins BJ, Schneier H, Johnston JM. Efficacy and

safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C:

results from a randomized, double-blind, placebo-controlled phase 3 trial. Gastroenterol

2011; 140: S135 (Ab#837).

204. Maneerattanaporn M, Baker J, Chey WD. The number of retained rectosigmoid markers

during colonic transit testing does not reliably predict the presence of dyssynergic

defecation. Gastroenterol 2011; 140: S609 (Ab#Mo1313).

205. Smith TM, Menees SB, Xu X, Saad RJ, Chey WD, Fenner D. Factors associated with

quality of life among women with fecal incontinence. Gastroenterol 2011; 140: S201

(Ab#Sa1002).

206. Ferreccio C, Anderson GL, Morgan DR, Torres J, Bravo LE, Dominguez R, Herrero R,

Meza-Montenegro M, Peña R, Salazar-Martinez E, Chey WD, Valdivieso M, Crowley J,

Goodman GE, Greenberg ER, Baker LH. A randomized trial comparing 14-day triple,

10-day sequential, and 5-day concomitant therapy to eradicate Helicobacter pylori in

seven Latin American populations. Gastroenterol 2011; 140: S137 (Ab#842).

207. Chey WD, Pimentel M, Riff DS, Weinstock LB, Yu J, Mareya SM, Bortey E, Forbes

WP. Time to onset and durability of relief in non-constipation IBS patients over 12 weeks

following a 2-week course of rifaximin. Gastroenterol 2011; 140: S605 (Ab#Mo1299).

208. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A3309, an ileal bile acid

transport (IBAT /ASBT) inhibitor, significantly improved stool frequency and other

constipation-related complaints in adults with chronic constipation: data from an 8-week,

randomized, double-blind, placebo-controlled study. Gastroenterol 2011; 140: S3

(Ab#10).

209. Menees SB, Maneerattanaporn M, Chey WD. Efficacy of rifaximin in patients with

irritable bowel syndrome: a meta-analysis. Gastroenterol 2011; 140: S49-50 (Ab#215).

210. Menees SB, Smith TM, Xu X, Chey WD, Saad RJ, Fenner D. Factors associated with

severity of fecal incontinence: a study of patient characteristics and fecal incontinence

severity index (FISI). Gastroenterol 2011; 140: S801-802 (Ab#Tu1343).

211. Maneerattanaporn M, Luther J, Waljee AK, Saini SD, Chey WD. Biofeedback therapy

compared to standard treatment for patients with dyssynergic defecation: results from a

meta-analysis. Gastroenterol 2011; 140: S797 (Ab#Tu1323).

212. Spiegel BM, Bolus RE, Agarwal N, Sayuk GS, Harris LA, Lucak SL, Esrailian E, Chey

WD, Lembo A, Karsan HA, Tillisch K, Talley J, Chang L. Factors analysis of bowel

symptoms in IBS: guidance for patient reported outcome (PRO) development.

Gastroenterol 2011; 140: S605-606 (Ab#Mo1299).

213. Spiegel BM, Bolus RE, Agarwal N, Sayuk GS, Harris LA, Lucak SL, Esrailian E, Chey

WD, Lembo A, Karsan HA, Tillisch K, Talley J, Chang L. Do patients understand the

Bristol Stool Scale? Results of cognitive de-briefing of IBS patients. Gastroenterol 2011;

140: S615 (Ab#Mo1337).

214. Chey W, Rao S, Lembo A, Shao J, Shi K, Lavins B, Shiff S, Schneier H, Johnston J.

Efficacy and safety of once-daily linaclotide administered orally for 12 weeks to patients

with IBS-C: pooled results from two randomized, double-blind, placebo-controlled phase

3 trials. Am J Gastroenterol 2011; 106: S504-5 (Ab#1322).


215. Pimentel M, Lembo A, Chey W, Yu J, Merchant K, Bortey E, Forbes W. Evaluation of

rifaximin efficacy in non C-IBS patients by baseline disease severity: subanalysis of the

TARGET 1 and TARGET 2 studies. Am J Gastroenterol 2011; 106: S505 (Ab#1323).

216. Chey WD, Spiegel BM, Lavins BJ, Hao X, Currie MG, Schneier H, Johnston JM. The

Effect of Comorbid Psychological Distress on Baseline Irritable Bowel Syndrome with

Constipation Symptoms and Response to Linaclotide Treatment. Gastroenterol 2012;

142: S301 (Ab#Sa1421).

217. Chey WD, Shringarpure R, Nicandro JPA, Chuang E, Olden K. Alosetron Treatment

Reduced Health Care Utilization and Improved Symptoms More Effectively Than

Traditional Therapy in Women with Severe IBS-D. Gastroenterol 2012; 142: S818

(Ab#Tu1386).

218. Chey WD, Quigley EM, Lavins BJ, Baird MJ, Fitch DA, Hao X, Shi K, Currie MG,

Schneier H, Johnston JM. Effects of 26 Weeks of Linaclotide Treatment on Adequate

Relief and IBS Severity in Patients with Irritable Bowel Syndrome with Constipation.

Gastroenterol 2012; 142: S817 (Ab#Tu1381).

219. Chang L, Chey WD, Drossman DA, Lembo A, Pimentel M, Schoenfeld PS, Yu J,

Merchant K, Paterson C, Bortey E, Forbes WP. Safety and Tolerability Profile of

Rifaximin for Treatment of IBS Without Constipation: Results of a Pooled Analysis of

Double-Blind, Placebo-Controlled Randomized Controlled Trials. Gastroenterol 2012;

142: S823 (Ab#Tu1403).

220. Baker J, Chey WD, Fenner D, Menees SB. Anorectal Manometry Parameters in a Fecal

Incontinence Cohort Related to Body Mass Index. Gastroenterol 2012; 142: S904

(Ab#Tu2025).

221. Ferch C, Chey WD, Saad RJ. The Prevalence and Impact of Lower Gastrointestinal

Symptoms in an Ambulatory Elderly Outpatient Population. Gastroenterol 2012; 142:

S710-S711 (Ab#Mo1969).

222. Rai J, Chey WD, Maneerattanaporn M, Baker J, Saad RJ. Do Constipation Symptoms

Identify Patients with Dyssynergic Defecation? Gastroenterol 2012; 142: S901

(Ab#Tu2013).

223. Locke GR, Chey WD, Kurtz CB, Carson R, Baird MJ, MacDougall JE, Jia XD, Currie

MG, Schneier H, Johnston JM. Effects of Linaclotide Treatment on Patient-Reported

Ratings of Change for Symptoms of Irritable Bowel Syndrome with Constipation (IBS-

C): Pooled 12-Week Findings from Two Phase 3 Trials. Gastroenterol 2012; 142: S737

(Ab#Tu1086).

224. Schoenfeld PS, Chey WD, Lavins BJ, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD,

Schneier H, Currie MG, Johnston JM. Linaclotide Significantly Improved Abdominal

Pain Compared with Placebo in Patients with Irritable Bowel Syndrome Regardless of

Baseline Pain Severity in Two Phase 3 Trials. Gastroenterol 2012; 142: S701

(Ab#Mo1856).

225. Jones MP, Chey WD, Gong H, Shringarpure R, Chuang E, Singh S, Talley NJ.

Psychological Variables Add Incremental Value to Biological Markers in Differentiating

IBS from Healthy Volunteers. Gastroenterol 2012; 142: S820 (Ab#Tu1392).

226. Lembo A, Chang L, Chey WD, Drossman DA, Pimentel M, Schoenfeld PS, Yu J,

Merchant K, Paterson C, Bortey E, Forbes WP. Impact of Concurrent use of PPIs or

Anti-Depressants on Efficacy of Rifaximin for IBS Without Constipation. Gastroenterol

2012; 142: S824 (Ab#Tu1406).


227. Pimentel M, Chang L, Chey WD, Drossman DA, Lembo A, Schoenfeld PS, Yu J,

Merchant K, Paterson C, Bortey E, Forbes WP. Efficacy of Rifaximin for IBS Without

Constipation in Men and Women. Gastroenterol 2012; 142: S182-S183 (Ab#1041).

228. Baker J, Wilding GE, Chey WD, Hasler WL. Gastrocolonic Response Activity After

Meal Ingestion in Health vs. Constipation: Rigorous Quantification in Relation to Colon

Transit and Associated IBS in a Large Cohort. Gastroenterol 2012; 142: S308

(Ab#Sa1448).

229. Rubenstein JH, Morgenstern H, Chey WD, Murray J, Scheiman JM, Schoenfeld PS,

Appelman HD, McMahon LF, Metko V, Near E, Inadomi JM. Acid Reflux, Erosive

Esophagitis, and Barrett's Esophagus Are Associated with Different Measures of

Abdominal Obesity in Men. Gastroenterol 2012; 142: S754 (Ab#Tu1131).

230. Hasler WL, Wilding GE, Chey WD, Baker J. Comparison of Sleep Inhibition of Colon

Motor Activity in Healthy Humans vs. Patients with Constipation: Relation to Colon

Transit, IBS, and Sleep Parameters. Gastroenterol 2012; 142: S833-S834 (Ab#Tu1441).

231. Menees SB, Smith TM, Xu X, Chey WD, Saad RJ, Fenner D. Depressive Symptoms in

Patients with Fecal Incontinence: Is There a Gender Difference? Gastroenterol 2012; 142:

S904 (Ab#Tu2024).

232. Saad RJ, Semler JR, Wilding GE, Chey WD. Advancing Age is Associated With

Progressive Delays in Colon Transit in Patients With Chronic Constipation. Gastroenterol

2012; 142: S710 (Ab#Mo1968).

233. Morgan DR, Torres J, Greenberg ER, Sexton R, Salazar-Martinez E, Dominguez R,

Ferreccio C, Bravo LE, Pena EM, Herrero R, Meza-Montenegro M, Martinez ME, Correa

P, Chey WD, Valdivieso M, Anderson GL, Baker LH. H. pylori Recurrence One Year

After Eradication Treatment in a Population Randomized Trial (SWOG S0701) in Seven

Latin American Sites. Gastroenterol 2012; 142: S478-S479 (Ab#Su1673).

234. Herrero R, Salazar-Martinez E, Sexton R, Morgan DR, Dominguez R, Torres, Ferreccio

C, Bravo LE, Martinez ME, Pena EM, Correa P, Valdivieso M, Meza-Montenegro M,

Anderson GL, Chey WD, Greenberg ER, Crowley J, Baker LH. Predictors of Success of

Helicobacter pylori Eradication Treatment in a Multicentric Randomized Clinical Trial

(SWOG S0701) in Latin America. Gastroenterol 2012; 142: S183-S184 (Ab#1046).

235. Torres J, Morgan DR, Greenberg ER, Salazar-Martinez E, Dominguez R, Ferreccio C,

Bravo LE, Pena R, Herrero R, Meza-Montenegro M, Martinez ME, Correa P, Valdivieso

M, Anderson GL, Chey WD, Crowley J, Baker LH. One-Year Effectiveness and Costs of

Six Alternative H. Pylori Test/Treat and Retest/Retreat Strategies Using Triple,

Concomitant or Sequential Drug Regimens in Seven Latin American Sites (SWOG Trial

S0701). Gastroenterol 2012; 142: S115-S116 (Ab#590).

236. Dominguez R, Morgan DR, Sexton R, Pena EM, Greenberg ER, Rollan A, Chey WD.

ROME III Criteria-Based Prevalence of Dyspepsia Symptoms in General Populations in

Six Countries in Latin America (SWOG Trial S0701). Gastroenterol 2012; 142: S465

(Ab#Su1618).

237. Chey WD, Baker JRB, Shifferd J. Assessment of abdominal symptoms before and after

biofeedback therapy in patients with dyssynergic defecation. Am J Gastroenterol 2012;

107 (suppl 1): S718 (Ab#1764).

238. Kurlander JE, Zhao B, Rupley D, Drossman DA, Chey WD. Factors associated with

positive and negative patient-physician interactions: Results from focus groups with IBS

patients (1598831). Gastroenterol 2013; 144: S572 (Ab#Mo1083).

http://www.sciencedirect.com/science/article/pii/S001650851260688X




239. Chey WD, Webster L, Sostek M, Lappalainen JN, Barker PN, Tack JF. Efficacy and

Safety of Naloxegol in Patients with Opioid-Induced Constipation: Results From 2

Prospective, Randomized, Controlled Trials (1594557). Gastroenterol 2013; 144: S159-

S160 (Ab#900).

240. Baker J, Eswaran SL, Rai J, Chey WD. Comparison Between Spontaneously Reported

Stool Form using the Bristol Stool Form Scale and Stool Form Calculated from a Seven-

Day Diary in Patients with Chronic Constipation (1606280). Gastroenterol 2013; 144:

S921 (Ab#Tu2075).

241. Chey WD, Lavins BJ, Shiff SJ, MacDougall JE, Kurts CB, Shi K, Currie MG, Johnston

JM. Determining the Minimum Duration for Initial Treatment with Linaclotide in IBS-C

Patients: Results from Pooled Phase 3 Trials. Gastroenterol 2013; 144: S537-S538

(Ab#Su2033).

242. Saad R, Nahlawi L, Chey W. Effect of the chloride channel activator, lubiprostone, on

gastrointestinal and colonic transit, motility and pH in patients with the irritable bowel

syndrome and constipation (IBS-C). Am J Gastroenterol 2013; 108: S565 (Ab#1872).

243. Baker J, Chey W. Does rectal hyposensitivity play a role in outlet obstruction

constipation? Am J Gastroenterol 2013; 108: S568 (Ab#1879).

244. Webster L, Chey W, Tack J, Lappalainen J, Barker P, Sostek M. Long-term safety and

tolerability of naloxegol in patients with opioid-induced constipation. Am J Gastroenterol

2013; 108: S568-S569 (Ab#1880).

245. Chey W, Tack J, Webster L, Lappalainen J, Barker P, Sostek M. Naloxegol symptom

responder rates in patients with opioid-induced constipation: results from two

prospective, randomized controlled trials. Am J Gastroenterol 2013; 108: S570

(Ab#1883).

246. Chey W, Tack J, Webster L, Barker P, Lappalainen J, Sostek M. Efficacy of naloxegol in

a subpopulation of patients with opioid-induced constipation and an inadequate baseline

response to laxatives: results from two prospective, randomized controlled trials. Am J


247. Chey W, Shiff S, Schneier H, Xinming H, Lavins B, Chickering J, Kurtz, C, Currie M,

Johnston J. Two years on linaclotide: tolerability and treatment satisfaction in IBS-C

patients with and without diarrhea. Am J Gastroenterol 2014; 109: S530 (Ab#1791).

248. Chey W, Baker J, Menees S, Maneerattanaporn M, Saad R. Predictive value and

interexaminer variability of digital rectal examination for dyssynergic defecation in

constipated patients undergoing anorectal manometry. Am J Gastroenterol 2014; 109:

S537 (Ab#1814).

249. Haefner J, Baker J, Chey W, Fairchild P, Berger M. Assessment of sexual function and

attitudes in female patients with functional bowel disorders. Am J Gastroenterol 2014;

109: S646 (Ab#2224).

250. Nojkov B, Eswaran S, Chey WD. Dietary restrictions predict worse disease-specific

quality of life in patients with irritable bowel syndrome. Gastroenterol 2014; 146: S199

(Ab#Sa1099).

251. Baker J, Chey WD, Kao J, Saad R. The impact of helicobacter pylori status following a

course of eradication therapy on common gastrointestinal symptoms. Gastroenterol 2014;

146: S564 (Ab#Mo1129).


252. Guentner A, Menees S, Saad R, Chey WD. How do US gastroenterologist use over-the-

counter and prescription laxatives in patients with chronic constipation? Gastroenterol

2014; 146: S194 (Ab#Sa1082).

253. Chey WD, Baker J, Attari A, Spiegel B, Ashton-Miller J. A glove-based, disposable,

point-of service device which allows detailed physiological assessment of the anorectum:

A proof of concept study in healthy volunteers. Gastroenterol 2014; 146: S720

(Ab#Mo2022).

254. Guentner A, Menees S, Saad R, Chey WD. US gastroenterologists’ use of over-the-

counter medications for gastroesophageal reflux disease (GERD): translating perception

to reality. Gastroenterol 2014; 146: S756-S756 (Ab#Tu1111).

255. Menees S, Kurlander J, Goel A, Powell C, Chey WD. A meta-analysis of the utility of

common serum and fecal biomarkers in adults with IBS. Gastroenterol 2014; 146: S194

(Ab#Sa1079).

256. Baker J, Chey WD, Saad R, Menees S. Effects of vaginal delivery on anorectal

parameters and rectal sensation measurements in a fecal incontinence cohort.

Gastroenterol 2014; 146: S721 (Ab#Mo2027).

257. Guivatchian T, Koeppe E, Foor-Pessin C, Chey WD, Eswaran S, Kolars J, Menees S,

Rajala M, Rice M, Rizk R, Rubenstein J, Sharma P, Todisco A, Stoffel E.

Implementation of a brief familial cancer assessment tool improves surveillance

recommendations and identification of patients at increased risk for colorectal cancer.

Gastroenterol 2014; 146: S408-S409 (Ab#Su1231).

258. Almario C, Chey WD, Kaung A, Whitman C, Fuller G, Reid M, Bolus R, Dennis R,

Encarnacion R, Martinez B, Talley J, Modi R, Agarwal N, Lee A, Bolus S, Chang L,

Spiegel B. Computer Automated Evaluation of Gastrointestinal Symptoms (AEGIS)

Outperforms Physician-Documented History of Presenting Illness (HPI): Results of a

Blinded Comparison. Gastroenterol 2014; 146: S189 (Ab#Sa1064).

259. Nojkov B, Chey WD. Effects of age and gender on disease-specific quality of life (QOL)

in patients with irritable bowel syndrome (IBS). Gastroenterol 2015; 148: S656

(Ab#Mo1272).

260. Chey WD, Lembo A, Phillips J, Rosenbaum D. Efficacy and safety of tenapanor in

patients with constipation predominant irritable bowel syndrome: a12-week, double-

blind, placebo-controlled, randomized phase 2b trial. Gastroenterol 2015; 148: S191-

S192 (Ab#1020).

261. Chey WD, Baker J, Attari A, Ashton-Miller J. A glove-based, disposable, point-of

service device which allows physiological assessment of the anorectum: concordance

with anorectal manometry in chronic constipation patients. Gastroenterol 2015; 148:

S178 (Ab#931).

262. Baker J, Haefner J, Fairchild P, Chey WD, Saad R, Menees S, Berger M. Assessment of

sexual function in relation to a male cohort experiencing functional bowel disorders.

Gastroenterol 2015; 148: S307 (Ab#Sa1374).

263. Chang L, Chey WD, Drossman D, Losch-Beridon T, Wang M, Lichtlen P, Mareya S.

Effects of baseline abdominal pain on response to lubiprostone in patients with

constipation-predominant irritable bowel syndrome. Gastroenterol 2015; 148: S653

(Ab#Mo1262).


264. Spencer M, Chey WD, Evans S, Han-Markey T, Ball S, Eswaran S. Differences in

nutrient intake between irritable bowel syndrome (IBS) patients and healthy volunteers.

Gastroenterol 2015; 148: S489-S490 (Ab#Su1374).

265. Chey WD, Dove S, Andrae D, Davenport J. Michael, Turner L, Lopez R, Covington P.

Eluxadoline demonstrates sustained efficacy for the treatment of diarrhea-predominant

irritable bowel syndrome in phase 3 clinical trials. Gastroenterol 2015; 148: S70

(Ab#316).

266. Chey WD, Chang L, Lembo A, Aggarwal K, Bortey E, Paterson C, Forbes W. Effects of

rifaximin on urgency, bloating, and abdominal pain in patients with IBS-D: a

randomized, controlled, repeat treatment study. Gastroenterol 2015; 148: S69 (Ab#313).

267. Almario C, Chey WD, Iriana S, Whitman C, Fuller G, Reid M, Bolus R, Dennis R,

Encarnacion R, Martinez B, Talley J, Modi R, Agarwal N, Lee A, Kubomoto S, Bolus S,

Chang L, Spiegel B. Automated evaluation of gastrointestinal symptoms (AEGIS) versus

physician identification of gastrointestinal alarm features. Gastroenterol 2015; 148: S205-

S206 (Ab#Sa1044).

268. Lacy B, Chey W, Lembo A, Dove L, Covington P. Eluxadoline demonstrates efficacy for

the treatment of irritable bowel syndrome (IBS) with diarrhea (IBS-D) among multiple

clinically relevant patient subgroups. Am J Gastroenterol 2015; 110: S747 (Ab#1760).

269. Chey WD, Lembo A, Wolf R. Infection-related safety profile of rifaximin repeat

treatment for diarrhea-predominant irritable bowel syndrome (IBS-D). Am J


270. Chey WD, Lembo A, Rosenbaum D. Tenpanor’s sustained response in patients with

constipation predominant irritable bowel syndrome: post-hoc analysis from a 12-week,

double-blind, placebo-controlled, randomized phase 2b trial. Am J Gastroenterol 2015;

110: S756 (Ab#1779).

271. Fass R, Chey WD, Want M, Mareya S, Losch-Beridon T. Durability and predictability of

treatment response to lubiprostone in patients with constipation-predominant irritable

bowel syndrome. Am J Gastroenterol 2015; 110: S761 (Ab#1792).

272. Spiegel B, Doshi J, Buono J, Taylor D, Goolsby Hunter A, Carson R, Martin C, Buzinec

P, Essor B, Chey WD. Characteristics Associated with Probiotic Use Among Patients

Experiencing Constipation-Related Symptoms: Results from the Contor Study. Am J


273. Taylor C, Chey WD, Doshi J, Buono J, Martin C, Buzinec P, Goolsby Hunter A, Carson

R, Essor B, Spiegel B. Treatment satisfaction among patients with constipation-related

bowel and abdominal symptoms: results from the Contor study. Am J Gastroenterol

2015; 110: S933 (Ab#2246).

274. Almario C, Chey WD, Khanna D, Whitman C, Fuller G, Reid M, Bolus R, Dinnis B,

Encarnacion R, Martinez B, Soares J, Modi R, Agarwal N, Lee A, Kubomato S, Sharma

G, Bolus S, Spiegel B. Impact of NIH patient-related outcome measurement information

system (PROMIS): gastrointestinal measures on patient outcomes. Am J Gastroenterol

2015; 110: S944 (Ab#2277).

275. Almario C, Chey WD, Khanna D, Whitman CB, Fuller G, Reid M, Bolus R, Dennis B,

Encarnacion R, Martinez B, et al. Impact of NIH Patient-Reported Outcome

Measurement Information System (PROMIS ® ): Gastrointestinal Measures on Patient

Outcomes. Am J Gastroenterol Oct 2015: S944-S945 (Ab#2277).


276. Almario CV, Chey WD, Spiegel B. Prevalence and Predictors of Irritable Bowel

Syndrome in the United States. Gastroenterol Apr 2016; 150: S172 (Ab#822).

277. Chey SW, Menees SB, Saini SD, Weissman A, Harris LJ, Chey WD. US Primary Care

Providers Use of Over-the-Counter Medications for Gastroesophageal Reflux Disease

and Chronic Constipation. Gastroenterol Apr 2016; 150: S236-S237 (Ab#Sa1089).

278. Chey WD, Almario CV, Spiegel B. Differences in Lower and Upper Gastrointestinal

Symptoms in Individuals with Constipation Taking and Not Taking Opioids: Results

from a Survey of Over 70,000 Persons Residing in the United States. Gastroenterol Apr

2016; 150: S193 (Ab#965).

279. Eswaran SL, Chey WD, Jackson K, Ball S, Han-Markey T. A Low FODMAP Diet

Reduces Abdominal Symptoms to a Greater Degree than Bowel Symptoms in Patients

with Irritable Bowel Syndrome and Diarrhea: Results of Daily Data from a US

Randomized Controlled Trial. Gastroenterol Apr 2016; 150: S229-S230 (Ab#1132).

280. Eswaran SL, Chey WD, Han-Markey T, Jackson K, Ball S. A United States,

Randomized, Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE

Guidelines in Adults with IBS-D: Primary and Key Secondary Endpoints. Gastroenterol

Apr 2016; 150: S160 (Ab#774).

281. Eswaran SL, Chey WD, Jackson K, Pillai SG, Chey SW, Han-Markey T. A Low

FODMAP Diet Improves Quality of Life, Reduces Activity Impairment, and Improves

Sleep Quality in Patients with Irritable Bowel Syndrome and Diarrhea: Results from a US

Randomized, Controlled Trial. Gastroenterol Apr 2016; 150: S172 (Ab#821).

282. Shah ED, Chey WD, Almario CV, Spiegel B. Similarities and Differences in Clinical

Phenotype Between Individuals with Irritable Bowel Syndrome with Constipation and

Chronic Functional. Gastroenterol Apr 2016; 150: S231 (Ab#1136).

283. Zhou SY, Eswaran SL, Wu XY, Chey WD, Chung OY. Low FODMAP Diet Modulates

Visceral Nociception by Changing Gut Microbiota and Intestinal Permeability in IBS.

Gastroenterol Apr 2016; 150: S63-S64 (Ab#261).

284. Almario CV, Chey WD, Spiegel B. Burden of Gastrointestinal Symptoms in the United

States: Results from a Survey of over 71,000 Americans. Gastroenterol Apr 2016; 150:

S831-S832) (Ab#Tu1066).

285. Chey WD, Andrae D, Dove LS, Covington PS. A 1-month Trial with Eluxadoline for

IBS-D Predicts a Durable Response: Continuation Analysis of Response in Two Phase 3

Studies. Gastroenterol Apr 2016; 150: S494-S495 (Ab#Su1204).

286. Cohen ER, Almario CV, Chey WD, Spiegel B. Comparing Irritable Bowel Syndrome

Symptoms and Severity Between Men and Women. Gastroenterol Apr 2016; 150: S900

(Ab#Tu1421).

287. Freeman AE, Roberts SC, Chey WD, Kao JY, Rao K. New Onset Functional GI

Disorders Following Fecal Microbiota Transplant for Recurrent Clostridium Difficile

Infection-Prevalence and Risk Factors. Gastroenterol Apr 2016; 150: S495 (Ab#Su1206).

288. Hosmer A, Baker J, Chey WD, Fisher LR, Sheth N, Rice MD. Does Sedation Affect

Upper Gastrointestinal Transit and Study Completion Rates Measured by Small Bowel

Video Capsule Endoscopy? Gastroenterol Apr 2016; 150: S1016 (Ab#Tu2075).

289. Kurlander JE, Chey WD, Morris C, Hu YM, Bangdiwala S, Norton NJ, Norton W,

Drossman DA. Development and Validation of the Patient-Provider Relationship Scale

among Patients with Irritable Bowel Syndrome. Gastroenterol Apr 2016; 150: S900-S901

(Ab#Tu1423).


290. Merchant JL, Photenhauer A, Eswaran SL, Jackson K, Chey WD. A US, Randomized,

Controlled Trial Comparing the Low FODMAP Diet vs NICE Guidelines in Adults IBS-

D Adults: Predictive Value of a Tryptophan Hydroxlase 1 (TPH1) Promoter Variant.

Gastroenterol Apr 2016; 150: S953 (Ab#Tu1807).

291. Nojkov B, Baker J, Saad RJ, Chey WD. Dyssynergic Defecation is More Common in

Younger Patients with Chronic Constipation in Both Females and Males. Gastroenterol

Apr 2016; 150: S539 (Ab#Su1598).

292. Pan DN, Almario CV, Chey WD, Spiegel B. Prevalence and Severity of Concomitant

Gastrointestinal Symptoms in Crohn’s Disease. Gastroenterol Apr 2016; 150: S790

(Ab#Mo1839).

293. Riehl ME, Chey WD, Stidham RW. Comparison of Quality of Life and Treatment

Response in IBS and IBD Patients Undergoing GI-Focused Behavioral Health

Interventions. Gastroenterol Apr 2016; 150: S443 (Ab#Su1011).

294. Zhang A, Almario CV, Chey WD, Spiegel B. Prevalence and Severity of Gastrointestinal

Symptoms in Cirrhosis. Gastroenterol Apr 2016; 150: S1051-S1052 (Ab#817).

295. Irvine AJ, Ford AC, Chey WD. Screening for Coeliac Disease in Irritable Bowel

Syndrome is Still Worthwhile: An Updated Systematic Review and Meta-Analysis. Gut

Jun 2016; 65: A113 (Ab#PTU-117).

296. Ahmed S, Almario CV, Chey WD, Ahn J, Ko JZ, Robbins L, Spiegel B. Marked

Disagreement Between Referring Physicians and Patients’ Reason for GI Consultation.

Gastroenterol Apr 2016; 150: S234-S235 (Ab#Sa1083).

297. Zhou SY, Eswaran SL, Wu X, Chey WD, Owyang C. LPS mediated intestinal barrier

dysfunction and visceral hypersensitivity in the IBS is prevented by low FODMAP diet.

Neurogastroenterol and Motility Aug 2016; 28:9 (Ab#13).

298. Baker JR, Chey WD, Saad R, Nojkov B. Anorectal Manometry characteristics of

constipated fibromyalgia patients in relationship to self-reported abdominal symptom

severity. Neurogastroenterol and Motility Aug 2016; 28:34 (Ab#97).

299. Abel JL, Taylor DCA, Doshi JA, Martin C, Hunter AG, Essoi B, Buzinec P, Carson RD,

Reasner DS, Spiegel B, Chey WD, et al. Chronic Constipation and IBS-C Treatment and

Outcomes Real World Research Platform (CONTOR): A Large, Longitudinal

Observational Study. Am J Gastroenterol Oct 2016; 111: S257 (Ab#563).

300. Chey WD, Lembo AJ, Rosenbaum D. The Effect of Tenapanor on Global Endpoints in

Patients with Constipation Predominant Irritable Bowel Syndrome: Results from a 12-

Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial. Am J

Gastroenterol Oct 2016; 111: S236 (Ab#520).

301. Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS. Efficacy and Safety

of Eluxadoline in IBS-D Patients Who Report Prior Inadequate Symptom Control with

Loperamide. Am J Gastroenterol Oct 2016; 111: S249-S250 (Ab#547).

302. Menees SB, Almario CV, Chey WE, Spiegel B. Prevalence and Predictors of Bowel

Incontinence: Results from a US Population-Based Study 2016 ACG Category Award

(Functional Bowel Disease). Am J Gastroenterol Oct 2016; 111: S247-S248 (Ab#543).

303. Taylor DCA, Abel JL, Spiegel B, Doshi JA, Martin C, Buzinec P, Hunter AG, Essoi B,

Reasner DS, Carson RD, Chey WD, et al. Impact of Linaclotide and Stool Form on

Bowel Movement Satisfaction in Patients with Irritable Bowel Syndrome with

Constipation or Chronic Idiopathic Constipation: Results from the Contor Study. Am J

Gastroenterol Oct 2016; 111: S238-S239 (Ab#526).


304. Abel J, Taylor DC, Doshi JA, Martin C, Hunter AG, Essoi B, Buzinec P, Carson RT,

Reasner DS, Chey WD. Differences in Demographic and Symptom-Related

Characteristics Among Patients with Irritable Bowel Syndrome with Constipation (IBS-

C) and Chronic Idiopathic Constipation (CIC): Results from the CONTOR Study.

Gastroenterol Apr 2017; 152: S745 (Ab#Mo1666).

305. Almario CV, Chey WD, Spiegel B. Prevalence and Predictors of “IBS-Like” Symptoms

in the United States: Results from a Survey of over 71,000 Americans. Gastroenterol Apr

2017; 152: S67-S68 (Ab#258).

306. Baker J, Saad RJ, Menees SB, Eswaran SL, Lee A, Chey WD, Nojkov B. Symptom and

Anorectal Manometry Characteristics of Constipated Patients with Fibromyalgia.

Gastroenterol Apr 2017; 152: S508 (Ab#Su1521).

307. Chey WD, Chamberlin P, Bochenek W, Tripp K, Higgins CS, Omniewski N, Fox SM,

Hall M, Hashash A, Miller M, et al. Targeted Delivery of Linaclotide to Specific Areas of

the Intestine Affects Clinical Efficacy in Patients with Irritable Bowel Syndrome with

Constipation (IBS-C). Gastroenterol Apr 2017; 152: S1314-S1315 (Ab#Tu2013).

308. Chey WD, Lacy BE, Cash BD, Epstein M, Shah SM. yy Randomized Controlled Trial to

Assess the Efficacy & Safety of Caraway Oil/L-Menthol Plus Usual Care Polypharmacy

vs. Placebo Plus Usual Care Polypharmacy for Functional Dyspepsia. Gastroenterol Apr

2017; 152: S306 (Ab#Sa1618).

309. Chey WD, Lacy BE, Cash BD, et al. Efficacy of Caraway Oil/L-Menthol Plus Usual Care

vs. Placebo Plus Usual Care, in Functional Dyspepsia Patients with Post-Prandial

Distress (PDS) or Epigastric Pain (EPS) Syndromes: Results from a US RCT.

Gastroenterol Apr 2017; 152: S307 (Ab#Sa1619).

310. Eswaran SL, Chey WD, Jackson K, Han-Markey T. The Low Fodmap Diet is Equally

Efficacious in IBS-D Patients with and without Baseline Anxiety: A Post-Hoc Analysis

from a US Randomized, Controlled Trial. Gastroenterol Apr 2017; 152: S719

(Ab#Mo1562).

311. Eswaran SL, Merchant JL, Photenhauer A, Jackson K, Madriaga D, Selvaraj FM, Princen

F, Chey WD. Tryptophan Hydroxlase 1 (TPH1) Promoter Genotype but not Serum

Serotonin Levels Identify IBS-D Patients More Likely to Benefit from the Low

FODMAP Diet. Gastroenterol Apr 2017; 152: S69 (Ab#262).

312. Eswaran SL, Selvaraj FM, Princen F, Tooker P, Harvie G, Chey WD. Serum 7C4 Levels

Decrease After Low FODMAP Diet in IBS Patients: A Potential Mechanism for Benefit.

Gastroenterol Apr 2017; 152: S160 (Ab#733).

313. Lacy BE, Chey WD, Cash BD, Epstein M, Shah SM. yy A Caraway Oil/Menthol

Combination Improves Functional Dyspepsia (FD) Symptoms within the First 24 Hours:

Results of a Randomized Controlled Trial, Which Allowed Usual FD Treatments.

Gastroenterol Apr 2017; 152: S307 (Ab#Sa1620).

314. Lubarda J, Warters M, Chatterjee P, Cash BD, Chey WD. How is OIC Diagnosed and

Managed? Insights from a Virtual Patient Simulation. Gastroenterol Apr 2017; 152: S230

(Ab#Sa1131).

315. Menees SB, Almario CV, Spiegel B, Chey WD. Sex Differences in Fecal Incontinence:

Results from a US Population-Based Study. Gastroenterol Apr 2017; 152: S308-S309

(Ab#Sa1623).

316. Nojkov B, Baker J, Lee A, Eswaran SL, Menees SB, Saad RJ, Chey WD. Impact of Age

and Gender to Severity of Constipation-Related Symptoms and Quality of Life Indices in


Patients with Chronic Idiopathic Constipation. Gastroenterol Apr 2017; 152: S514

(Ab#Su1539).

317. Shah ED, Chey WD, Stidham RW. Assessing Long-Term Persistence with

Pharmacotherapy for Constipation-Predominant Irritable Bowel Syndrome and

Functional Constipation in Clinical Practice: A Retrospective Cohort Analysis.

Gastroenterol Apr 2017; 152: S713 (Ab#Mo1546).

318. Shah ED, Almario CV, Spiegel B, Chey WD. Patients with IBS-C Report More Severe,

Bothersome, Frequent and Diffuse Abdominal Pan vs. INS-D: Results of a Nationwide

Population-Based Study. Gastroenterol Apr 2017; 152: S712-S713 (Ab#Mo1545).

319. Shah ED, Farida J, Chey WD. A Systematic Review and Meta-Analysis to Determine

Whether Balloon Expulsion Testing Might be an Appropriate Initial Office-Based Test

for Dyssynergic Defecation. Gastroenterol Apr 2017; 152: S315 (Ab#Sa1638).

320. Shah ED, Andraska E, Li J, Zhang S, Chey WD. How Cost Affects the Treatment Choice

for Irritable Bowel Syndrome with Diarrhea Patients: A Cost-Effectiveness Analysis of

Tricyclic Agents and Rifaximin. Gastroenterol Apr 2017; 152: S118 (Ab#515).

321. Brenner D, Chey WD, Dove LS, Andrae D, Gutman CR, Covington PS. Using Radar

Plots to Display Disparate Global Effects of Eluxadoline in Patients with Irritable Bowel

Syndrome with Diarrhea. Am J Gastroenterol Oct 2018; 112: S255-S256 (Ab#486).

322. Chey WD, Lembo AJ, Korner P, Yan A, Rosenbaum DP. Efficacy and Safety of

Tenapanor in Patients with Constipation Predominant Irritable Bowel Syndrome: A 12-

week, Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. Am J Gastroenterol

Oct 2017; 112: S226-S227 (Ab#421).

323. Chey WD, Lacy BE, Cash BD, Epstein M, Shah SM. Rapid Relief of Functional

Dyspepsia Symptoms with a Novel Formulation of Caraway Oil and L-menthol:

Outcomes from a Self-Reported Patient Outcomes Study. Am J Gastroenterol Oct 2017;

112: S663 (Ab#1209).

324. Chey WD, Bochenek W, Tripp KJ, Higgins CS, Fox SM, Cronin JA, Chamberlin P.

Effect of Linaclotide DR1, a Delayed-Release Formulation of Linaclotide, in IBS-C

Patients: Analysis of Symptom Improvement Using Responder Radar Plots. Am J

Gastroenterol Oct 2017; 112: S236-S237 (Ab#445).

325. Farida JP, Shah ED, Ball S, Chey WD, Eswaran S. Micronutrient Intake Changes with

the Low FODMAP and mNICE Diets. Am J Gastroenterol Oct 2017; 112: S247

(Ab#468).

326. Lenhart A, Ferch C, Shaw M, Chey WD. Use of Dietary Management for Irritable Bowel

Syndrome: Results of a Survey of Over 1,500 Members of the American College of

Gastroenterology. Am J Gastroenterol Oct 2017; 112: S250-S251 (Ab#475).

327. Lubarda J, Chatterjee P, Muino J, Chey WD. Improving Diagnosis and Management of

IBS-D Through Continuing Medical Education. Am J Gastroenterol Oct 2017; 112:

S1468 (Ab#2699).

328. Menees S, Almario C, Spiegel BM, Chey WD. Does Obstetrical History Impact

Women’s FI PROMIS Severity Scores? Am J Gastroenterol Oct 2017; 112: S248-S249

(Ab#471).

329. Pambianco DJ, Adler DG, Cash BD, Chey WD, DeVault K, Karlitz JJ, Knapple W,

Leavitt J, Oxentenko AS, Shah NL, et al. Gastroenterologists Attitudes about

Maintenance of Certification: A Multi-Practice National Survey. Am J Gastroenterol Oct

2017; 112: S607-S608 (Ab#1110).


330. Quigley E, Camilleri M, Yishai R, Chey WD, Morliere C, Misra B, Lane P, et al. A

Comparison of the Efficacy and Safety of 2 Dosing Regimens, 2 and 5 Times per Week,

of an Intraluminal Vibrating Capsule in the Management of Chronic Idiopathic

Constipation. Am J Gastroenterol Oct 2017; 112: S226 (Ab #420).

331. Shah ED, Eswaran S, Chey WD. How Cost-Effectiveness Impacts Treatment Choice in

Irritable Bowel Syndrome: A Cost-Effectiveness Analysis of Guideline Recommended

Over-the-Counter Treatments and Low FODMAP Diet from a Patient Perspective. Am J

Gastroenterol Oct 2017; 112: S618 (Ab#1132).

332. Shah ED, Almario C, Spiegel BM, Chey WD. Constipation Symptoms Differ Between

Individuals with Irritable Bowel Syndrome with Constipation and Chronic Idiopathic

Constipation. Am J Gastroenterol Oct 2017; 112: S241-S242 (Ab#456).

333. Shah ED, Eswaran S, Chey WD. Understanding How Low FODMAP Diet Fits into the

IBS Treatment Paradigm: A Cost-Effectiveness Analysis of Low FODMAP Diet versus

Guideline-Recommended Prescription Therapy. Am J Gastroenterol Oct 2017; 112: S242

(Ab#457).

334. Taylor DCA, Abel JL, Doshi JA, Martin C, Hunter AG, Essoi B, Korrer S, Carson RT,

Reasner DS, Chey WD. Impact of Stool Consistency on Bowel Movement Satisfaction in

IBS-C or CIC Patients Treated with Linaclotide or Other Medications: Results from the

CONTOR Study. Am J Gastroenterol Oct 2017; 112: S228 (Ab#425).

335. Baker J, Chey WD, Lee A, Amat L, Saad R, Harer K, Hasler WL. Comparative

Quantitative Analysis Between the North American Consensus Positive Hydrogen Breath

Test – Small Intestinal Bacterial Overgrowth Versus Traditional Thresholds.

Gastroenterol May 2018; 154: S957 (Ab#Tu1584).

336. Baker J, Read AJ, Rubenstein J, Saini S, Chey WD, Kurlander JE, Chen JW. Trends in

utilization of Esophageal Manometry and Ambulatory Reflux Monitoring. Gastroenterol

May 2018; 154: S742-743 (Ab#Mo1529).

337. Chey WD, Lembo AJ, Yan A, Rosenbaum DP. Efficacy and Safety of Tenapanor in

Patients with Constipation Predominant Irritable Bowel Syndrome: A 6-month, Double-

blind, Placebo-controlled Phase 3 Trial (T3MPO-2). Gastroenterol May 2018; 154:

S1362 (Ab#885).

338. Dionne JC, Ford AC, Yuan YH, Chey WD, Quigley EM, Moayyedi P. Exclusion Diets

and Irritable Bowel Symptoms: A systematic Review and Meta-Analysis. Gastroenterol

May 2018; 154: S783 (Ab#Mo1648).

339. Jou J, Suresh S, Stidham RW, Chey WD, Shah, ED. Mood Disorders do not Appear to

Impact Discontinuation of Chronic Pharmacotherapy for IBS with Constipation and

Chronic Constipation. Gastroenterol May 2018; 154: S976 (Ab#Tu1634).

340. Maneerattanaporn M, Boonanuwat R, Kriengsinyos W, Chey WD. The Impact of High

vs. Low Fodmap Diet on GI Symptoms and Breath Hydrogen & Methane Excretion in

Thai Healthy Volunteers and Subjects with Functional Floating. Gastroenterol May 2018;

154: S865 (Ab#Mo1962).

341. Menees SB, Baker J, Chey WD. What is the Prevalence of Dyssynergic Defecation in

Patients with Fecal Incontinence Undergoing High Resolution Anorectal Manometry?

Gastroenterol May 2018; 154: S551 (Ab#Su1620).

342. Jusufagic A, Dzubur E, Almario CV, Howard A, Martinez MB, Chey WD, Spiegel B.

Validation and feasibility of a Food and Symptom Tracker (FAST) Score using a Mobile

Health Application. Gastroenterol May 2018; 154: S867 (Ab#Mo1965).


343. Menees SB, Baker J, Chey WD. Gender Difference in Patients with Fecal Incontinence:

Symptom Severit, Quality of Life, and HR Anorectal Manometry Results. Gastroenterol

May 2018; 154: S550-S551 (Ab#Su1619).

344. Riehl ME, Stidham RW, Goldstein C, Kinnucan JA, Chey WD. The Impact of a GI-

Specific Behavioral Intervention on Sleep Quality in Functional Bowel Disorder Patients.

Gastroenterol May 2018; 154: S539 (Ab#Su1591).

345. Ritter AJ, Chey WD, Foyt HL, Sandborn WJ, Savaiano DA. Improvement of Clinical

Symptoms of Lactose Intolerance with a Novel Prebiotic Galacto-Oligosaccharide, RP-

G28. Gastroenterol May 2018; 154: S1047 (Ab#Tu1884).

346. Ritter AJ, Chey WD, Foyt HL, Lundy JJ, Coon CD, Savaiano DA. A Novel Tool to

Assess Symptoms of Lactose Intolerance and Define Meaningful Patient Benefit.

Gastroenterol May 2018; 154: S683 (Ab#Mo1048).

347. Simmer S, Chey WD, Eswaran SL, Ranagan J, Petrucelli S. Is Sucrase-Isomaltase

Deficiency an Under-Recognized Cause of IBS-D Symptoms? Gastroenterol May 2018;

154: S867 (Ab#Mo1966).

348. Spechler SJ, Lee RH, Smith BR, Mashimo H, Sanchez V, Dunbar KB, Pham T, Murthy

UK, Kim T, Jackson CS, Chey WD, et al. A VA Cooperative, Randomized Trial of

Medical and Surgical Treatments for Patients with Heartburn that is Refractory to Proton

Pump Inhibitors. Gastroenterol May 2018; 154: S129 (Ab#615).

349. Spechler SJ, Lee RH, Smith BR, Mashimo H, Sanchez V, Dunbar KB, Pham T, Murthy

UK, Kim T, Jackson CS, Chey WD, et al. Characterization of Conditions Underlying

Heartburn Refractory to Proton Pump Inhibitors (PPIS) in a VA Cooperative Study of

Medical and Surgical Treatments for PPI-Refractory Heartburn. Gastroenterol May 2018;

154: S101-S102 (Ab#444).

350. Suresh S, Jou J, Stidham RW, Chey WD, Shah ED. Evaluating Why and When Patients

Discontinue Chronic Therapy for IBS with Constipation and Chronic Constipation: A

Real-World Experience. Gastroenterol May 2018; 154: S93 (Ab#387).

351. Taylor DCA, Abel JL, Doshi JA, Martin C, Hunter AG, Essoi B, Korrer S, Carson RT,

Reasner DS, Chey WD. Effect of stool consistency on bowel movement satisfaction in

patients with Irritable Bowel Syndrome with constipation or chronic idiopathic

constipation: results from the CONTOR study. Neurogastroenterology and Motility Aug

2018; 30: S1 (Ab#394).